≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

L01XE Protein kinase inhibitors

Endpoint Browser

RX_L01XE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Medicine purchases: ATC — L01XE

1 out of 7 registries used, show all original rules.

2002

4. Check minimum number of events

Min. number of events 3
2002

5. Include endpoints

None

2002

6. Filter based on genotype QC (FinnGen only)

1924

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze
DF3

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 1924 1011 913
Unadjusted period prevalence (%) 0.39 0.36 0.42
Median age at first event (years) 67.59 66.11 69.22

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
2002
Matched controls
20020
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
25.9
320.7
228
99
L01XE01
ATC
[U] imatinib
+∞
309.6
289
*
189
Kela drug reimbursment
Imatinib
1146.0
308.6
294
*
L01XE04
ATC
[U] sunitinib
1726.6
308.4
292
*
284
Kela drug reimbursment
Nintedanib and pirfenidone
83.0
307.7
195
26
L01XE33
ATC
[U] palbociclib
4122.9
307.7
354
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
120.6
307.7
619
74
Z51.5
ICD-10 Finland
Palliative care
11.2
307.7
856
1248
394
Kela drug reimbursment
Palbociclib
169.1
307.7
314
22
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
12.8
307.7
455
450
A04AA02
ATC
granisetron; systemic, transdermal
8.2
307.7
504
786
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
25.9
307.7
694
402
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
18.6
307.7
334
213
H02AB02
ATC
dexamethasone; systemic
8.7
307.7
860
1602
JN4AD
NOMESCO Finland
Body CT examination
6.3
307.7
740
1709
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
20.4
307.7
373
222
192
Kela drug reimbursment
Fulvestrant
93.3
307.7
224
27
197
Kela drug reimbursment
Sunitinib
283.1
307.7
331
14
130
Kela drug reimbursment
Malignant tumour
18.5
307.7
1072
1173
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
50.7
307.7
261
59
L01EF01
ATC
palbociclib; oral
92.0
307.7
184
22
1501
Kela drug reimbursment
Palbociclib
196.6
307.7
356
22
JN4BD
NOMESCO Finland
Extensive body CT
13.1
307.7
977
1359
N02AA05
ATC
oxycodone; systemic
7.8
307.7
1139
2886
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
17.6
307.7
278
182
WF049
NOMESCO Finland
Radiotherapy of metastasis
24.0
307.7
639
383
A03FA01
ATC
metoclopramide; systemic, rectal
10.5
307.7
1328
3165
L02BA03
ATC
fulvestrant; parenteral
65.7
307.7
253
44
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
97.6
307.7
178
20
KAC10
NOMESCO Finland
Total nephrectomy with capsule
42.8
303.1
183
47
198
Kela drug reimbursment
Sorafenib
158.6
296.4
147
10
JN4CD
NOMESCO Finland
Very extensive body CT
10.4
292.2
355
407
356
Kela drug reimbursment
Nintedanib and pirfenidone
63.9
287.3
159
27
M05BX04
ATC
denosumab; parenteral
7.4
283.3
483
827
A04AA01
ATC
ondansetron; systemic, rectal
6.7
281.3
546
1067
1502
Kela drug reimbursment
Cabozantinib
92.6
279.0
146
17
WF004
NOMESCO Finland
Palliative radiotherapy
14.8
273.7
256
197
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
27.0
268.9
187
76
L02BG06
ATC
exemestane; oral
17.1
266.4
228
149
3012
Kela drug reimbursment
Cabozantinib
88.5
266.0
140
17
8310/3-C64.9
ICD-O-3
Clear cell adenocarcinoma, NOS, of kidney, NOS
20.4
260.4
204
111
L01CA04
ATC
vinorelbine; systemic
26.1
259.7
183
77
322
Kela drug reimbursment
Sunitinib
127.4
259.2
131
11
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
8.4
249.2
358
503
L01BC06
ATC
capecitabine; oral
8.8
244.2
336
448
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
18.7
219.3
178
104
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
7.6
218.0
341
525
L03AA02
ATC
filgrastim; parenteral
9.6
216.3
271
320
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
10.6
211.6
245
260
WW500
NOMESCO Finland
Blood transfusion
8.2
207.8
300
421
L01XE31
ATC
[U] nintedanib
+∞
205.9
194
*
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
13.3
205.1
202
168
115
Kela drug reimbursment
Breast cancer
5.5
198.2
457
1026
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
7.6
196.0
305
465
L01EX09
ATC
nintedanib; oral
66.4
194.8
107
17
L02BG04
ATC
letrozole; oral
6.0
191.1
385
763
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
6.2
188.4
366
700
159
Kela drug reimbursment
Pazopanib
394.0
182.8
181
5
L02BA01
ATC
tamoxifen; oral
7.7
181.9
274
402
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
7.9
178.9
263
375
X76
ICPC
Malignant neoplasm breast female
11.6
178.6
191
180
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
15.2
175.7
158
112
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
308.7
168.5
169
6
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
17.8
167.1
138
83
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
18.2
166.5
136
80
176
Kela drug reimbursment
Regorafenib
48.5
166.2
97
21
WZC00
NOMESCO Finland
Treatment plan or consultation
3.5
164.2
1168
5720
L03AA13
ATC
pegfilgrastim; parenteral
6.5
160.4
288
507
ZX120
NOMESCO Finland
Intravenous
4.7
159.8
443
1146
158
Kela drug reimbursment
Everolimus
422.4
158.7
157
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.2
158.2
526
1562
L01XE11
ATC
[U] pazopanib
1628.6
154.2
148
*
L04AX05
ATC
pirfenidone; oral
41.4
150.3
91
23
AA1BD
NOMESCO Finland
Extensive CT of head and brain
8.9
149.5
195
240
L01EA01
ATC
imatinib; oral
387.1
146.0
145
*
8312/3-C64.9
ICD-O-3
Renal cell carcinoma, NOS, of kidney, NOS
20.9
145.5
111
56
HAC20
NOMESCO Finland
Total mastectomy
6.8
143.5
241
395
316
Kela drug reimbursment
Imatinib
1452.5
140.3
135
*
XW000
NOMESCO Finland
Bone marrow biopsy
6.1
138.8
263
486
WZC30
NOMESCO Finland
Teaching
3.5
138.1
661
2486
L01EX07
ATC
cabozantinib; oral
46.9
137.8
81
18
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
7.6
137.1
204
293
A79
ICPC
Malignancy NOS
10.5
135.3
154
158
NK6AN
NOMESCO Finland
Total body bone isotope imaging
7.4
134.2
205
303
UGC12
NOMESCO Finland
Flexible bronchoscopy
4.5
133.9
374
965
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.3
131.7
1420
8479
L01XE05
ATC
[U] sorafenib
456.5
130.5
129
*
R50.9
ICD-10 Finland
Fever, unspecified
3.5
127.2
558
1973
155
Kela drug reimbursment
Afatinib and gefitinib
1286.1
125.4
121
*
369
Kela drug reimbursment
Regorafenib
38.1
124.5
77
21
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
4.6
121.0
320
788
L01XE26
ATC
[U] cabozantinib
1229.6
120.1
116
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.5
117.6
509
1775
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
10.1
116.6
136
144
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
40.3
114.8
70
18
XX3DW
NOMESCO Finland
Time consuming IT work
3.6
114.7
459
1520
191
Kela drug reimbursment
Erlotinib
306.5
114.3
115
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
5.0
114.2
268
597
A06AH03
ATC
naloxegol; oral
10.2
114.2
132
138
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
10.2
114.2
132
138
C50.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of breast
32.9
113.3
73
23
L01XE03
ATC
[U] erlotinib
585.1
113.1
111
*
L01XE23
ATC
[U] dabrafenib
1151.0
112.7
109
*
L01EX01
ATC
sunitinib; oral
59.1
112.3
63
11
ZX090
NOMESCO Finland
Other technic of radiotherapy
6.7
110.9
184
296
167
Kela drug reimbursment
Dabrafenib, trametinib and vemurafenib
384.6
110.5
110
*
L01XE10
ATC
[U] everolimus
+∞
109.4
104
*
C34.82
ICD-10 Finland
Malignant overall tumor of bronchial and pulmonary adenocarcinoma
29.1
108.9
73
26
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
33.5
106.1
68
21
U75
ICPC
Malignant neoplasm of kidney
48.4
104.5
61
13
C50.4
ICD-10 Finland
Malignant neoplasm: Upper-outer quadrant of breast
12.1
101.3
103
89
1CD02, ,
NOMESCO Finland
13.8
101.2
95
72
168
Kela drug reimbursment
Axitinib
1028.6
101.1
98
*
C22.0
ICD-10 Finland
Malignant neoplasm: Liver cell carcinoma
16.3
100.5
86
55
A04AD12
ATC
aprepitant; systemic
8.0
99.7
140
187
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
5.7
99.0
194
367
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
4.6
98.2
253
606
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
9.1
98.1
123
143
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
5.7
96.5
190
361
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
7.5
96.1
143
204
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
20.2
96.0
74
38
9863/3-C42.1
ICD-O-3
Chronic myeloid leukemia, NOS, of bone marrow
973.5
95.8
93
*
362
Kela drug reimbursment
Dabrafenib, trametinib and vemurafenib
962.5
94.7
92
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
4.4
93.5
255
638
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.4
93.1
401
1377
L01XE27
ATC
[U] ibrutinib
940.5
92.6
90
*
C34.12
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary adenocarcinoma
10.2
92.6
106
109
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
8.1
92.5
128
168
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
11.5
91.5
96
87
TGC00
NOMESCO Finland
Bronchial lavation
6.6
91.4
154
251
N02AA01
ATC
morphine; systemic, rectal
7.7
90.9
132
183
L01XX05
ATC
hydroxycarbamide; oral
9.7
89.9
107
116
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
4.8
88.5
214
486
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
88.2
988
5581
A04AA55
ATC
palonosetron, combinations; systemic
5.3
87.0
186
380
180
Kela drug reimbursment
Interferon alfa
27.6
86.5
59
22
8170/3-C22.0
ICD-O-3
Hepatocellular carcinoma, NOS, of liver
22.0
86.2
64
30
340
Kela drug reimbursment
Everolimus
230.0
86.1
88
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.5
85.9
349
1152
390
Kela drug reimbursment
Ibrutinib
157.0
85.8
90
6
HA1AA
NOMESCO Finland
X-ray mammography
3.7
85.5
313
965
B01AB05
ATC
enoxaparin; parenteral
2.5
85.4
917
5059
L01XE13
ATC
[U] afatinib
+∞
85.0
81
*
L03AB05
ATC
interferon alfa-2b; parenteral
27.9
83.9
57
21
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
15.3
83.9
74
50
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
6.2
83.2
147
251
L01XE25
ATC
[U] trametinib
+∞
82.9
79
*
C78.2
ICD-10 Finland
Secondary malignant neoplasm of pleura
21.3
82.4
62
30
J94.8
ICD-10 Finland
Other specified pleural conditions
8.4
81.1
108
135
WX302
NOMESCO Finland
Thoracal epidural anesthesy
4.3
81.1
230
591
B01AB10
ATC
tinzaparin; parenteral
3.1
81.0
400
1482
L01EF03
ATC
abemaciclib; oral
48.1
80.3
47
10
WX408
NOMESCO Finland
General anesthesy, balanced
2.5
78.7
728
3720
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.5
78.3
307
987
1512
Kela drug reimbursment
Ibrutinib
140.6
76.5
81
6
1515, ,
Kela drug reimbursment
35.1
75.8
48
14
3030
Kela drug reimbursment
Abemaciclib
35.1
75.8
48
14
C50.81
ICD-10 Finland
Overall malignant tumor of the mammary gland, ductal tumor
8.2
75.8
103
132
C34.32
ICD-10 Finland
Malignant tumor of the lower lobe, bronchus or lung adenocarcinoma
11.9
75.2
77
67
C50.99
ICD-10 Finland
Breast, unspecified
5.5
74.2
149
287
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
10.9
72.8
79
75
ZX050
NOMESCO Finland
Stereotactic radiotherapy
11.4
72.2
76
69
HA1AT
NOMESCO Finland
Biopsy of mammary glands with ultrasound guidance
6.5
71.1
119
192
L01XE18
ATC
[U] ruxolitinib
712.6
70.5
69
*
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
6.6
69.3
115
184
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.4
69.0
726
3884
JN6AD
NOMESCO Finland
CT of torso and neck
6.9
68.8
109
166
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
6.2
68.7
122
209
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
12.8
68.6
67
54
B01AB04
ATC
dalteparin; parenteral
4.1
68.5
204
542
C03CA01
ATC
furosemide; systemic
2.3
67.5
844
4849
L01XE21
ATC
[U] regorafenib
86.6
67.4
75
9
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.3
67.0
277
917
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
18.7
66.6
53
29
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
4.7
65.8
159
359
361
Kela drug reimbursment
Axitinib
659.1
65.3
64
*
A02BC02
ATC
pantoprazole; systemic
2.6
64.5
1609
12214
174
Kela drug reimbursment
Ruxolitinib
173.2
64.4
67
*
C79.31
ICD-10 Finland
Secondary malignant tumor of the cerebellum
22.9
64.3
47
21
D70.82
ICD-10 Finland
Drug-induced neutropenia
7.5
63.9
93
129
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
12.5
63.5
63
52
J01MA12
ATC
levofloxacin; systemic
2.4
63.4
547
2664
GAA10
NOMESCO Finland
Intercostal insertion of pleural drainage tube
6.6
63.0
103
162
TPX10
NOMESCO Finland
Implantation of vascular injection port
5.0
62.9
141
299
L01XE17
ATC
[U] axitinib
+∞
61.8
59
*
8520/3-C50.9
ICD-O-3
Lobular carcinoma, NOS, of breast, NOS
7.7
61.4
87
117
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
5.1
60.3
131
270
C49.49
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the abdomen other or unspecified tumor
97.5
60.2
66
7
R84
ICPC
Malignant neoplasm bronchus/lung
18.2
59.5
48
27
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
16.5
59.1
50
31
H02AB06
ATC
prednisolone; systemic
2.1
58.6
1144
7697
8140/3-C34.1
ICD-O-3
Adenocarcinoma, NOS, of upper lobe, lung
11.2
58.3
62
57
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
16.9
57.5
48
29
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
11.9
56.9
58
50
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.9
56.8
315
1229
341
Kela drug reimbursment
Afatinib and gefitinib
+∞
56.5
54
*
8140/3-C34.3
ICD-O-3
Adenocarcinoma, NOS, of lower lobe, lung
16.4
56.5
48
30
L02BG03
ATC
anastrozole; oral
6.7
56.4
91
141
343
Kela drug reimbursment
Pazopanib
151.9
56.2
59
*
3024
Kela drug reimbursment
Dabrafenib and trametinib (adjuvant treatment)
123.7
56.1
60
5
1509
Kela drug reimbursment
Dabrafenib (adjuvant treatment)
123.7
56.1
60
5
ZX112
NOMESCO Finland
Subcutaneous
5.5
55.9
111
211
152
Kela drug reimbursment
Nilotinib
563.3
55.9
55
*
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
5.2
55.7
117
234
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
4.8
55.4
131
290
150
Kela drug reimbursment
Dasatinib
+∞
54.4
52
*
374
Kela drug reimbursment
Ruxolitinib
146.6
54.1
57
*
8140/3-C34.9
ICD-O-3
Adenocarcinoma, NOS, of lung, NOS
12.6
54.0
53
43
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.5
53.8
199
611
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
8.5
53.7
70
85
L01XX28
ATC
[U] imatinib
+∞
53.4
51
*
J01MA14
ATC
moxifloxacin; systemic
2.9
53.0
286
1097
C43.5
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of trunk
13.1
52.1
50
39
L01XE07
ATC
[U] lapatinib
181.4
51.1
53
*
156
Kela drug reimbursment
Lapatinib
261.8
50.3
51
*
L01XE06
ATC
[U] dasatinib
+∞
50.2
48
*
GA1AE
NOMESCO Finland
Ultrasound examination of thorax
5.0
49.7
111
234
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
15.0
49.4
44
30
C34.1
ICD-10 Finland
Malignant neoplasm: Upper lobe, bronchus or lung
6.6
49.3
81
128
C50.90
ICD-10 Finland
Malignant tumor in other or unspecified location in mammary gland without histology
6.9
49.0
77
116
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
9.3
48.8
59
65
E0000UV, ,
ATC
2.0
48.6
951
6253
M04AA01
ATC
allopurinol; systemic
2.4
47.9
396
1866
C50.82
ICD-10 Finland
Overall malignant tumor of the mammary gland, lobular tumor
10.2
47.9
54
54
L01XE02
ATC
[U] gefitinib
478.9
47.5
47
*
C50.40
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, no histological veryfication
5.4
47.1
95
183
L01EL01
ATC
ibrutinib; oral
128.1
47.0
50
*
323
Kela drug reimbursment
Sorafenib
61.6
46.5
54
9
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.2
46.1
489
2556
C43.53
ICD-10 Finland
Malignant melanoma of the torso nodular
14.9
46.0
41
28
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
14.9
46.0
41
28
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.1
45.7
211
740
GA4AT
NOMESCO Finland
Cathetrisation of pleural cavity with ultrasound guidance
6.6
44.9
73
114
B03XA02
ATC
darbepoetin alfa; parenteral
4.8
44.4
103
224
TPH04
NOMESCO Finland
Cathetrisation of vein
2.1
44.4
586
3326
GD1AD
NOMESCO Finland
Thorax CT examination
2.9
44.4
223
820
L01EJ01
ATC
ruxolitinib; oral
120.3
43.9
47
*
C50.91
ICD-10 Finland
Malignant tumor in another specified localization in ductal mammary gland
6.2
43.6
75
124
PJA12
NOMESCO Finland
Sentinel node biopsy
2.7
43.6
255
1016
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
71.6
43.2
49
7
C79.39
ICD-10 Finland
Secondary malignant tumor of the meninges, ventricle or other part of the brain
17.8
42.9
35
20
YX8VG
NOMESCO Finland
Stereotactic MRI exmaination with high intensity magnet for dose design of radiotherapy
17.8
42.9
35
20
L01EK01
ATC
axitinib; oral
426.4
42.3
42
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
2.9
42.2
220
824
PJ3AT
NOMESCO Finland
Cytology of lymphnode with ultrasound guidance
7.0
42.1
65
96
QX3AT
NOMESCO Finland
Ultrasound guided biopsy of subcutaneous tissue
9.5
41.9
50
54
3004
Kela drug reimbursment
Osimertinib
115.0
41.9
45
*
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
10.9
41.8
45
42
ZX080
NOMESCO Finland
Image guided radiotherapy
4.7
41.4
99
221
C50.9
ICD-10 Finland
Malignant neoplasm: Breast, unspecified
10.7
41.2
45
43
L01EG02
ATC
everolimus; oral
146.4
40.9
43
*
L01XE08
ATC
[U] nilotinib
+∞
40.8
39
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
9.3
40.5
49
54
TQW20
NOMESCO Finland
Tatoe
7.9
40.1
55
71
N05BA06
ATC
lorazepam; systemic, sublingual
3.2
39.7
168
559
ZXE20
NOMESCO Finland
More than three and less than five hours
2.3
39.4
367
1808
C43.59
ICD-10 Finland
Malignant melanoma of the trunk other or unspecified histology
10.0
39.3
45
46
FM1FN
NOMESCO Finland
Heart function isotope examination
11.3
39.0
41
37
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
4.4
38.4
100
239
C34.3
ICD-10 Finland
Malignant neoplasm: Lower lobe, bronchus or lung
7.3
37.8
56
79
HAE20
NOMESCO Finland
Reconstruction of areola and mamilla using graft or flap
6.7
37.5
60
92
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
4.5
37.0
93
216
A06AD11
ATC
lactulose; oral
2.2
36.9
388
2002
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
3.8
36.8
115
314
THW99
NOMESCO Finland
Other minor procedure in surgery of mammary gland
4.5
36.7
90
205
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
7.8
36.6
51
67
C43.50
ICD-10 Finland
Malignant melanoma of the torso without histology
9.4
36.6
44
48
PJD42
NOMESCO Finland
Excision of axillary lymph nodes
7.4
36.5
53
73
NK6AQ
NOMESCO Finland
Whole body bone SPET with low dose CT
11.8
36.1
37
32
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.0
35.9
484
2737
R4190
NOMESCO Finland
Nutritional therapy
3.5
35.7
125
369
D37.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Small intestine
10.2
35.4
40
40
R4110
NOMESCO Finland
Physiotherapy
1.9
35.2
667
4224
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
9.7
35.1
41
43
SPAT1109
SPAT
Analgesia with portable analgesic pump
9.7
35.1
41
43
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.3
34.9
307
1471
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
2.9
34.9
169
607
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
6.3
34.9
59
96
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
3.1
34.2
155
536
328
Kela drug reimbursment
Nilotinib
342.8
34.0
34
*
1519, ,
Kela drug reimbursment
77.6
33.9
38
5
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
3.5
33.4
117
345
HAE10
NOMESCO Finland
Reconstruction of breast using graft or flap
6.1
33.4
58
97
C50.42
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, lobular tumor
4.7
33.1
77
168
XG410
NOMESCO Finland
Flow-volume spirometry
3.3
33.0
130
413
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
5.5
33.0
64
119
3016
Kela drug reimbursment
Binimetinib and encorafenib
172.8
32.8
34
*
C50.89
ICD-10 Finland
Overall malignant tumor of the mammary gland, other or undeterminated histology
9.5
32.7
39
42
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
2.9
32.6
167
618
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
12.5
32.4
32
26
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
2.6
32.4
202
827
L03AA14
ATC
lipegfilgrastim; parenteral
4.7
32.4
75
163
L01AX03
ATC
temozolomide; systemic
8.7
32.3
41
48
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
7.4
32.3
47
65
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
2.6
32.3
204
841
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
4.8
32.1
73
156
WB501
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of primary tumour
62.8
32.1
37
6
R18
ICD-10 Finland
Ascites
4.4
32.1
82
193
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
3.9
32.0
95
250
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
4.6
31.9
77
173
C78.8
ICD-10 Finland
Secondary malignant neoplasm of other and unspecified digestive organs
10.5
31.6
35
34
3001
Kela drug reimbursment
Alectinib
+∞
31.3
30
*
324
Kela drug reimbursment
Dasatinib
+∞
31.3
30
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
3.7
31.2
102
287
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
4.4
31.1
80
189
C50.92
ICD-10 Finland
Malignant tumor in another specified localization in lobular gland, lobular tumor
10.2
31.0
35
35
1513
Kela drug reimbursment
Binimetinib and encorafenib
162.5
30.8
32
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
5.9
30.6
55
95
WF002
NOMESCO Finland
Radical radiotherapy
2.6
30.5
183
735
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
4.9
30.3
67
140
WW200, ,
SPAT
0.5
30.2
254
4834
C10AA07
ATC
rosuvastatin; oral
0.5
30.1
325
5666
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
5.4
30.0
59
111
L01EA03
ATC
nilotinib; oral
306.9
29.9
30
*
D37.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Stomach
8.3
29.5
39
48
1504
Kela drug reimbursment
Alectinib
+∞
29.2
28
*
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
10.2
29.2
33
33
K03.82
ICD-10 Finland
Split tooth for reasons other than trauma
0.4
29.1
221
4380
HA1CG
NOMESCO Finland
Extensive MRI examination of mammary gland with high intensity magnet
4.9
28.9
64
134
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.1
28.3
126
431
L01EB04
ATC
osimertinib; oral
55.9
28.2
33
6
L01EB03
ATC
afatinib; oral
285.4
27.8
28
*
Z31.5
ICD-10 Finland
Genetic counselling
3.1
27.6
122
415
L01BC59
ATC
trifluridine, combinations; systemic
11.3
27.6
29
26
ZXE10
NOMESCO Finland
More than one and less than three hours
1.7
27.3
784
5506
C16.9
ICD-10 Finland
Malignant neoplasm: Stomach, unspecified
8.9
27.2
34
39
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.6
27.2
173
714
WF003
NOMESCO Finland
Adjuvant radiotherapy
3.2
27.0
111
362
L01EC02
ATC
dabrafenib; oral
62.9
27.0
31
5
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.9
27.0
129
459
169
Kela drug reimbursment
Crizotinib
274.6
26.8
27
*
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
5.4
26.6
53
101
JDA63
NOMESCO Finland
Local excision of lesion of stomach
46.4
26.5
32
7
C50.21
ICD-10 Finland
Malignant tumor of the upper inner quadrant of the mammary gland,ductal tumor
3.9
26.1
79
211
N03AX14
ATC
levetiracetam; systemic
3.4
26.0
95
288
TGA30
NOMESCO Finland
Thoracocentesis
6.7
24.7
39
59
L01EX03
ATC
pazopanib; oral
131.7
24.6
26
*
L01EX05
ATC
regorafenib; oral
43.4
24.6
30
7
C79.2
ICD-10 Finland
Secondary malignant neoplasm of skin
43.4
24.6
30
7
D45
ICD-10 Finland
Polycythaemia vera
5.9
24.5
44
76
GAA96
NOMESCO Finland
Other open or percutaneous drainage of pleural cavity
9.5
24.4
29
31
B03XA01
ATC
erythropoietin; parenteral
6.8
24.3
38
57
WX892
NOMESCO Finland
Monitored bed care
2.3
24.1
206
969
L01XE36
ATC
[U] alectinib
+∞
24.0
23
*
L01XE35
ATC
[U] osimertinib
+∞
24.0
23
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
3.3
23.8
93
294
C34.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bronchus and lung
7.3
23.8
35
49
L01XE16
ATC
[U] crizotinib
242.8
23.7
24
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
4.3
23.6
62
149
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
5.1
23.5
50
101
Z76.0
ICD-10 Finland
Issue of repeat prescription
0.5
23.5
195
3788
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.0
23.4
290
1571
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.7
23.4
583
3908
GDB11
NOMESCO Finland
Thoracoscopic wedge resection of lung
7.3
23.3
34
47
8720/3-C44.5
ICD-O-3
Malignant melanoma, NOS, of skin of trunk
6.2
23.3
40
66
Z2446
NOMESCO Finland
Social worker
2.5
23.3
156
659
Z3231
NOMESCO Finland
Registered nurse
1.7
23.2
586
3942
ZX070
NOMESCO Finland
Intensity modified radiotherapy
3.9
23.0
67
174
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
9.1
23.0
28
31
SPAT1255
SPAT
Intravenous administration of medicine
2.3
23.0
180
816
L01ED03
ATC
alectinib; oral
+∞
23.0
22
*
127
Kela drug reimbursment
Transplant complication
4.7
22.9
53
115
212
Kela drug reimbursment
Gout
4.0
22.8
66
171
C50.51
ICD-10 Finland
Malignant tumor of the lower outer quadrant of the mammary gland, ductal tumor
4.5
22.7
56
128
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
4.8
22.7
51
108
N05CF01
ATC
zopiclone; oral
1.6
22.7
686
4828
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
8.2
22.7
30
37
H03AA01
ATC
levothyroxine sodium; systemic
1.7
22.5
497
3219
L01EX02
ATC
sorafenib; oral
52.6
22.1
26
5
L01EE01
ATC
trametinib; oral
52.6
22.1
26
5
UGC18
NOMESCO Finland
Flexible bronchoscopy with biopsy of lung
8.2
21.8
29
36
L01EA02
ATC
dasatinib; oral
222.3
21.6
22
*
L02AE03
ATC
goserelin; implant
5.1
21.0
44
88
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
5.0
20.9
45
92
JFB00
NOMESCO Finland
Partial resection of small intestine
4.2
20.9
56
137
L01XE29
ATC
[U] lenvatinib
+∞
20.9
20
*
C43.99
ICD-10 Finland
Unspecified localization of malignant melanoma of the skin other or unspecified histology
19.7
20.8
31
16
ZX100
NOMESCO Finland
Oral
4.6
20.8
49
108
OAB38
NOMESCO Finland
Psychosocial guidance and counselling
8.8
20.7
26
30
1BA04, ,
NOMESCO Finland
212.1
20.6
21
*
C49.4
ICD-10 Finland
Malignant neoplasm: Connective and soft tissue of abdomen
111.2
20.6
22
*
SPAT1245
SPAT
Provision of support and information to patient’s family members
2.7
20.5
114
440
C50
ICD-10 Finland
Malignant neoplasm of breast
3.4
20.5
75
228
B73
ICPC
Leukaemia
25.8
20.4
28
11
ZXE30
NOMESCO Finland
More than five and less than seven hours
2.6
20.4
126
512
L01XX52
ATC
venetoclax; oral
22.6
20.4
29
13
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
3.5
20.4
70
204
5BA08, ,
NOMESCO Finland
7.5
20.4
29
39
L01BB05
ATC
fludarabine; systemic
32.9
20.2
26
8
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.6
20.1
1017
8004
WB303
NOMESCO Finland
Simple adjuvant therapy of malignancy with biomodifiers
21.0
19.9
29
14
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
3.8
19.8
61
165
372
Kela drug reimbursment
Idelalisib
+∞
19.8
19
*
L01XE15
ATC
[U] vemurafenib
+∞
19.8
19
*
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.5
19.7
190
3535
C43.52
ICD-10 Finland
Malignant melanoma on the torso: 'superficial spreading' type
4.9
19.7
43
89
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
4.6
19.7
47
105
PJA10
NOMESCO Finland
Exploration of lymph nodes
4.6
19.7
47
105
C64.80
ICD-10 Finland
Wilms tumour
29.2
19.6
26
9
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
2.9
19.6
91
319
D77
ICPC
Malignant digestive neopl other/NOS
7.8
19.6
27
35
399
Kela drug reimbursment
Venetoclax
21.8
19.5
28
13
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
4.6
19.4
46
102
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
2.4
19.4
143
631
R11
ICD-10 Finland
Nausea and vomiting
2.1
19.3
199
1006
HA013
NOMESCO Finland
Radiotherapy after total ablation of mammary gland
4.1
19.2
52
128
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
3.8
19.2
58
155
ZXD10
NOMESCO Finland
Scheduled procedure
1.6
19.1
770
5741
TPH07
NOMESCO Finland
Cathetrisation of artery
1.9
19.0
277
1580
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
5.3
18.9
38
73
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
2.4
18.9
136
593
OAB43, ,
SPAT
0.4
18.9
101
2355
ZXA00
NOMESCO Finland
Right side
1.6
18.8
573
4004
EP1AE
NOMESCO Finland
Neck ultrasound examination
2.3
18.7
153
706
Z3226
NOMESCO Finland
Physiotherapist
1.7
18.7
387
2449
ZXE00
NOMESCO Finland
One hour or less
1.5
18.5
765
5725
H02AB09
ATC
hydrocortisone; systemic
3.4
18.5
68
207
C50.11
ICD-10 Finland
Malignant tumor of the central part of the mammary gland,ductal tumor
4.1
18.5
50
123
C10AX09
ATC
ezetimibe; oral
0.4
18.4
134
2764
C34.92
ICD-10 Finland
Malignant tumor in unspecified localization in bronchial and pulmonary adenocarcinoma
16.3
18.3
29
18
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
19.5
18.2
27
14
XX9BW
NOMESCO Finland
Submitting image material and/or investigation material to authority or other institution
4.1
18.1
49
121
D70.89
ICD-10 Finland
Neutropenic splenomegaly
4.6
18.0
43
96
C77.1
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrathoracic lymph nodes
15.5
18.0
29
19
SPAT1088
SPAT
Blood transfusion
6.7
17.9
28
42
J01DB01
ATC
cefalexin; oral
1.7
17.8
1630
14466
WW200
NOMESCO Finland
Immunization
3.2
17.8
71
228
C50.2
ICD-10 Finland
Malignant neoplasm: Upper-inner quadrant of breast
13.8
17.8
30
22
335
Kela drug reimbursment
Lapatinib
95.9
17.6
19
*
XW3AT
NOMESCO Finland
Biopsy of other superficial organ with ultrasound guidance
6.4
17.6
29
46
SPAT1269
SPAT
Other puncture and/or drainage
6.8
17.4
27
40
KAD00
NOMESCO Finland
Partial nephrectomy
6.8
17.4
27
40
A28
ICPC
Limited function/disability NOS
1.7
17.4
427
2821
N03AX16
ATC
[U] pregabalin
1.6
17.4
492
3367
C91.9
ICD-10 Finland
Lymphoid leukaemia, unspecified
21.1
17.3
25
12
3019
Kela drug reimbursment
Lenvatinib
42.4
17.3
21
5
KAC00
NOMESCO Finland
Nephrectomy
14.0
17.3
29
21
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
0.6
17.1
275
4405
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
5.1
17.0
35
69
JN3AD
NOMESCO Finland
Abdominal CT examination
1.8
16.9
307
1867
3002
Kela drug reimbursment
Ribociclib
25.8
16.9
23
9
1514, ,
Kela drug reimbursment
25.8
16.9
23
9
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
4.4
16.9
42
97
GD1AA, ,
SPAT
0.4
16.8
70
1828
N02AX02
ATC
tramadol; systemic, rectal
1.5
16.7
896
7038
NF3AA
NOMESCO Finland
Femur X-ray examination
3.1
16.7
68
221
EB4VA, ,
NOMESCO Finland
0.4
16.7
79
1947
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
3.3
16.6
63
196
L01EC03
ATC
encorafenib; oral
90.8
16.6
18
*
1XC14, ,
NOMESCO Finland
171.4
16.5
17
*
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
27.8
16.5
22
8
A41.9
ICD-10 Finland
Sepsis, unspecified
2.6
16.4
94
368
C79.7
ICD-10 Finland
Secondary malignant neoplasm of adrenal gland
20.2
16.4
24
12
WB133
NOMESCO Finland
Very demanding adjuvant cytostatic therapy
14.4
16.3
27
19
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
2.4
16.2
114
492
WPB10
NOMESCO Finland
Making a convalescent care decision
6.6
16.2
26
40
ZZF00
NOMESCO Finland
Graft of adipose tissue
5.5
16.2
31
57
TPW99
NOMESCO Finland
Other minor surgical procedure on peripheral vessel or lymphatic system
4.5
16.1
39
88
1508
Kela drug reimbursment
Lenvatinib
47.9
16.0
19
*
GDC01
NOMESCO Finland
Thoracoscopic lobectomy of lung
4.3
16.0
41
97
L01EF02
ATC
ribociclib; oral
21.1
16.0
23
11
XF400
NOMESCO Finland
ECG with 12 standard connections
1.7
15.9
344
2193
B03BA03
ATC
hydroxocobalamin; parenteral
2.2
15.9
132
612
N02BE01
ATC
paracetamol; systemic, rectal
1.9
15.9
1809
16654
XX9XW, ,
NOMESCO Finland
6.4
15.8
26
41
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
6.4
15.8
26
41
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.1
15.8
149
728
JN3KE
NOMESCO Finland
Abdominal ultrasound with added contrast
5.9
15.7
28
48
E83.50
ICD-10 Finland
Hypercalcemia
3.8
15.7
47
125
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.5
15.7
808
6275
L01XX47
ATC
[U] idelalisib
+∞
15.6
15
*
L01XE41
ATC
[U] binimetinib
+∞
15.6
15
*
L01XE46
ATC
[U] encorafenib
+∞
15.6
15
*
L03AB04
ATC
interferon alfa-2a; parenteral
19.4
15.6
23
12
C77.3
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Axillary and upper limb lymph nodes
11.8
15.5
28
24
325
Kela drug reimbursment
Erlotinib
161.2
15.5
16
*
L01EE03
ATC
binimetinib; oral
161.2
15.5
16
*
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
12.4
15.4
27
22
GDA11
NOMESCO Finland
Thoracoscopic biopsy of lung
12.4
15.4
27
22
C77.0
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
6.7
15.3
24
36
C17.9
ICD-10 Finland
Malignant neoplasm: Small intestine, unspecified
11.3
15.3
28
25
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
3.9
15.2
44
114
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
2.7
15.2
80
300
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
2.8
15.2
77
283
1518, ,
Kela drug reimbursment
17.9
15.1
23
13
8936/3-C16.9
ICD-O-3
Gastrointestinal stromal tumor of stomach, NOS
23.6
15.1
21
9
D07AA02
ATC
hydrocortisone; topical
1.8
15.1
251
1486
XGX32
NOMESCO Finland
Bronchoscopic ultrasonography
4.8
15.0
33
69
C50.49
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, other or undeterminated histology
3.6
14.9
49
139
C34.00
ICD-10 Finland
Malignant tumor of the main bronchus without histology
11.4
14.8
27
24
ZXA05
NOMESCO Finland
Left side
1.5
14.7
512
3656
9875/3-C42.1
ICD-O-3
Chronic myelogenous leukemia, BCR/ABL positive of bone marrow
+∞
14.6
14
*
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
4.1
14.5
40
100
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.5
14.5
828
6530
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.5
14.4
625
4671
AA1AD
NOMESCO Finland
CT of head and brain
1.5
14.3
640
4809
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
4.6
14.2
33
72
5BX04, ,
NOMESCO Finland
19.3
14.2
21
11
C50.5
ICD-10 Finland
Malignant neoplasm: Lower-outer quadrant of breast
13.5
14.2
24
18
D64.9
ICD-10 Finland
Anaemia, unspecified
1.7
14.2
254
1535
SPAT1254
SPAT
Administration of medicine
1.7
14.1
297
1876
ZZR10
NOMESCO Finland
Flap of skin and muscle
4.8
14.0
31
65
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
2.4
13.9
95
406
N05AD01
ATC
haloperidol; systemic
2.8
13.8
69
252
8936/1-C16.9
ICD-O-3
Gastrointestinal stromal tumor, NOS, of stomach, NOS
53.7
13.8
16
*
1XC07, ,
NOMESCO Finland
11.5
13.8
25
22
R06AE07
ATC
cetirizine; oral
1.4
13.8
796
6274
C34.99
ICD-10 Finland
Malignant tumor in unspecified localization in bronchial and pulmonary other or unspecified histology
5.7
13.7
25
44
ZXE40
NOMESCO Finland
More than seven and less than nine hours
3.0
13.6
59
199
OAA67, ,
SPAT
0.3
13.6
46
1333
170
Kela drug reimbursment
Bosutinib
+∞
13.6
13
*
363
Kela drug reimbursment
Crizotinib
140.9
13.5
14
*
C73
ICD-10 Finland
Malignant neoplasm of thyroid gland
12.9
13.4
23
18
GDG10
NOMESCO Finland
Bilateral transplantation of lung
25.9
13.4
18
7
Z94.2
ICD-10 Finland
Lung transplant status
21.3
13.3
19
9
QBB10
NOMESCO Finland
Major dressing of wound of skin of trunk
2.4
13.3
88
370
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
3.8
13.3
40
107
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
3.0
13.2
59
203
C34.9
ICD-10 Finland
Malignant neoplasm: Bronchus or lung, unspecified
5.0
13.1
28
57
YJ1AD
NOMESCO Finland
CT examination of abdomen for dose design of radiotherapy
12.2
13.1
23
19
OAB42, ,
SPAT
0.4
13.1
76
1725
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
3.3
13.0
49
152
1XC03, ,
NOMESCO Finland
10.1
13.0
25
25
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
19.2
12.9
19
10
C34.22
ICD-10 Finland
Malignant tumor of the middle lobe, bronchus or lung adenocarcinoma
19.2
12.9
19
10
PC2ET
NOMESCO Finland
Extensive embolisation of lesion of liver
19.2
12.9
19
10
EB1VA, ,
NOMESCO Finland
0.5
12.8
125
2351
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
4.8
12.6
28
59
1XC17, ,
NOMESCO Finland
+∞
12.5
12
*
ZX121
NOMESCO Finland
Central venous catheter
9.4
12.5
25
27
8260/3-C73.9
ICD-O-3
Papillary adenocarcinoma, NOS, of thyroid gland
3.8
12.5
37
98
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
20.2
12.5
18
9
8936/3-C17.9
ICD-O-3
Gastrointestinal stromal tumor of small intestine, NOS
130.8
12.4
13
*
8936/1-C17.9
ICD-O-3
Gastrointestinal stromal tumor, NOS, of small intestine, NOS
130.8
12.4
13
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
3.0
12.3
55
189
TQW99
NOMESCO Finland
Other minor procedure on skin
2.1
12.3
126
635
TQB05
NOMESCO Finland
Puncture of skin of trunk
4.3
12.2
31
73
L01
ICPC
Neck symptom/complaint
0.5
12.2
110
2123
C50.50
ICD-10 Finland
Malignant tumor of the lower outer quadrant of the mammary gland, no histological veryfication
12.5
12.1
21
17
V03AE01
ATC
polystyrene sulfonate; oral
3.7
12.1
38
105
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
26.9
12.0
16
6
N95.1
ICD-10 Finland
Menopausal and female climacteric states
0.4
12.0
48
1285
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
5.3
12.0
24
46
C10AA05
ATC
atorvastatin; oral
0.7
11.9
606
7681
1XC02, ,
NOMESCO Finland
4.9
11.9
26
54
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
4.9
11.9
26
54
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
2.2
11.9
102
480
M75.1
ICD-10 Finland
Rotator cuff syndrome
0.6
11.9
266
3980
XF600
NOMESCO Finland
Bloodpressure measurement
2.0
11.8
138
729
N05BA04
ATC
oxazepam; oral
1.5
11.8
493
3630
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
1.6
11.7
329
2226
C34.90
ICD-10 Finland
Malignant tumor in unspecified location in bronchus and lung without histology
4.0
11.7
32
80
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
16.5
11.7
18
11
C50.00
ICD-10 Finland
Malignant tumor of nipple and areola, no histological veryfication
4.8
11.7
26
55
WZC00, ,
SPAT
0.5
11.6
100
1964
XX1XW
NOMESCO Finland
Extensive written report from radiologist
2.9
11.5
54
191
B99
ICD-10 Finland
Other and unspecified infectious diseases
3.0
11.5
49
164
TJA10
NOMESCO Finland
Laparocentesis
8.7
11.5
24
28
QCE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in upper limb
2.6
11.5
66
260
L01XE14
ATC
[U] bosutinib
+∞
11.5
11
*
L01EB01
ATC
gefitinib; oral
+∞
11.5
11
*
P20
ICPC
Memory disturbance
0.5
11.4
120
2209
PHE70
NOMESCO Finland
Thrombectomy of inferior vena cava
120.7
11.4
12
*
ZX108
NOMESCO Finland
Inhalation
4.7
11.4
26
56
C50.20
ICD-10 Finland
Malignant tumor of the upper inner quadrant of the mammary gland,no histological veryfication
5.4
11.4
22
41
PJD55
NOMESCO Finland
Block dissection of inguinal lymph nodes
11.9
11.3
20
17
N07BC02
ATC
methadone; systemic
8.4
11.3
24
29
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.5
11.2
406
2901
A05AA02
ATC
ursodeoxycholic acid; oral
3.6
11.2
36
101
HAE05
NOMESCO Finland
Reconstruction of breast using soft tissue and prosthesis
5.6
11.2
21
38
C17.1
ICD-10 Finland
Malignant neoplasm: Jejunum
20.1
11.1
16
8
YG1CD
NOMESCO Finland
Very extensive CT examination of thorax for dose design of radiotherapy
5.3
11.1
22
42
TGD00
NOMESCO Finland
Needle biopsy of lung
5.3
11.1
22
42
NK6BQ
NOMESCO Finland
Whole body extensive bone SPET with low dose CT
4.3
11.0
28
66
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
2.1
11.0
99
475
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
1.7
11.0
207
1266
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
1.8
11.0
177
1036
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
0.6
10.9
168
2767
R4110, ,
SPAT
0.5
10.9
108
2023
YJ1BD
NOMESCO Finland
Extensive CT examination of abdomen for dose design of radiotherapy
15.6
10.8
17
11
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
3.7
10.8
34
94
L04AA06
ATC
mycophenolic acid; systemic
3.1
10.8
45
149
JA2AT
NOMESCO Finland
Abdominal puncture with ultrasound guidance
4.0
10.8
30
76
C20
ICD-10 Finland
Malignant neoplasm of rectum
4.5
10.7
26
59
FB1AD
NOMESCO Finland
CT examination of arteria pulmonalis
2.5
10.7
65
263
ZX114
NOMESCO Finland
Intramuscular
3.4
10.7
37
109
I26.0
ICD-10 Finland
Pulmonary embolism with mention of acute cor pulmonale
2.8
10.6
53
194
JAH00
NOMESCO Finland
Laparotomy
2.5
10.6
63
252
HA1DG
NOMESCO Finland
Very extensive MRI examination of mammary gland with high intensity magnet
4.2
10.6
28
68
XW4AT
NOMESCO Finland
Biopsy of other inner organ with ultrasound guidance
8.0
10.6
23
29
C43
ICD-10 Finland
Malignant melanoma of skin
9.2
10.5
21
23
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
14.3
10.5
17
12
8000/3-C22.0
ICD-O-3
Neoplasm, malignant of liver
14.3
10.5
17
12
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
0.7
10.5
316
4446
M25.5
ICD-10 Finland
Pain in joint
0.7
10.5
351
4835
M907, C6488,
ICD-10 Finland
110.6
10.4
11
*
L01ED01
ATC
crizotinib; oral
+∞
10.4
10
*
L15
ICPC
Knee symptom/complaint
0.6
10.4
261
3821
HAB40
NOMESCO Finland
Wedge excision of mammary gland
2.0
10.4
117
611
N06DX01
ATC
memantine; oral
0.3
10.4
29
926
GD6BD
NOMESCO Finland
Extensive CT of chest and neck
12.1
10.3
18
15
NG1AA, ,
SPAT
0.3
10.3
22
816
C50.80
ICD-10 Finland
Overall malignant tumor of the mammary gland, no histological veryfication
8.2
10.3
22
27
J02AC03
ATC
voriconazole; systemic
10.6
10.3
19
18
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
2.3
10.2
75
331
BCA30
NOMESCO Finland
Unilateral adrenalectomy
23.5
10.2
14
6
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
23.5
10.2
14
6
WVC10
NOMESCO Finland
Subcutaneous infusion of drugs
7.5
10.2
23
31
C34.10
ICD-10 Finland
Malignant tumor of the upper lobe, bronchus or lung without histology
3.7
10.2
31
84
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
2.8
10.1
51
188
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
5.3
10.1
20
38
L08
ICPC
Shoulder symptom/complaint
0.6
10.1
234
3489
C50.1
ICD-10 Finland
Malignant neoplasm: Central portion of breast
11.3
10.1
18
16
C43.79
ICD-10 Finland
Malignant melanoma of the lower extremity including hip or other unspecified histology
10.1
10.0
19
19
L02AB02
ATC
medroxyprogesterone; systemic
4.6
10.0
23
50
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
1.9
10.0
129
706
L82
ICD-10 Finland
Seborrhoeic keratosis
0.6
9.9
189
2952
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
0.6
9.9
149
2472
Z2221
NOMESCO Finland
Medical doctor
1.4
9.9
494
3746
PC2DT
NOMESCO Finland
Embolisation of lesion of liver
16.8
9.9
15
9
Z80.3
ICD-10 Finland
Family history of malignant neoplasm of breast
3.0
9.9
42
141
C78.1
ICD-10 Finland
Secondary malignant neoplasm of mediastinum
12.2
9.8
17
14
WX721
NOMESCO Finland
Oxygen concentrator therapy
8.2
9.8
21
26
HAD40
NOMESCO Finland
Mastopexy
8.2
9.8
21
26
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
2.9
9.8
45
158
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.4
9.8
504
3842
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
2.0
9.7
102
519
ZXD05
NOMESCO Finland
Urgent procedure
1.4
9.7
533
4110
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
55.3
9.6
11
*
HA1RA, ,
SPAT
0.2
9.6
7
420
GDC00
NOMESCO Finland
Lobectomy of lung
5.3
9.6
19
36
J96.1
ICD-10 Finland
Chronic respiratory failure
2.7
9.6
52
199
C83.1
ICD-10 Finland
Mantle cell lymphoma
8.4
9.6
20
24
J01CA04
ATC
amoxicillin; systemic
1.4
9.5
1525
13888
S50
ICPC
Skin, Medication/prescr/renewal
4.6
9.5
22
48
Z51.88
ICD-10 Finland
Other specified medical care
2.6
9.5
52
200
M84.4
ICD-10 Finland
Pathological fracture, not elsewhere classified
10.1
9.5
18
18
TJA40
NOMESCO Finland
Percutaneous local drainage of peritoneal cavity
15.1
9.5
15
10
I97.2
ICD-10 Finland
Postmastectomy lymphoedema syndrome
7.2
9.5
22
31
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
1.5
9.5
320
2248
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
2.0
9.4
96
484
8000/3-C64.9
ICD-O-3
Neoplasm, malignant of kidney, NOS
30.2
9.4
12
*
C16.29
ICD-10 Finland
Malignant tumor of the corpus ventriculi other or unspecified carcinoma
30.2
9.4
12
*
L01EX08
ATC
lenvatinib; oral
30.2
9.4
12
*
1XC13, ,
NOMESCO Finland
17.6
9.4
14
8
PJD43
NOMESCO Finland
Excision of aortic lymph nodes
17.6
9.4
14
8
SPAT1290
SPAT
Preparation of deceased person
12.4
9.4
16
13
XW1AT
NOMESCO Finland
Biopsy from other organ close to skin with ultrasound quidance
4.4
9.3
23
53
WZC30, ,
SPAT
0.4
9.3
49
1162
HA2AT
NOMESCO Finland
Cytology of mammary gland with ultrasound guidance
8.7
9.3
19
22
8260/3-C64.9
ICD-O-3
Papillary adenocarcinoma, NOS, of kidney, NOS
8.7
9.3
19
22
J05AB11
ATC
valaciclovir; oral
1.5
9.2
280
1922
R83
ICPC
Respiratory infection other
0.6
9.2
169
2670
C50.32
ICD-10 Finland
Malignant tumor of the lower inner quadrant of the mammary gland, lobular tumor
13.7
9.2
15
11
C50.12
ICD-10 Finland
Malignant tumor of the central part of the mammary gland,lobular tumor
5.0
9.1
19
38
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
4.8
9.1
20
42
D75.2
ICD-10 Finland
Essential thrombocytosis
4.6
9.1
21
46
WF099
NOMESCO Finland
Other radiotherapy
4.6
9.1
21
46
HA1CM
NOMESCO Finland
Mammary gland extensive MRI examination with 3 Tesla magnet
11.5
9.1
16
14
QBE20
NOMESCO Finland
Excision and repair of scar or web of skin of trunk
4.0
9.1
25
63
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
15.6
9.0
14
9
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
1.6
9.0
213
1381
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
4.2
8.9
23
55
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
3.3
8.9
32
97
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.5
8.9
297
2081
C22.9
ICD-10 Finland
Malignant neoplasm: Liver, unspecified
6.8
8.8
21
31
K74.6
ICD-10 Finland
Other and unspecified cirrhosis of liver
2.9
8.8
39
134
JMA10
NOMESCO Finland
Transabdominal total splenectomy
4.7
8.8
20
43
C43.7
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of lower limb, including hip
9.5
8.8
17
18
1CD01, ,
NOMESCO Finland
9.5
8.8
17
18
M54.5
ICD-10 Finland
Low back pain
0.7
8.7
415
5400
C43.9
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of skin, unspecified
14.1
8.7
14
10
C50.3
ICD-10 Finland
Malignant neoplasm: Lower-inner quadrant of breast
14.1
8.7
14
10
WD705, ,
NOMESCO Finland
50.2
8.7
10
*
M90.7
ICD-10 Finland
Fracture of bone in neoplastic disease
50.2
8.7
10
*
C43.90
ICD-10 Finland
Unspecified localization of malignant melanoma of the skin without histology
50.2
8.7
10
*
SPAT1276
SPAT
Outlining of treatment with patient or their family members
2.5
8.7
51
204
ND2AA, ,
SPAT
0.2
8.7
9
429
S77
ICPC
Malignant neoplasm of skin
3.2
8.7
34
109
L01AA01
ATC
cyclophosphamide; systemic
6.6
8.7
21
32
M79.6
ICD-10 Finland
Pain in limb
0.7
8.6
570
7037
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
4.8
8.6
19
40
207
Kela drug reimbursment
Chronic arrhythmias
0.6
8.6
162
2541
JN4ED
NOMESCO Finland
Body CT examination with specail preparation
16.4
8.5
13
8
EBA15
NOMESCO Finland
Extraction of multiple teeth
2.0
8.5
88
446
F51.0
ICD-10 Finland
Nonorganic insomnia
0.6
8.5
109
1896
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
3.4
8.5
29
85
C50.10
ICD-10 Finland
Malignant tumor of the central part of the mammary gland, no histological veryfication
7.4
8.4
19
26
8936/3-C26.9
ICD-O-3
Gastrointestinal stromal tumor of gastrointestinal tract, NOS
90.4
8.4
9
*
A10BK03
ATC
empagliflozin; oral
0.5
8.4
83
1562
A98
ICPC
Health maint/preventive medicine
0.7
8.4
1757
18353
XX1AT
NOMESCO Finland
Other puncture with ultrasound guidance
3.1
8.4
33
106
C79.3
ICD-10 Finland
Secondary malignant neoplasm of brain and cerebral meninges
12.8
8.4
14
11
C50.30
ICD-10 Finland
Malignant tumor of the lower inner quadrant of the mammary gland, no histological veryfication
12.8
8.4
14
11
WPA13
NOMESCO Finland
Palliative consultation
4.7
8.4
19
41
M05BA02
ATC
clodronic acid; systemic
4.7
8.4
19
41
373
Kela drug reimbursment
Ponatinib
+∞
8.3
8
*
360
Kela drug reimbursment
Bosutinib
+∞
8.3
8
*
Z01.7
ICD-10 Finland
Laboratory examination
0.6
8.3
141
2275
A46
ICD-10 Finland
Erysipelas
1.5
8.3
297
2107
M01AH05
ATC
etoricoxib; oral
0.8
8.3
882
10200
3AA13, ,
NOMESCO Finland
10.8
8.3
15
14
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
1.7
8.3
166
1033
OAB44, ,
SPAT
0.4
8.3
54
1174
C50.31
ICD-10 Finland
Malignant tumor of the lower inner quadrant of the mammary gland, ductal tumor
3.1
8.3
33
107
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
1.5
8.2
292
2069
C77.9
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph node, unspecified
14.5
8.2
13
9
Z51.0
ICD-10 Finland
Radiotherapy session
2.9
8.2
37
129
C50.52
ICD-10 Finland
Malignant tumor of the lower outer quadrant of the mammary gland, lobular tumor
6.5
8.2
20
31
XX9AW
NOMESCO Finland
Production of copy from X-ray picture
2.2
8.1
67
312
J01FF01
ATC
clindamycin; systemic
1.4
8.1
499
3902
OAB48, ,
SPAT
0.5
8.1
60
1244
ZX122
NOMESCO Finland
Intra-arterial
8.2
8.1
17
21
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
3.8
8.1
24
64
C34.01
ICD-10 Finland
Malignant tumor of the main bronchial epidermoid carcinoma
17.2
8.1
12
7
HAE99
NOMESCO Finland
Other reconstruction of breast
4.0
8.1
22
55
I31.9
ICD-10 Finland
Disease of pericardium, unspecified
4.0
8.1
22
55
QX3HE
NOMESCO Finland
Ultrsound examination of lesion close to skin
2.8
8.0
38
136
G30.1
ICD-10 Finland
Alzheimer disease with late onset
0.3
8.0
23
721
N06DA02
ATC
donepezil; oral
0.3
8.0
24
735
C34.11
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary epidermoid carcinoma
3.7
7.9
24
65
Z42.1
ICD-10 Finland
Follow-up care involving plastic surgery of breast
4.6
7.9
18
39
C43.73
ICD-10 Finland
Malignant melanoma of the lower extremity including the hip nodular
13.1
7.9
13
10
8500/3-C50.4
ICD-O-3
Infiltrating duct carcinoma, NOS, of upper-outer quadrant of breast
2.4
7.9
51
214
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
10.8
7.8
14
13
GD2CT
NOMESCO Finland
Cytology of the lungs with CT guidance
10.8
7.8
14
13
X19
ICPC
Breast lump/mass female
3.0
7.8
33
111
C43.69
ICD-10 Finland
Malignant melanoma of the upper extremity including shoulder other or unspecified histology
7.0
7.8
18
26
C50.59
ICD-10 Finland
Malignant tumor of the lower outer quadrant of the mammary gland, other or undeterminated histology
7.0
7.8
18
26
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
2.0
7.7
83
427
NAR00
NOMESCO Finland
Complete excision of tumour of bone or cartilage of spine, unspecified
45.2
7.7
9
*
C34.2
ICD-10 Finland
Malignant neoplasm: Middle lobe, bronchus or lung
15.1
7.7
12
8
XX4BW, ,
NOMESCO Finland
15.1
7.7
12
8
TPX15
NOMESCO Finland
Removal of vascular injection port
6.4
7.7
19
30
HAD30
NOMESCO Finland
Reduction mammoplasty with transposition of areola
2.2
7.7
64
299
R96
ICPC
Asthma
0.5
7.7
68
1325
T88.7
ICD-10 Finland
Unspecified adverse effect of drug or medicament
2.8
7.7
37
134
B01AF01
ATC
rivaroxaban; oral
0.6
7.6
118
1950
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
2.5
7.6
44
175
C50.93
ICD-10 Finland
Malignant tumor in other specified localization in mammary gland other or unspecified histology
8.1
7.6
16
20
JN5PN
NOMESCO Finland
Isotope imaging of secondary neoplasms of thyroid origin
8.1
7.6
16
20
1506
Kela drug reimbursment
The combination of trifluridine and tipiracil
8.1
7.6
16
20
3018
Kela drug reimbursment
The combination of trifluridine and tipiracil
8.1
7.6
16
20
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
3.6
7.6
24
67
C34.02
ICD-10 Finland
Malignant tumor of the main bronchial adenocarcinoma
25.1
7.6
10
*
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
2.1
7.6
68
328
L03
ICPC
Low back symptom/complaint
0.7
7.6
316
4220
M15.9
ICD-10 Finland
Polyarthrosis, unspecified
0.4
7.6
36
888
C26.9
ICD-10 Finland
Malignant neoplasm: Ill-defined sites within the digestive system
8.9
7.5
15
17
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
3.4
7.5
26
77
G47.3
ICD-10 Finland
Sleep apnoea
0.7
7.5
243
3402
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
1.7
7.5
133
801
QB9S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in torso, unspecified
4.3
7.5
19
45
ZZA00
NOMESCO Finland
Split skin graft
2.2
7.4
60
277
ZXK00
NOMESCO Finland
Conversion from percutaneous endoscopic to open procedure
3.9
7.4
21
54
GDA97
NOMESCO Finland
Other thoracoscopic incision, excision of lesion or repair of lung
80.4
7.4
8
*
WC501
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of local recurrence of tumour
80.4
7.4
8
*
GD1BA
NOMESCO Finland
Extensive X-ray examination of thorax
3.2
7.4
28
88
ZYC01, ,
SPAT
0.5
7.4
60
1205
8720/3-C44.9
ICD-O-3
Malignant melanoma, NOS, of skin, NOS
3.3
7.4
27
83
A07AA02
ATC
nystatin; oral
1.8
7.4
114
661
TQW40, ,
SPAT
0.5
7.4
75
1397
379
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep veinthrombosis and pulmonary embolism
2.1
7.3
64
305
E000001, ,
ATC
1.4
7.3
324
2391
JLC10
NOMESCO Finland
Distal pancreatectomy
8.4
7.3
15
18
3026
Kela drug reimbursment
Lorlatinib
+∞
7.3
7
*
WB502
NOMESCO Finland
Demanding pharmacotherapy for primary neoplasm, enzyme inhibitor or similar agent
+∞
7.3
7
*
WA010
NOMESCO Finland
Adjuvant whole body radiotherapy
+∞
7.3
7
*
3017
Kela drug reimbursment
Brigatinib
+∞
7.3
7
*
L01EB02
ATC
erlotinib; oral
+∞
7.3
7
*
8936/3-C17.1
ICD-O-3
Gastrointestinal stromal tumor of jejunum
+∞
7.3
7
*
JN4DD
NOMESCO Finland
Scout CT scan of torso
10.9
7.3
13
12
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
6.8
7.3
17
25
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
6.8
7.3
17
25
C83.00
ICD-10 Finland
Lymphocytic lymphoma
9.4
7.3
14
15
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
3.5
7.3
24
69
ZXE50
NOMESCO Finland
More than nine and less than 12 hours
3.0
7.2
31
105
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
2.2
7.2
61
287
NB6AA
NOMESCO Finland
Humerus X-ray examination
2.3
7.2
51
223
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
4.0
7.2
20
51
1XC08, ,
NOMESCO Finland
30.1
7.1
9
*
C79.6
ICD-10 Finland
Secondary malignant neoplasm of ovary
30.1
7.1
9
*
C95.9
ICD-10 Finland
Leukaemia, unspecified
30.1
7.1
9
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
2.6
7.1
40
157
HA1AA, ,
SPAT
0.0
7.1
*
207
GDB10
NOMESCO Finland
Wedge resection of lung
12.1
7.1
12
10
C25.4
ICD-10 Finland
Malignant neoplasm: Endocrine pancreas
12.1
7.1
12
10
G04BD12
ATC
mirabegron; oral
0.6
7.1
113
1852
J91
ICD-10 Finland
Pleural effusion in conditions classified elsewhere
10.1
7.0
13
13
HAB00
NOMESCO Finland
Excision of lesion of mammary gland
2.3
7.0
52
232
SPAT1262
SPAT
Handing over of treatment supplies
1.4
7.0
330
2462
L04AX03
ATC
methotrexate; systemic
0.5
7.0
59
1167
WD315
NOMESCO Finland
Multiple therapy of methastized malignancy with biomodifiers
6.3
6.9
17
27
D76
ICPC
Malignant neoplasm pancreas
6.3
6.9
17
27
G20
ICD-10 Finland
Parkinson disease
0.2
6.9
7
336
R99
ICD-10 Finland
Other ill-defined and unspecified causes of mortality
2.2
6.9
55
253
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
2.3
6.9
52
234
M70.6
ICD-10 Finland
Trochanteric bursitis
0.6
6.9
117
1888
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
1.6
6.8
144
908
D13.1
ICD-10 Finland
Benign neoplasm: Stomach
2.3
6.8
47
203
M17.9
ICD-10 Finland
Gonarthrosis, unspecified
0.6
6.8
120
1920
YX9AW, ,
NOMESCO Finland
3.8
6.8
20
53
E66.01
ICD-10 Finland
Obesity due to excess calories
0.5
6.8
45
972
N06DA03
ATC
rivastigmine; oral, transdermal
0.3
6.8
14
526
L13
ICPC
Hip symptom/complaint
0.7
6.8
218
3061
C43.6
ICD-10 Finland
Malignant neoplasm: Malignant melanoma of upper limb, including shoulder
11.0
6.8
12
11
8249/3-C25.9
ICD-O-3
Neuroendocrine tumor, grade 2 of pancreas, NOS
40.2
6.8
8
*
8140/3-C34.2
ICD-O-3
Adenocarcinoma, NOS, of middle lobe, lung
40.2
6.8
8
*
OAA65, ,
SPAT
0.5
6.8
70
1297
TPH00
NOMESCO Finland
Phlebotomy
4.3
6.8
17
40
L71
ICPC
Malignant neoplasm musculoskeletal
16.7
6.7
10
6
L04AD01
ATC
ciclosporin; systemic
2.6
6.7
36
138
JN1BD
NOMESCO Finland
Extensive CT examination of upper part of abdomen
3.9
6.7
19
49
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
0.6
6.7
148
2245
L01AA02
ATC
chlorambucil; oral
7.2
6.7
15
21
X21
ICPC
Breast sympt/compl female other
2.5
6.7
40
162
KAC01
NOMESCO Finland
Percutaneous endoscopic nephrectomy
22.6
6.7
9
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
1.4
6.7
370
2836
N17
ICPC
Vertigo/dizziness
0.6
6.7
114
1837
M19.0
ICD-10 Finland
Primary arthrosis of other joints
0.6
6.6
83
1453
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
1.9
6.6
79
423
9761/3-C42.0
ICD-O-3
Waldenstrom macroglobulinemia of blood
12.3
6.6
11
9
R06.0
ICD-10 Finland
Dyspnoea
1.3
6.6
530
4296
C50.22
ICD-10 Finland
Malignant tumor of the upper inner quadrant of the mammary gland,lobular tumor
4.2
6.5
17
41
E86
ICD-10 Finland
Volume depletion
2.2
6.5
53
246
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
10.1
6.5
12
12
F00.10*G30.1
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
0.2
6.5
8
345
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
0.7
6.5
306
4020
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.4
6.5
254
1832
B81
ICPC
Anaemia vit B12/folate deficiency
1.9
6.5
78
419
JN3AE, ,
SPAT
0.2
6.4
9
362
N03AX18
ATC
lacosamide; systemic
3.9
6.4
18
46
L17
ICPC
Foot/toe symptom/complaint
0.7
6.4
376
4775
8936/1-C17.1
ICD-O-3
Gastrointestinal stromal tumor, NOS, of jejunum
70.1
6.4
7
*
I10
ICD-10 Finland
Essential (primary) hypertension
0.8
6.4
1031
11495
JAH01
NOMESCO Finland
Laparoscopy
1.9
6.4
75
399
JN1AE, ,
SPAT
0.2
6.4
5
280
N17.9
ICD-10 Finland
Acute renal failure, unspecified
1.8
6.4
91
516
DM1QA, ,
SPAT
0.2
6.4
5
283
9962/3-C42.1
ICD-O-3
Essential thrombocythemia of bone marrow
6.6
6.3
15
23
GD2AT
NOMESCO Finland
Cytology of the lungs with ultrasound guidance
8.2
6.3
13
16
E03.2
ICD-10 Finland
Hypothyroidism due to medicaments and other exogenous substances
6.0
6.3
16
27
GAC00
NOMESCO Finland
Biopsy of pleura
6.0
6.3
16
27
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
11.1
6.3
11
10
J70.0
ICD-10 Finland
Acute pulmonary manifestations due to radiation
9.3
6.3
12
13
JJ6LT
NOMESCO Finland
Coagulation of focal hepatic lesion under ultrasound guidance
9.3
6.3
12
13
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
0.2
6.3
6
298
L01XE24
ATC
[U] ponatinib
+∞
6.3
6
*
L01EA04
ATC
bosutinib; oral
+∞
6.3
6
*
L01ED05
ATC
lorlatinib; oral
+∞
6.3
6
*
1529, ,
Kela drug reimbursment
+∞
6.3
6
*
T93
ICPC
Lipid disorder
0.5
6.2
54
1060
KA1AE
NOMESCO Finland
Kidney ultrasound examination
2.1
6.2
53
251
JFA73
NOMESCO Finland
Excision of lesion of small intestine
26.8
6.2
8
*
YX9CD
NOMESCO Finland
Other very extensive CT eamination for dose design of radiotherapy
26.8
6.2
8
*
WD215
NOMESCO Finland
Multiple therapy of methastized malignancy with hormones
7.0
6.2
14
20
WZA10
NOMESCO Finland
Extensive medical or dental certificate
2.7
6.2
31
115
G03CA03
ATC
estradiol; nasal, systemic, rectal, transdermal, vaginal
0.8
6.2
596
7078
A09AA02
ATC
multienzymes (lipase, protease etc.); oral
2.2
6.2
50
232
D19
ICPC
Teeth/gum symptom/complaint
0.7
6.2
323
4176
Z63.7
ICD-10 Finland
Other stressful life events affecting family and household
3.1
6.2
24
77
RS221, ,
NOMESCO Finland
2.8
6.2
29
104
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
2.9
6.2
27
93
3AC01, ,
NOMESCO Finland
3.2
6.1
23
72
PG1PT
NOMESCO Finland
Extensive endovascular embolisation for bleeding with radiological guidance not elsewhere classified
5.8
6.1
16
28
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
1.8
6.1
93
537
GAA31
NOMESCO Finland
Thoracoscopy
7.7
6.1
13
17
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
7.7
6.1
13
17
SDA01
NOMESCO Finland
Periodontal treatment, very brief
0.7
6.1
281
3709
SPAT1229
SPAT
Assessment of need for aid
1.6
6.1
144
934
ECB20
NOMESCO Finland
Oral alveoplasty
2.9
6.1
28
99
HA3AT
NOMESCO Finland
Pucture of mammary gland cyst with ultrasound examination
4.1
6.1
16
39
M90.7*C90.0
ICD-10 Finland
Pathological fracture in multiple myeloma
12.6
6.1
10
8
1AA09, ,
NOMESCO Finland
12.6
6.1
10
8
KKB10
NOMESCO Finland
Excision of retroperitoneal tumour
12.6
6.1
10
8
H02
ICPC
Hearing complaint
0.7
6.1
160
2338
C88.0
ICD-10 Finland
Waldenström macroglobulinaemia
6.7
6.0
14
21
WB323
NOMESCO Finland
Demanding adjuvant therapy of malignancy with biomodifiers
10.0
6.0
11
11

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Pharmacy visit
OMOP4822462 [581458]
5.3e-01
1.6e+00
1.1e+00
8.9e+00
1.7e+00
5.0e+00
1.0e+50
cases:98.55%
controls:97.56%
cases:98.40%
controls:92.32%
cases:80.40%
controls:57.70%
cases:99.55%
controls:2.98%
cases:87.95%
controls:57.52%
cases:99.95%
controls:92.47%
cases:100.00%
controls:98.19%
1971
19512
29
488
1968
18464
32
1536
1608
11541
392
8459
1991
596
9
19404
1759
11495
241
8490
1866
18291
1
1490
1191
18407
0
340
Other malignant neoplasm of kidney, except renal pelvis
C64.88 [2000501096]
3.3e+00
4.3e+00
6.2e+00
—
5.3e+00
4.4e+00
3.9e+00
cases:6.15%
controls:0.24%
cases:14.80%
controls:0.25%
cases:16.20%
controls:0.04%
—
—
cases:13.50%
controls:0.08%
cases:17.51%
controls:0.25%
cases:16.46%
controls:0.42%
123
48
1877
19952
296
49
1704
19951
324
8
1676
19992
—
270
16
1730
19969
327
50
1540
19731
196
78
995
18669
Medical Oncology
90 [38004507]
2.1e+00
3.0e+00
4.8e+00
4.8e+00
4.4e+00
3.9e+00
3.2e+00
cases:30.95%
controls:5.18%
cases:45.20%
controls:4.07%
cases:64.30%
controls:1.45%
cases:11.35%
controls:0.11%
cases:54.70%
controls:1.46%
cases:67.22%
controls:3.99%
cases:64.65%
controls:6.74%
619
1036
1381
18964
904
813
1096
19187
1286
290
714
19710
227
22
1773
19978
1094
291
906
19694
1255
789
612
18992
770
1264
421
17483
Other interstitial pulmonary diseases with fibrosis
J84.1 [45557630]
3.1e+00
4.0e+00
5.3e+00
1.0e+50
5.0e+00
4.2e+00
3.8e+00
cases:4.25%
controls:0.20%
cases:8.75%
controls:0.18%
cases:7.15%
controls:0.04%
cases:0.50%
controls:0.00%
cases:5.00%
controls:0.04%
cases:10.18%
controls:0.17%
cases:12.17%
controls:0.30%
85
40
1915
19960
175
36
1825
19964
143
8
1857
19992
10
0
1990
20000
100
7
1900
19978
190
33
1677
19748
145
56
1046
18691
Secondary malignant neoplasm of other specified sites
C79.8 [45547524]
3.4e+00
3.7e+00
4.6e+00
—
4.4e+00
4.3e+00
4.3e+00
cases:6.40%
controls:0.24%
cases:10.25%
controls:0.28%
cases:13.10%
controls:0.16%
—
—
cases:10.55%
controls:0.15%
cases:19.98%
controls:0.32%
cases:26.78%
controls:0.50%
128
47
1872
19953
205
56
1795
19944
262
31
1738
19969
—
211
30
1789
19955
373
64
1494
19717
319
93
872
18654
Metastasis
OMOP4998856 [36769180]
3.4e+00
3.7e+00
4.6e+00
—
4.4e+00
4.3e+00
4.3e+00
cases:6.45%
controls:0.24%
cases:10.25%
controls:0.28%
cases:13.25%
controls:0.16%
—
—
cases:10.55%
controls:0.15%
cases:19.98%
controls:0.32%
cases:26.78%
controls:0.51%
129
48
1871
19952
205
56
1795
19944
265
31
1735
19969
—
211
30
1789
19955
373
64
1494
19717
319
95
872
18652
Metastasis to lung
OMOP4999962 [36770283]
3.4e+00
4.0e+00
4.6e+00
1.0e+50
4.3e+00
4.3e+00
3.7e+00
cases:1.95%
controls:0.07%
cases:4.55%
controls:0.09%
cases:4.75%
controls:0.05%
cases:0.60%
controls:0.00%
cases:3.60%
controls:0.05%
cases:7.71%
controls:0.12%
cases:8.90%
controls:0.25%
39
13
1961
19987
91
18
1909
19982
95
10
1905
19990
12
0
1988
20000
72
10
1928
19975
144
23
1723
19758
106
46
1085
18701
Secondary malignant neoplasm of lung
C78.0 [45537839]
3.4e+00
4.0e+00
4.6e+00
1.0e+50
4.3e+00
4.3e+00
3.7e+00
cases:1.95%
controls:0.07%
cases:4.55%
controls:0.09%
cases:4.75%
controls:0.05%
cases:0.60%
controls:0.00%
cases:3.60%
controls:0.05%
cases:7.71%
controls:0.12%
cases:8.90%
controls:0.25%
39
13
1961
19987
91
18
1909
19982
95
10
1905
19990
12
0
1988
20000
72
10
1928
19975
144
23
1723
19758
106
46
1085
18701
Simple therapy of methastized malignancy with biomodifiers
WD305 [2001310685]
3.1e+00
4.0e+00
4.5e+00
—
3.9e+00
4.5e+00
3.6e+00
cases:2.25%
controls:0.10%
cases:2.55%
controls:0.05%
cases:2.10%
controls:0.03%
—
—
cases:1.45%
controls:0.03%
cases:5.62%
controls:0.07%
cases:7.64%
controls:0.22%
45
20
1955
19980
51
10
1949
19990
42
5
1958
19995
—
29
6
1971
19979
105
13
1762
19768
91
42
1100
18705
Metastasis to bone marrow
OMOP5031538 [35226074]
3.2e+00
3.8e+00
4.5e+00
—
4.0e+00
4.2e+00
3.5e+00
cases:3.45%
controls:0.14%
cases:6.70%
controls:0.17%
cases:6.70%
controls:0.08%
—
—
cases:5.50%
controls:0.11%
cases:9.69%
controls:0.17%
cases:11.92%
controls:0.41%
69
29
1931
19971
134
33
1866
19967
134
16
1866
19984
—
110
22
1890
19963
181
33
1686
19748
142
76
1049
18671
Secondary malignant neoplasm of bone and bone marrow
C79.5 [45571540]
3.2e+00
3.8e+00
4.5e+00
—
4.0e+00
4.2e+00
3.5e+00
cases:3.45%
controls:0.14%
cases:6.70%
controls:0.17%
cases:6.70%
controls:0.08%
—
—
cases:5.50%
controls:0.11%
cases:9.69%
controls:0.17%
cases:11.92%
controls:0.41%
69
29
1931
19971
134
33
1866
19967
134
16
1866
19984
—
110
22
1890
19963
181
33
1686
19748
142
76
1049
18671
Metastasis to bone
OMOP4998978 [36769301]
3.2e+00
3.8e+00
4.5e+00
—
4.0e+00
4.2e+00
3.5e+00
cases:3.45%
controls:0.14%
cases:6.70%
controls:0.17%
cases:6.70%
controls:0.08%
—
—
cases:5.50%
controls:0.11%
cases:9.69%
controls:0.17%
cases:11.92%
controls:0.41%
69
29
1931
19971
134
33
1866
19967
134
16
1866
19984
—
110
22
1890
19963
181
33
1686
19748
142
76
1049
18671
Radiotherapy of metastasis
WF049 [2001310705]
3.0e+00
3.9e+00
4.4e+00
1.0e+50
4.0e+00
3.8e+00
3.5e+00
cases:3.45%
controls:0.18%
cases:6.85%
controls:0.16%
cases:3.70%
controls:0.05%
cases:0.35%
controls:0.00%
cases:1.35%
controls:0.03%
cases:8.19%
controls:0.20%
cases:16.29%
controls:0.58%
69
36
1931
19964
137
31
1863
19969
74
9
1926
19991
7
0
1993
20000
27
5
1973
19980
153
40
1714
19741
194
108
997
18639
Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay
83083-6 [42529200]
3.0e+00
3.6e+00
4.9e+00
—
3.8e+00
3.8e+00
3.0e+00
cases:2.35%
controls:0.12%
cases:5.65%
controls:0.17%
cases:5.30%
controls:0.04%
—
—
cases:1.30%
controls:0.03%
cases:6.48%
controls:0.15%
cases:7.56%
controls:0.39%
47
23
1953
19977
113
34
1887
19966
106
8
1894
19992
—
26
6
1974
19979
121
30
1746
19751
90
74
1101
18673
Malignant tumor of the lower lobe, bronchus or lung adenocarcinoma
C34.32 [2000500619]
3.0e+00
3.5e+00
4.5e+00
—
3.6e+00
3.7e+00
3.5e+00
cases:1.05%
controls:0.06%
cases:2.30%
controls:0.07%
cases:2.60%
controls:0.03%
—
—
cases:1.85%
controls:0.05%
cases:3.05%
controls:0.08%
cases:3.44%
controls:0.11%
21
11
1979
19989
46
14
1954
19986
52
6
1948
19994
—
37
10
1963
19975
57
16
1810
19765
41
20
1150
18727
Chronic lymphocytic leukaemia of B-cell type
C91.1 [45600564]
2.9e+00
3.2e+00
4.6e+00
1.0e+50
4.2e+00
3.1e+00
3.1e+00
cases:3.05%
controls:0.17%
cases:3.45%
controls:0.15%
cases:3.35%
controls:0.04%
cases:0.35%
controls:0.00%
cases:2.85%
controls:0.05%
cases:3.54%
controls:0.17%
cases:5.12%
controls:0.24%
61
33
1939
19967
69
30
1931
19970
67
7
1933
19993
7
0
1993
20000
57
9
1943
19976
66
33
1801
19748
61
45
1130
18702
Hematology
82 [38004501]
1.9e+00
2.6e+00
3.7e+00
3.6e+00
3.6e+00
2.9e+00
2.8e+00
cases:9.50%
controls:1.49%
cases:11.55%
controls:0.99%
cases:12.60%
controls:0.35%
cases:2.05%
controls:0.06%
cases:11.65%
controls:0.37%
cases:15.80%
controls:1.05%
cases:25.02%
controls:2.08%
190
298
1810
19702
231
198
1769
19802
252
69
1748
19931
41
11
1959
19989
233
74
1767
19911
295
208
1572
19573
298
390
893
18357
Malignant tumor of the anterior, bronchial or pulmonary adenocarcinoma
C34.12 [2000500601]
2.2e+00
3.0e+00
4.8e+00
—
4.5e+00
3.5e+00
2.7e+00
cases:1.25%
controls:0.14%
cases:2.90%
controls:0.14%
cases:3.60%
controls:0.03%
—
—
cases:3.00%
controls:0.04%
cases:4.02%
controls:0.13%
cases:3.53%
controls:0.25%
25
27
1975
19973
58
29
1942
19971
72
6
1928
19994
—
60
7
1940
19978
75
26
1792
19755
42
47
1149
18700
Malignant neoplasm breast female
X76 [2002001361]
1.9e+00
2.9e+00
4.0e+00
1.0e+50
4.6e+00
3.6e+00
3.5e+00
cases:2.40%
controls:0.35%
cases:2.75%
controls:0.15%
cases:2.15%
controls:0.04%
cases:0.30%
controls:0.00%
cases:2.80%
controls:0.03%
cases:5.20%
controls:0.15%
cases:7.72%
controls:0.26%
48
70
1952
19930
55
30
1945
19970
43
8
1957
19992
6
0
1994
20000
56
6
1944
19979
97
30
1770
19751
92
48
1099
18699
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
9.6e-01
2.2e+00
4.1e+00
3.4e+00
4.0e+00
3.1e+00
2.5e+00
cases:25.85%
controls:11.82%
cases:48.15%
controls:9.24%
cases:51.45%
controls:1.78%
cases:2.90%
controls:0.10%
cases:50.95%
controls:1.78%
cases:69.09%
controls:9.09%
cases:81.78%
controls:26.89%
517
2365
1483
17635
963
1848
1037
18152
1029
356
971
19644
58
20
1942
19980
1019
356
981
19629
1290
1799
577
17982
974
5042
217
13705
Spread to lymph node
OMOP4998263 [36768587]
2.3e+00
3.2e+00
4.5e+00
1.0e+50
3.6e+00
3.7e+00
2.7e+00
cases:1.40%
controls:0.14%
cases:2.45%
controls:0.11%
cases:3.10%
controls:0.04%
cases:0.55%
controls:0.00%
cases:2.15%
controls:0.06%
cases:4.02%
controls:0.10%
cases:4.28%
controls:0.30%
28
28
1972
19972
49
21
1951
19979
62
7
1938
19993
11
0
1989
20000
43
12
1957
19973
75
20
1792
19761
51
56
1140
18691
Overall malignant tumor of the mammary gland, ductal tumor
C50.81 [2000501014]
2.6e+00
2.9e+00
4.0e+00
—
4.4e+00
3.0e+00
2.9e+00
cases:2.55%
controls:0.19%
cases:3.10%
controls:0.18%
cases:2.85%
controls:0.06%
—
—
cases:2.45%
controls:0.03%
cases:2.84%
controls:0.14%
cases:4.11%
controls:0.24%
51
38
1949
19962
62
35
1938
19965
57
11
1943
19989
—
49
6
1951
19979
53
28
1814
19753
49
45
1142
18702
Metastasis to liver
OMOP5000224 [36770544]
2.9e+00
3.0e+00
3.8e+00
1.0e+50
3.4e+00
3.4e+00
2.9e+00
cases:2.40%
controls:0.14%
cases:3.65%
controls:0.18%
cases:3.70%
controls:0.09%
cases:0.55%
controls:0.00%
cases:3.05%
controls:0.11%
cases:5.36%
controls:0.20%
cases:6.63%
controls:0.37%
48
28
1952
19972
73
36
1927
19964
74
17
1926
19983
11
0
1989
20000
61
22
1939
19963
100
39
1767
19742
79
70
1112
18677
Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.7 [45595688]
2.9e+00
3.0e+00
3.8e+00
1.0e+50
3.4e+00
3.4e+00
2.9e+00
cases:2.40%
controls:0.14%
cases:3.65%
controls:0.18%
cases:3.70%
controls:0.09%
cases:0.55%
controls:0.00%
cases:3.05%
controls:0.11%
cases:5.36%
controls:0.20%
cases:6.63%
controls:0.37%
48
28
1952
19972
73
36
1927
19964
74
17
1926
19983
11
0
1989
20000
61
22
1939
19963
100
39
1767
19742
79
70
1112
18677
Metastasis to intrahepatic bile ducts
OMOP5031661 [35226180]
2.9e+00
3.0e+00
3.8e+00
1.0e+50
3.4e+00
3.4e+00
2.9e+00
cases:2.40%
controls:0.14%
cases:3.65%
controls:0.18%
cases:3.70%
controls:0.09%
cases:0.55%
controls:0.00%
cases:3.05%
controls:0.11%
cases:5.36%
controls:0.20%
cases:6.63%
controls:0.37%
48
28
1952
19972
73
36
1927
19964
74
17
1926
19983
11
0
1989
20000
61
22
1939
19963
100
39
1767
19742
79
70
1112
18677
Malignant neoplasm of breast
C50 [45571518]
1.9e+00
3.1e+00
5.5e+00
1.0e+50
3.2e+00
3.1e+00
2.3e+00
cases:4.95%
controls:0.78%
cases:6.50%
controls:0.32%
cases:11.40%
controls:0.06%
cases:0.25%
controls:0.00%
cases:0.75%
controls:0.03%
cases:4.61%
controls:0.22%
cases:7.72%
controls:0.82%
99
156
1901
19844
130
64
1870
19936
228
11
1772
19989
5
0
1995
20000
15
6
1985
19979
86
44
1781
19737
92
153
1099
18594
Extensive body CT
JN4BD [2001310899]
2.0e+00
3.0e+00
4.2e+00
1.0e+50
2.5e+00
3.6e+00
3.3e+00
cases:17.70%
controls:2.77%
cases:22.80%
controls:1.39%
cases:11.30%
controls:0.19%
cases:0.50%
controls:0.00%
cases:2.05%
controls:0.17%
cases:22.66%
controls:0.78%
cases:17.80%
controls:0.81%
354
554
1646
19446
456
278
1544
19722
226
37
1774
19963
10
0
1990
20000
41
33
1959
19952
423
154
1444
19627
212
152
979
18595
Overall malignant tumor of the mammary gland, lobular tumor
C50.82 [2000501015]
2.4e+00
2.9e+00
4.0e+00
—
3.6e+00
2.8e+00
2.4e+00
cases:1.50%
controls:0.14%
cases:1.75%
controls:0.10%
cases:1.65%
controls:0.03%
—
—
cases:1.45%
controls:0.04%
cases:1.93%
controls:0.12%
cases:1.85%
controls:0.17%
30
27
1970
19973
35
19
1965
19981
33
6
1967
19994
—
29
8
1971
19977
36
23
1831
19758
22
32
1169
18715
Cystostatic therapy of methastized malignancy
WD105 [2001310678]
2.7e+00
3.2e+00
3.3e+00
—
2.4e+00
3.1e+00
3.1e+00
cases:4.95%
controls:0.34%
cases:8.20%
controls:0.35%
cases:2.35%
controls:0.09%
—
—
cases:0.80%
controls:0.07%
cases:6.91%
controls:0.32%
cases:11.75%
controls:0.62%
99
68
1901
19932
164
70
1836
19930
47
17
1953
19983
—
16
14
1984
19971
129
64
1738
19717
140
116
1051
18631
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.3e-01
1.9e+00
3.4e+00
3.4e+00
3.5e+00
2.6e+00
2.3e+00
cases:27.55%
controls:14.27%
cases:46.40%
controls:11.82%
cases:47.90%
controls:3.06%
cases:3.45%
controls:0.12%
cases:49.10%
controls:2.94%
cases:66.52%
controls:12.56%
cases:80.60%
controls:29.70%
551
2853
1449
17147
928
2365
1072
17635
958
612
1042
19388
69
24
1931
19976
982
588
1018
19397
1242
2484
625
17297
960
5567
231
13180
fulvestrant; parenteral
L02BA03 [21603833]
3.6e+00
4.0e+00
—
1.0e+50
—
5.3e+00
5.0e+00
cases:1.60%
controls:0.05%
cases:2.35%
controls:0.05%
—
—
cases:3.90%
controls:0.00%
—
—
cases:7.39%
controls:0.04%
cases:8.48%
controls:0.06%
32
9
1968
19991
47
9
1953
19991
—
78
0
1922
20000
—
138
8
1729
19773
101
12
1090
18735
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
1.8e+00
2.7e+00
4.0e+00
—
4.0e+00
3.0e+00
2.2e+00
cases:1.40%
controls:0.23%
cases:2.75%
controls:0.19%
cases:2.20%
controls:0.04%
—
—
cases:1.80%
controls:0.04%
cases:3.48%
controls:0.18%
cases:5.63%
controls:0.63%
28
46
1972
19954
55
38
1945
19962
44
8
1956
19992
—
36
7
1964
19978
65
35
1802
19746
67
119
1124
18628
pirfenidone; oral
L04AX05 [40254039]
2.9e+00
3.9e+00
2.4e+00
—
-1.0e+50
3.6e+00
4.3e+00
cases:0.55%
controls:0.03%
cases:1.75%
controls:0.04%
cases:0.40%
controls:0.04%
—
—
cases:0.00%
controls:0.03%
cases:1.12%
controls:0.03%
cases:3.61%
controls:0.05%
11
6
1989
19994
35
7
1965
19993
8
7
1992
19993
—
0
6
2000
19979
21
6
1846
19775
43
10
1148
18737
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.0e-01
1.8e+00
3.5e+00
3.2e+00
3.5e+00
2.5e+00
2.0e+00
cases:36.90%
controls:24.25%
cases:58.15%
controls:18.77%
cases:56.05%
controls:3.56%
cases:3.20%
controls:0.14%
cases:55.35%
controls:3.56%
cases:73.70%
controls:19.03%
cases:85.98%
controls:45.61%
738
4851
1262
15149
1163
3753
837
16247
1121
711
879
19289
64
27
1936
19973
1107
711
893
19274
1376
3764
491
16017
1024
8550
167
10197
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
7.9e-01
1.6e+00
3.5e+00
4.0e+00
3.4e+00
2.1e+00
1.6e+00
cases:16.15%
controls:8.01%
cases:21.65%
controls:5.07%
cases:21.60%
controls:0.83%
cases:1.30%
controls:0.03%
cases:19.55%
controls:0.82%
cases:30.69%
controls:4.92%
cases:47.86%
controls:15.36%
323
1601
1677
18399
433
1014
1567
18986
432
166
1568
19834
26
5
1974
19995
391
163
1609
19822
573
974
1294
18807
570
2879
621
15868
granisetron; oral, parenteral, transdermal
A04AA02 [21600494]
2.1e+00
2.7e+00
3.0e+00
—
3.7e+00
3.1e+00
2.5e+00
cases:5.95%
controls:0.80%
cases:5.95%
controls:0.44%
cases:1.25%
controls:0.07%
—
—
cases:1.80%
controls:0.05%
cases:5.73%
controls:0.27%
cases:8.31%
controls:0.73%
119
160
1881
19840
119
88
1881
19912
25
13
1975
19987
—
36
9
1964
19976
107
53
1760
19728
99
136
1092
18611
capecitabine
L01BC06 [21601440]
2.4e+00
2.9e+00
2.7e+00
—
2.9e+00
2.6e+00
3.1e+00
cases:4.50%
controls:0.41%
cases:5.60%
controls:0.33%
cases:1.50%
controls:0.10%
—
—
cases:1.20%
controls:0.07%
cases:3.86%
controls:0.30%
cases:8.48%
controls:0.42%
90
82
1910
19918
112
66
1888
19934
30
20
1970
19980
—
24
13
1976
19972
72
59
1795
19722
101
78
1090
18669
Palliative radiotherapy
WF004 [2001310703]
3.2e+00
3.3e+00
3.8e+00
—
—
3.4e+00
2.9e+00
cases:2.15%
controls:0.09%
cases:2.85%
controls:0.11%
cases:1.50%
controls:0.04%
—
—
—
—
cases:2.62%
controls:0.09%
cases:5.54%
controls:0.34%
43
18
1957
19982
57
21
1943
19979
30
7
1970
19993
—
—
49
17
1818
19764
66
63
1125
18684
Blood transfusion
WW500 [2001310603]
1.8e+00
2.6e+00
3.0e+00
—
3.6e+00
3.0e+00
2.5e+00
cases:2.10%
controls:0.37%
cases:2.55%
controls:0.19%
cases:0.95%
controls:0.05%
—
—
cases:1.10%
controls:0.03%
cases:4.12%
controls:0.22%
cases:6.05%
controls:0.55%
42
73
1958
19927
51
37
1949
19963
19
10
1981
19990
—
22
6
1978
19979
77
43
1790
19738
72
103
1119
18644
Cancer Ag 15-3 [Units/volume] in Serum or Plasma
6875-9 [3006588]
2.8e+00
3.7e+00
—
—
3.1e+00
3.9e+00
3.0e+00
cases:5.60%
controls:0.37%
cases:9.40%
controls:0.27%
—
—
—
—
cases:1.05%
controls:0.05%
cases:10.98%
controls:0.25%
cases:11.17%
controls:0.64%
112
74
1888
19926
188
53
1812
19947
—
—
21
10
1979
19975
205
50
1662
19731
133
120
1058
18627
Malignancy NOS
A79 [2002000213]
2.2e+00
2.4e+00
2.6e+00
—
3.4e+00
3.0e+00
2.7e+00
cases:1.00%
controls:0.12%
cases:0.95%
controls:0.09%
cases:0.35%
controls:0.03%
—
—
cases:0.85%
controls:0.03%
cases:2.52%
controls:0.13%
cases:4.37%
controls:0.30%
20
23
1980
19977
19
17
1981
19983
7
5
1993
19995
—
17
6
1983
19979
47
25
1820
19756
52
57
1139
18690
Therapy of methastized malignancy with hormones
WD205 [2001310682]
3.5e+00
4.2e+00
—
1.0e+50
—
4.9e+00
3.6e+00
cases:2.25%
controls:0.07%
cases:2.50%
controls:0.04%
—
—
cases:0.45%
controls:0.00%
—
—
cases:5.84%
controls:0.05%
cases:7.22%
controls:0.20%
45
14
1955
19986
50
8
1950
19992
—
9
0
1991
20000
—
109
9
1758
19772
86
38
1105
18709
Body CT examination
JN4AD [2001310897]
2.2e+00
2.3e+00
3.6e+00
—
2.2e+00
3.3e+00
2.6e+00
cases:3.05%
controls:0.35%
cases:4.05%
controls:0.41%
cases:3.05%
controls:0.09%
—
—
cases:0.50%
controls:0.06%
cases:13.82%
controls:0.58%
cases:31.57%
controls:3.37%
61
70
1939
19930
81
81
1919
19919
61
18
1939
19982
—
10
11
1990
19974
258
114
1609
19667
376
632
815
18115
Short blood count panel - Blood
55429-5 [40758558]
8.5e-01
1.7e+00
3.2e+00
3.4e+00
3.3e+00
2.2e+00
1.4e+00
cases:16.05%
controls:7.57%
cases:24.60%
controls:5.82%
cases:25.70%
controls:1.37%
cases:1.80%
controls:0.06%
cases:25.80%
controls:1.29%
cases:32.51%
controls:5.04%
cases:34.84%
controls:11.24%
321
1513
1679
18487
492
1164
1508
18836
514
273
1486
19727
36
12
1964
19988
516
257
1484
19728
607
996
1260
18785
415
2108
776
16639
exemestane; oral
L02BG06 [21603844]
2.9e+00
3.0e+00
3.2e+00
1.0e+50
—
3.5e+00
3.4e+00
cases:1.85%
controls:0.11%
cases:2.00%
controls:0.10%
cases:1.10%
controls:0.05%
cases:0.65%
controls:0.00%
—
—
cases:3.32%
controls:0.11%
cases:7.47%
controls:0.26%
37
21
1963
19979
40
20
1960
19980
22
9
1978
19991
13
0
1987
20000
—
62
21
1805
19760
89
48
1102
18699
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.6e+00
2.4e+00
4.0e+00
—
3.3e+00
2.6e+00
2.2e+00
cases:8.10%
controls:1.83%
cases:15.45%
controls:1.66%
cases:14.25%
controls:0.31%
—
—
cases:8.45%
controls:0.34%
cases:18.26%
controls:1.69%
cases:34.26%
controls:5.60%
162
365
1838
19635
309
331
1691
19669
285
62
1715
19938
—
169
67
1831
19918
341
334
1526
19447
408
1050
783
17697
Malignant tumor of the upper inner quadrant of the mammary gland,ductal tumor
C50.21 [2000500994]
2.2e+00
2.2e+00
3.4e+00
1.0e+50
3.4e+00
2.8e+00
2.0e+00
cases:2.45%
controls:0.27%
cases:2.15%
controls:0.24%
cases:2.00%
controls:0.07%
cases:0.55%
controls:0.00%
cases:1.65%
controls:0.06%
cases:2.57%
controls:0.17%
cases:2.52%
controls:0.36%
49
54
1951
19946
43
47
1957
19953
40
14
1960
19986
11
0
1989
20000
33
11
1967
19974
48
33
1819
19748
30
68
1161
18679
dalteparin; parenteral
B01AB04 [21600975]
1.6e+00
2.5e+00
3.0e+00
1.0e+50
3.0e+00
3.2e+00
2.6e+00
cases:1.70%
controls:0.34%
cases:1.70%
controls:0.14%
cases:1.05%
controls:0.06%
cases:0.40%
controls:0.00%
cases:1.05%
controls:0.06%
cases:3.37%
controls:0.15%
cases:6.05%
controls:0.46%
34
68
1966
19932
34
28
1966
19972
21
11
1979
19989
8
0
1992
20000
21
11
1979
19974
63
29
1804
19752
72
87
1119
18660
denosumab; parenteral
M05BX04 [21604169]
1.9e+00
2.4e+00
3.2e+00
—
3.1e+00
2.9e+00
2.3e+00
cases:5.25%
controls:0.85%
cases:8.50%
controls:0.86%
cases:5.35%
controls:0.24%
—
—
cases:5.60%
controls:0.26%
cases:16.66%
controls:1.05%
cases:18.39%
controls:2.15%
105
170
1895
19830
170
171
1830
19829
107
48
1893
19952
—
112
51
1888
19934
311
208
1556
19573
219
403
972
18344
Treatment plan or consultation
WZC00 [2001310885]
8.1e-01
1.9e+00
4.0e+00
3.0e+00
2.2e+00
2.2e+00
1.6e+00
cases:13.75%
controls:6.61%
cases:16.85%
controls:2.88%
cases:17.05%
controls:0.38%
cases:0.50%
controls:0.03%
cases:3.75%
controls:0.42%
cases:19.76%
controls:2.69%
cases:34.51%
controls:9.83%
275
1322
1725
18678
337
576
1663
19424
341
75
1659
19925
10
5
1990
19995
75
83
1925
19902
369
532
1498
19249
411
1843
780
16904
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.7e+00
2.3e+00
3.4e+00
—
3.2e+00
2.7e+00
2.2e+00
cases:18.50%
controls:4.13%
cases:16.50%
controls:1.91%
cases:7.55%
controls:0.26%
—
—
cases:5.25%
controls:0.22%
cases:19.34%
controls:1.62%
cases:30.31%
controls:4.68%
370
826
1630
19174
330
381
1670
19619
151
52
1849
19948
—
105
43
1895
19942
361
321
1506
19460
361
878
830
17869
Demanding antibody therapy of methastized malignancy
WD415 [2001310689]
2.9e+00
3.2e+00
3.6e+00
—
2.1e+00
2.8e+00
3.0e+00
cases:2.50%
controls:0.14%
cases:3.00%
controls:0.12%
cases:0.90%
controls:0.03%
—
—
cases:0.25%
controls:0.03%
cases:1.45%
controls:0.09%
cases:3.19%
controls:0.17%
50
28
1950
19972
60
24
1940
19976
18
5
1982
19995
—
5
6
1995
19979
27
18
1840
19763
38
31
1153
18716
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
2.1e+00
2.6e+00
3.0e+00
—
2.8e+00
2.7e+00
2.3e+00
cases:5.55%
controls:0.74%
cases:6.10%
controls:0.50%
cases:1.45%
controls:0.07%
—
—
cases:1.35%
controls:0.08%
cases:6.86%
controls:0.50%
cases:12.34%
controls:1.39%
111
148
1889
19852
122
99
1878
19901
29
14
1971
19986
—
27
16
1973
19969
128
99
1739
19682
147
261
1044
18486
loperamide; oral
A07DA03 [21600646]
1.2e+00
1.6e+00
3.5e+00
—
3.3e+00
3.1e+00
2.8e+00
cases:4.65%
controls:1.45%
cases:4.15%
controls:0.87%
cases:5.30%
controls:0.17%
—
—
cases:3.40%
controls:0.14%
cases:16.23%
controls:0.88%
cases:26.28%
controls:2.04%
93
289
1907
19711
83
173
1917
19827
106
34
1894
19966
—
68
27
1932
19958
303
175
1564
19606
313
382
878
18365
loperamide oxide; oral
A07DA05 [21600648]
1.2e+00
1.6e+00
3.5e+00
—
3.3e+00
3.1e+00
2.8e+00
cases:4.65%
controls:1.45%
cases:4.15%
controls:0.87%
cases:5.30%
controls:0.17%
—
—
cases:3.40%
controls:0.14%
cases:16.23%
controls:0.88%
cases:26.28%
controls:2.04%
93
289
1907
19711
83
173
1917
19827
106
34
1894
19966
—
68
27
1932
19958
303
175
1564
19606
313
382
878
18365
Bone marrow biopsy
XW000 [2001310618]
1.9e+00
3.2e+00
4.2e+00
—
—
3.6e+00
2.5e+00
cases:3.25%
controls:0.51%
cases:4.65%
controls:0.20%
cases:1.95%
controls:0.03%
—
—
—
—
cases:4.77%
controls:0.13%
cases:6.80%
controls:0.60%
65
102
1935
19898
93
39
1907
19961
39
6
1961
19994
—
—
89
26
1778
19755
81
112
1110
18635
Radiotherapy with large shaped fields - isocentric therapy
ZX012 [2001311468]
1.7e+00
2.5e+00
3.6e+00
—
2.2e+00
2.9e+00
2.5e+00
cases:5.90%
controls:1.13%
cases:3.55%
controls:0.31%
cases:1.60%
controls:0.05%
—
—
cases:0.50%
controls:0.06%
cases:3.16%
controls:0.18%
cases:3.78%
controls:0.34%
118
225
1882
19775
71
61
1929
19939
32
9
1968
19991
—
10
11
1990
19974
59
35
1808
19746
45
63
1146
18684
goserelin; implant
L02AE03 [21603826]
2.3e+00
2.4e+00
3.2e+00
—
2.3e+00
2.5e+00
2.7e+00
cases:0.75%
controls:0.08%
cases:0.75%
controls:0.07%
cases:0.85%
controls:0.04%
—
—
cases:0.35%
controls:0.04%
cases:1.07%
controls:0.09%
cases:1.09%
controls:0.07%
15
15
1985
19985
15
14
1985
19986
17
7
1983
19993
—
7
7
1993
19978
20
18
1847
19763
13
14
1178
18733
Very extensive CT of head and brain
AA1CD [2001300114]
2.0e+00
3.0e+00
2.6e+00
—
—
3.6e+00
4.0e+00
cases:1.10%
controls:0.16%
cases:1.25%
controls:0.06%
cases:0.35%
controls:0.03%
—
—
—
—
cases:1.61%
controls:0.05%
cases:2.27%
controls:0.04%
22
31
1978
19969
25
12
1975
19988
7
5
1993
19995
—
—
30
9
1837
19772
27
8
1164
18739
Overall malignant tumor of the mammary gland, other or undeterminated histology
C50.89 [2000501016]
2.6e+00
3.2e+00
—
—
2.9e+00
3.1e+00
3.4e+00
cases:0.90%
controls:0.07%
cases:0.75%
controls:0.03%
—
—
—
—
cases:0.45%
controls:0.03%
cases:0.64%
controls:0.03%
cases:1.26%
controls:0.04%
18
13
1982
19987
15
6
1985
19994
—
—
9
5
1991
19980
12
6
1855
19775
15
8
1176
18739
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
2.0e+00
2.2e+00
3.5e+00
—
3.4e+00
2.3e+00
1.5e+00
cases:2.05%
controls:0.30%
cases:4.40%
controls:0.52%
cases:3.40%
controls:0.11%
—
—
cases:3.00%
controls:0.10%
cases:6.00%
controls:0.66%
cases:15.87%
controls:4.17%
41
59
1959
19941
88
104
1912
19896
68
21
1932
19979
—
60
20
1940
19965
112
131
1755
19650
189
782
1002
17965
vinorelbine
L01CA04 [21601450]
3.2e+00
3.7e+00
—
—
—
3.8e+00
4.1e+00
cases:1.45%
controls:0.06%
cases:2.45%
controls:0.07%
—
—
—
—
—
—
cases:1.55%
controls:0.04%
cases:5.12%
controls:0.09%
29
12
1971
19988
49
13
1951
19987
—
—
—
29
7
1838
19774
61
16
1130
18731
Very extensive body CT
JN4CD [2001310902]
1.9e+00
3.1e+00
—
—
2.7e+00
3.6e+00
3.3e+00
cases:4.60%
controls:0.73%
cases:6.70%
controls:0.33%
—
—
—
—
cases:0.45%
controls:0.03%
cases:4.18%
controls:0.12%
cases:4.37%
controls:0.16%
92
145
1908
19855
134
65
1866
19935
—
—
9
6
1991
19979
78
23
1789
19758
52
30
1139
18717
Pleural effusion, not elsewhere classified
J90 [45605897]
1.4e+00
2.6e+00
3.1e+00
—
2.4e+00
3.0e+00
2.1e+00
cases:1.05%
controls:0.27%
cases:2.35%
controls:0.18%
cases:0.80%
controls:0.04%
—
—
cases:0.45%
controls:0.04%
cases:2.04%
controls:0.11%
cases:3.44%
controls:0.43%
21
54
1979
19946
47
35
1953
19965
16
7
1984
19993
—
9
8
1991
19977
38
21
1829
19760
41
80
1150
18667
Outpatient Visit
OP [9202]
6.4e-01
1.8e+00
2.6e+00
2.9e+00
2.1e+00
1.7e+00
2.8e+00
cases:89.45%
controls:81.66%
cases:90.05%
controls:59.69%
cases:66.35%
controls:12.94%
cases:10.40%
controls:0.63%
cases:54.50%
controls:12.81%
cases:89.50%
controls:60.95%
cases:99.58%
controls:93.28%
1789
16331
211
3669
1801
11938
199
8062
1327
2588
673
17412
208
126
1792
19874
1090
2561
910
17424
1671
12056
196
7725
1186
17488
5
1259
Interstitial pulmonary disease, unspecified
J84.9 [45543277]
2.4e+00
2.7e+00
3.4e+00
—
1.9e+00
2.1e+00
2.0e+00
cases:2.35%
controls:0.22%
cases:2.80%
controls:0.19%
cases:0.85%
controls:0.03%
—
—
cases:0.40%
controls:0.06%
cases:1.55%
controls:0.19%
cases:2.43%
controls:0.34%
47
44
1953
19956
56
37
1944
19963
17
6
1983
19994
—
8
12
1992
19973
29
37
1838
19744
29
63
1162
18684
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.8e+00
2.2e+00
3.5e+00
—
3.3e+00
2.3e+00
1.4e+00
cases:2.40%
controls:0.42%
cases:5.25%
controls:0.64%
cases:4.10%
controls:0.14%
—
—
cases:3.70%
controls:0.14%
cases:7.23%
controls:0.81%
cases:16.88%
controls:4.61%
48
84
1952
19916
105
127
1895
19873
82
27
1918
19973
—
74
27
1926
19958
135
161
1732
19620
201
865
990
17882
Malignant tumour
130 [2001600128]
2.4e+00
3.3e+00
6.5e+00
—
—
1.1e+00
1.0e+00
cases:8.00%
controls:0.81%
cases:11.25%
controls:0.46%
cases:30.45%
controls:0.07%
—
—
—
—
cases:0.75%
controls:0.25%
cases:2.94%
controls:1.08%
160
162
1840
19838
225
92
1775
19908
609
13
1391
19987
—
—
14
49
1853
19732
35
203
1156
18544
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
1.8e+00
2.1e+00
3.3e+00
—
3.1e+00
2.3e+00
1.7e+00
cases:7.20%
controls:1.25%
cases:6.50%
controls:0.86%
cases:5.85%
controls:0.23%
—
—
cases:5.15%
controls:0.26%
cases:7.34%
controls:0.80%
cases:7.14%
controls:1.34%
144
249
1856
19751
130
172
1870
19828
117
46
1883
19954
—
103
51
1897
19934
137
158
1730
19623
85
252
1106
18495
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.8e+00
2.1e+00
3.4e+00
—
3.3e+00
2.2e+00
1.4e+00
cases:2.25%
controls:0.37%
cases:4.60%
controls:0.56%
cases:3.55%
controls:0.12%
—
—
cases:3.20%
controls:0.13%
cases:6.00%
controls:0.73%
cases:15.11%
controls:4.34%
45
74
1955
19926
92
113
1908
19887
71
24
1929
19976
—
64
25
1936
19960
112
145
1755
19636
180
814
1011
17933
Breast, unspecified
C50.99 [2000501021]
2.0e+00
2.1e+00
2.9e+00
—
3.1e+00
2.1e+00
1.9e+00
cases:2.65%
controls:0.38%
cases:1.35%
controls:0.16%
cases:0.90%
controls:0.05%
—
—
cases:0.90%
controls:0.04%
cases:1.45%
controls:0.17%
cases:2.94%
controls:0.46%
53
75
1947
19925
27
32
1973
19968
18
10
1982
19990
—
18
8
1982
19977
27
34
1840
19747
35
86
1156
18661
Malignant tumor of the upper outer quadrant of the mammary gland, lobular tumor
C50.42 [2000501003]
1.6e+00
2.1e+00
3.0e+00
—
3.0e+00
2.2e+00
2.1e+00
cases:1.85%
controls:0.37%
cases:2.00%
controls:0.25%
cases:1.85%
controls:0.09%
—
—
cases:1.40%
controls:0.07%
cases:2.04%
controls:0.22%
cases:2.52%
controls:0.33%
37
73
1963
19927
40
49
1960
19951
37
18
1963
19982
—
28
14
1972
19971
38
44
1829
19737
30
61
1161
18686
Dalteparin and tinzaparin (treatment for more than 6 months)
166 [2001600165]
3.1e+00
3.1e+00
—
—
—
4.1e+00
3.8e+00
cases:0.55%
controls:0.03%
cases:0.80%
controls:0.04%
—
—
—
—
—
—
cases:2.41%
controls:0.04%
cases:4.37%
controls:0.11%
11
5
1989
19995
16
7
1984
19993
—
—
—
45
8
1822
19773
52
20
1139
18727
oxycodone; oral, parenteral
N02AA05 [21604260]
1.3e+00
2.3e+00
2.8e+00
—
2.7e+00
2.8e+00
2.1e+00
cases:6.35%
controls:1.74%
cases:10.85%
controls:1.25%
cases:7.35%
controls:0.49%
—
—
cases:7.15%
controls:0.50%
cases:20.30%
controls:1.47%
cases:29.47%
controls:4.75%
127
347
1873
19653
217
251
1783
19749
147
97
1853
19903
—
143
99
1857
19886
379
291
1488
19490
351
891
840
17856
Demanding therapy of methastized malignancy with biomodifiers
WD325 [2001310687]
3.4e+00
2.9e+00
—
—
2.3e+00
4.1e+00
3.7e+00
cases:0.85%
controls:0.03%
cases:0.75%
controls:0.04%
—
—
—
—
cases:0.25%
controls:0.03%
cases:2.62%
controls:0.05%
cases:5.63%
controls:0.14%
17
6
1983
19994
15
8
1985
19992
—
—
5
5
1995
19980
49
9
1818
19772
67
27
1124
18720
dexamethasone; oral, parenteral
H02AB02 [21602730]
1.6e+00
2.5e+00
3.4e+00
—
2.4e+00
2.4e+00
1.8e+00
cases:12.45%
controls:2.92%
cases:15.50%
controls:1.44%
cases:3.85%
controls:0.14%
—
—
cases:2.25%
controls:0.20%
cases:12.10%
controls:1.27%
cases:21.58%
controls:4.42%
249
584
1751
19416
310
287
1690
19713
77
28
1923
19972
—
45
40
1955
19945
226
252
1641
19529
257
828
934
17919
Granulocytes/Leukocytes in Blood
30395-8 [3035933]
6.7e-01
2.1e+00
3.5e+00
—
3.2e+00
2.7e+00
2.5e+00
cases:1.20%
controls:0.62%
cases:3.80%
controls:0.49%
cases:2.30%
controls:0.07%
—
—
cases:1.30%
controls:0.06%
cases:3.86%
controls:0.27%
cases:4.11%
controls:0.36%
24
123
1976
19877
76
98
1924
19902
46
14
1954
19986
—
26
11
1974
19974
72
54
1795
19727
49
67
1142
18680
filgrastim; parenteral
L03AA02 [21603851]
2.6e+00
2.9e+00
2.4e+00
—
1.6e+00
3.0e+00
3.0e+00
cases:3.55%
controls:0.27%
cases:3.65%
controls:0.20%
cases:0.60%
controls:0.06%
—
—
cases:0.25%
controls:0.05%
cases:3.27%
controls:0.17%
cases:6.47%
controls:0.35%
71
53
1929
19947
73
40
1927
19960
12
11
1988
19989
—
5
10
1995
19975
61
34
1806
19747
77
65
1114
18682
Polycythaemia vera
D45 [45595761]
2.3e+00
2.3e+00
2.6e+00
—
2.6e+00
2.0e+00
2.0e+00
cases:1.80%
controls:0.18%
cases:1.50%
controls:0.16%
cases:0.80%
controls:0.06%
—
—
cases:0.70%
controls:0.05%
cases:1.12%
controls:0.16%
cases:1.76%
controls:0.23%
36
35
1964
19965
30
31
1970
19969
16
12
1984
19988
—
14
10
1986
19975
21
31
1846
19750
21
44
1170
18703
Leukocyte morphology finding [Identifier] in Blood
11156-7 [3008757]
2.2e+00
2.4e+00
3.9e+00
—
—
2.9e+00
2.5e+00
cases:1.15%
controls:0.14%
cases:1.70%
controls:0.16%
cases:1.25%
controls:0.03%
—
—
—
—
cases:2.04%
controls:0.12%
cases:4.03%
controls:0.34%
23
27
1977
19973
34
31
1966
19969
25
5
1975
19995
—
—
38
23
1829
19758
48
64
1143
18683
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.7e+00
1.9e+00
3.4e+00
—
3.3e+00
2.1e+00
1.3e+00
cases:1.25%
controls:0.22%
cases:2.70%
controls:0.40%
cases:2.50%
controls:0.09%
—
—
cases:2.50%
controls:0.09%
cases:5.03%
controls:0.63%
cases:14.27%
controls:4.32%
25
44
1975
19956
54
80
1946
19920
50
17
1950
19983
—
50
18
1950
19967
94
125
1773
19656
170
810
1021
17937
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
2.0e+00
2.3e+00
2.4e+00
—
2.5e+00
2.4e+00
2.1e+00
cases:3.55%
controls:0.50%
cases:3.20%
controls:0.32%
cases:0.95%
controls:0.09%
—
—
cases:0.85%
controls:0.07%
cases:3.32%
controls:0.30%
cases:7.81%
controls:1.01%
71
99
1929
19901
64
64
1936
19936
19
17
1981
19983
—
17
14
1983
19971
62
60
1805
19721
93
190
1098
18557
Simple antiboidy therapy of methastized malignancy
WD405 [2001310688]
2.1e+00
2.8e+00
2.4e+00
—
2.0e+00
2.4e+00
2.0e+00
cases:1.55%
controls:0.19%
cases:2.85%
controls:0.18%
cases:0.80%
controls:0.07%
—
—
cases:0.50%
controls:0.07%
cases:1.87%
controls:0.18%
cases:3.02%
controls:0.41%
31
38
1969
19962
57
35
1943
19965
16
14
1984
19986
—
10
14
1990
19971
35
35
1832
19746
36
76
1155
18671
Malignant tumor of the lower outer quadrant of the mammary gland, ductal tumor
C50.51 [2000501006]
2.0e+00
1.9e+00
2.8e+00
—
3.0e+00
2.3e+00
1.7e+00
cases:1.55%
controls:0.21%
cases:1.05%
controls:0.16%
cases:0.90%
controls:0.06%
—
—
cases:0.70%
controls:0.04%
cases:1.39%
controls:0.15%
cases:1.43%
controls:0.27%
31
41
1969
19959
21
31
1979
19969
18
11
1982
19989
—
14
7
1986
19978
26
29
1841
19752
17
50
1174
18697
Chronic myeloproliferative disease
D47.1 [45600598]
4.1e+00
—
—
1.0e+50
1.0e+50
4.8e+00
4.8e+00
cases:1.45%
controls:0.03%
—
—
—
—
cases:0.50%
controls:0.00%
cases:2.10%
controls:0.00%
cases:3.05%
controls:0.03%
cases:4.37%
controls:0.04%
29
5
1971
19995
—
—
10
0
1990
20000
42
0
1958
19985
57
5
1810
19776
52
7
1139
18740
pegfilgrastim; parenteral
L03AA13 [21603856]
2.5e+00
3.0e+00
2.9e+00
—
-1.0e+50
2.7e+00
2.4e+00
cases:4.95%
controls:0.44%
cases:4.05%
controls:0.21%
cases:0.85%
controls:0.05%
—
—
cases:0.00%
controls:0.05%
cases:2.04%
controls:0.14%
cases:4.95%
controls:0.46%
99
87
1901
19913
81
42
1919
19958
17
9
1983
19991
—
0
9
2000
19976
38
27
1829
19754
59
86
1132
18661
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
1.3e+00
2.1e+00
2.9e+00
—
2.3e+00
2.6e+00
2.4e+00
cases:0.85%
controls:0.25%
cases:2.40%
controls:0.31%
cases:0.70%
controls:0.04%
—
—
cases:0.50%
controls:0.05%
cases:3.32%
controls:0.25%
cases:8.31%
controls:0.78%
17
49
1983
19951
48
61
1952
19939
14
8
1986
19992
—
10
10
1990
19975
62
50
1805
19731
99
146
1092
18601
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
1.6e+00
2.6e+00
3.6e+00
—
1.6e+00
2.5e+00
1.7e+00
cases:9.50%
controls:2.17%
cases:19.70%
controls:1.78%
cases:12.55%
controls:0.39%
—
—
cases:1.60%
controls:0.34%
cases:17.46%
controls:1.71%
cases:20.99%
controls:4.45%
190
433
1810
19567
394
356
1606
19644
251
78
1749
19922
—
32
68
1968
19917
326
339
1541
19442
250
834
941
17913
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
5.7e-01
1.6e+00
2.9e+00
2.6e+00
2.3e+00
2.0e+00
1.6e+00
cases:18.20%
controls:11.15%
cases:30.90%
controls:8.46%
cases:21.50%
controls:1.44%
cases:0.90%
controls:0.07%
cases:13.85%
controls:1.54%
cases:42.64%
controls:9.18%
cases:66.83%
controls:29.20%
364
2231
1636
17769
618
1691
1382
18309
430
287
1570
19713
18
14
1982
19986
277
307
1723
19678
796
1815
1071
17966
796
5474
395
13273
tinzaparin; parenteral
B01AB10 [21600981]
1.3e+00
2.3e+00
2.9e+00
—
3.1e+00
2.6e+00
1.4e+00
cases:2.95%
controls:0.79%
cases:4.95%
controls:0.55%
cases:2.00%
controls:0.12%
—
—
cases:2.05%
controls:0.10%
cases:5.41%
controls:0.42%
cases:10.41%
controls:2.80%
59
157
1941
19843
99
109
1901
19891
40
23
1960
19977
—
41
19
1959
19966
101
84
1766
19697
124
525
1067
18222
Granulocytes [#/volume] in Blood
30394-1 [3035715]
6.5e-01
2.1e+00
3.4e+00
—
2.8e+00
2.6e+00
2.6e+00
cases:1.05%
controls:0.55%
cases:3.20%
controls:0.42%
cases:1.85%
controls:0.06%
—
—
cases:0.75%
controls:0.05%
cases:3.16%
controls:0.24%
cases:3.36%
controls:0.27%
21
110
1979
19890
64
84
1936
19916
37
12
1963
19988
—
15
9
1985
19976
59
47
1808
19734
40
50
1151
18697
Pulmonary Disease
29 [38004472]
7.1e-01
1.8e+00
2.7e+00
3.4e+00
2.2e+00
1.6e+00
1.1e+00
cases:19.70%
controls:10.77%
cases:28.70%
controls:6.27%
cases:16.70%
controls:1.31%
cases:1.15%
controls:0.04%
cases:10.60%
controls:1.35%
cases:24.64%
controls:6.19%
cases:33.00%
controls:14.15%
394
2153
1606
17847
574
1254
1426
18746
334
263
1666
19737
23
8
1977
19992
212
269
1788
19716
460
1225
1407
18556
393
2653
798
16094
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
1.4e+00
2.2e+00
3.0e+00
—
2.0e+00
2.5e+00
2.4e+00
cases:0.95%
controls:0.24%
cases:2.25%
controls:0.26%
cases:0.60%
controls:0.03%
—
—
cases:0.30%
controls:0.04%
cases:3.37%
controls:0.30%
cases:8.82%
controls:0.89%
19
48
1981
19952
45
52
1955
19948
12
6
1988
19994
—
6
8
1994
19977
63
59
1804
19722
105
167
1086
18580
Malignant neoplasm of kidney, except renal pelvis
C64 [45600516]
3.4e+00
4.8e+00
1.0e+50
—
—
—
5.2e+00
cases:1.00%
controls:0.04%
cases:2.90%
controls:0.03%
cases:9.15%
controls:0.00%
—
—
—
—
—
—
cases:10.75%
controls:0.06%
20
7
1980
19993
58
5
1942
19995
183
0
1817
20000
—
—
—
128
12
1063
18735
Demanding therapy of methastized malignancy with hormones
WD225 [2001310684]
2.6e+00
3.1e+00
—
1.0e+50
—
4.3e+00
3.4e+00
cases:1.00%
controls:0.08%
cases:1.65%
controls:0.08%
—
—
cases:0.40%
controls:0.00%
—
—
cases:4.12%
controls:0.06%
cases:3.44%
controls:0.12%
20
15
1980
19985
33
15
1967
19985
—
8
0
1992
20000
—
77
12
1790
19769
41
22
1150
18725
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
4.6e-01
1.6e+00
3.4e+00
—
3.1e+00
2.7e+00
2.1e+00
cases:4.60%
controls:2.96%
cases:10.25%
controls:2.21%
cases:7.45%
controls:0.27%
—
—
cases:7.50%
controls:0.37%
cases:20.73%
controls:1.72%
cases:37.03%
controls:6.85%
92
593
1908
19407
205
441
1795
19559
149
53
1851
19947
—
150
74
1850
19911
387
340
1480
19441
441
1284
750
17463
pH of Serum or Plasma
2753-2 [3018418]
6.4e-01
1.6e+00
2.9e+00
2.3e+00
2.5e+00
2.0e+00
1.5e+00
cases:11.05%
controls:6.17%
cases:19.45%
controls:4.87%
cases:12.90%
controls:0.79%
cases:0.55%
controls:0.06%
cases:9.10%
controls:0.83%
cases:28.71%
controls:5.26%
cases:45.68%
controls:16.46%
221
1233
1779
18767
389
974
1611
19026
258
158
1742
19842
11
11
1989
19989
182
166
1818
19819
536
1040
1331
18741
544
3085
647
15662
Teaching
WZC30 [2001310891]
8.0e-01
1.9e+00
4.6e+00
1.0e+50
2.7e+00
1.7e+00
1.5e+00
cases:4.75%
controls:2.19%
cases:7.50%
controls:1.19%
cases:9.40%
controls:0.11%
cases:2.10%
controls:0.00%
cases:2.30%
controls:0.16%
cases:6.37%
controls:1.18%
cases:17.55%
controls:4.38%
95
439
1905
19561
150
237
1850
19763
188
21
1812
19979
42
0
1958
20000
46
32
1954
19953
119
233
1748
19548
209
821
982
17926
enoxaparin; parenteral
B01AB05 [21600976]
7.7e-01
1.7e+00
2.4e+00
3.7e+00
2.2e+00
1.5e+00
8.9e-01
cases:15.80%
controls:8.01%
cases:14.65%
controls:2.92%
cases:4.70%
controls:0.44%
cases:1.00%
controls:0.03%
cases:3.55%
controls:0.42%
cases:9.43%
controls:2.31%
cases:14.86%
controls:6.67%
316
1602
1684
18398
293
583
1707
19417
94
87
1906
19913
20
5
1980
19995
71
84
1929
19901
176
456
1691
19325
177
1250
1014
17497
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
6.0e-01
1.6e+00
2.9e+00
2.2e+00
2.3e+00
1.9e+00
1.6e+00
cases:16.65%
controls:9.90%
cases:28.90%
controls:7.75%
cases:19.05%
controls:1.27%
cases:0.70%
controls:0.08%
cases:12.10%
controls:1.38%
cases:38.83%
controls:8.31%
cases:62.64%
controls:24.88%
333
1980
1667
18020
578
1549
1422
18451
381
254
1619
19746
14
15
1986
19985
242
276
1758
19709
725
1643
1142
18138
746
4664
445
14083
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
1.1e+00
1.6e+00
2.5e+00
—
2.4e+00
3.0e+00
2.4e+00
cases:0.80%
controls:0.27%
cases:1.10%
controls:0.22%
cases:1.00%
controls:0.08%
—
—
cases:1.30%
controls:0.12%
cases:5.09%
controls:0.27%
cases:7.05%
controls:0.65%
16
53
1984
19947
22
44
1978
19956
20
16
1980
19984
—
26
23
1974
19962
95
53
1772
19728
84
122
1107
18625
Neoplasm of uncertain or unknown behaviour: Kidney
D41.0 [45581311]
2.5e+00
3.5e+00
3.7e+00
—
—
1.9e+00
1.4e+00
cases:3.30%
controls:0.27%
cases:5.00%
controls:0.17%
cases:1.40%
controls:0.04%
—
—
—
—
cases:1.18%
controls:0.18%
cases:1.85%
controls:0.46%
66
54
1934
19946
100
33
1900
19967
28
7
1972
19993
—
—
22
35
1845
19746
22
86
1169
18661
Demanding cystostatic therapy of methastized malignancy
WD125 [2001310680]
2.3e+00
3.1e+00
2.8e+00
—
—
2.3e+00
2.5e+00
cases:4.15%
controls:0.43%
cases:6.75%
controls:0.34%
cases:1.90%
controls:0.12%
—
—
—
—
cases:3.21%
controls:0.34%
cases:6.63%
controls:0.58%
83
86
1917
19914
135
68
1865
19932
38
23
1962
19977
—
—
60
67
1807
19714
79
109
1112
18638
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
7.1e-01
2.1e+00
3.1e+00
—
2.6e+00
2.4e+00
1.9e+00
cases:2.50%
controls:1.24%
cases:3.35%
controls:0.41%
cases:0.75%
controls:0.04%
—
—
cases:0.40%
controls:0.03%
cases:3.70%
controls:0.35%
cases:8.14%
controls:1.32%
50
248
1950
19752
67
82
1933
19918
15
7
1985
19993
—
8
6
1992
19979
69
70
1798
19711
97
247
1094
18500
Malignant tumor of the central part of the mammary gland,ductal tumor
C50.11 [2000500990]
1.8e+00
1.8e+00
2.6e+00
—
2.9e+00
2.1e+00
1.6e+00
cases:1.10%
controls:0.19%
cases:0.80%
controls:0.14%
cases:0.65%
controls:0.05%
—
—
cases:0.65%
controls:0.04%
cases:1.07%
controls:0.13%
cases:1.01%
controls:0.21%
22
38
1978
19962
16
27
1984
19973
13
10
1987
19990
—
13
7
1987
19978
20
26
1847
19755
12
40
1179
18707
Malignant neoplasm: Head of pancreas
C25.0 [45590881]
2.2e+00
2.1e+00
2.5e+00
—
2.2e+00
1.9e+00
1.8e+00
cases:0.50%
controls:0.06%
cases:0.65%
controls:0.08%
cases:0.65%
controls:0.06%
—
—
cases:0.40%
controls:0.05%
cases:0.64%
controls:0.10%
cases:0.92%
controls:0.15%
10
11
1990
19989
13
16
1987
19984
13
11
1987
19989
—
8
9
1992
19976
12
19
1855
19762
11
28
1180
18719
palbociclib; oral
L01EF01 [947735]
—
—
—
1.0e+50
1.0e+50
6.8e+00
5.8e+00
—
—
—
—
—
—
cases:17.50%
controls:0.00%
cases:8.65%
controls:0.00%
cases:18.32%
controls:0.03%
cases:13.60%
controls:0.05%
—
—
—
350
0
1650
20000
173
0
1827
19985
342
5
1525
19776
162
9
1029
18738
Fever, unspecified
R50.9 [45582716]
1.1e+00
2.1e+00
2.8e+00
—
2.8e+00
2.1e+00
1.7e+00
cases:5.20%
controls:1.79%
cases:5.30%
controls:0.72%
cases:1.25%
controls:0.08%
—
—
cases:2.15%
controls:0.13%
cases:5.52%
controls:0.71%
cases:13.52%
controls:2.89%
104
358
1896
19642
106
143
1894
19857
25
15
1975
19985
—
43
26
1957
19959
103
140
1764
19641
161
541
1030
18206
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
8.8e-01
1.9e+00
3.7e+00
—
2.8e+00
2.0e+00
1.4e+00
cases:2.45%
controls:1.03%
cases:4.50%
controls:0.70%
cases:3.10%
controls:0.08%
—
—
cases:1.65%
controls:0.11%
cases:5.78%
controls:0.85%
cases:15.45%
controls:4.47%
49
206
1951
19794
90
140
1910
19860
62
16
1938
19984
—
33
21
1967
19964
108
169
1759
19612
184
838
1007
17909
letrozole; oral
L02BG04 [21603842]
2.0e+00
1.8e+00
2.8e+00
—
1.6e+00
2.2e+00
2.1e+00
cases:8.00%
controls:1.21%
cases:6.35%
controls:1.06%
cases:5.10%
controls:0.34%
—
—
cases:1.30%
controls:0.26%
cases:9.48%
controls:1.13%
cases:11.34%
controls:1.49%
160
242
1840
19758
127
212
1873
19788
102
68
1898
19932
—
26
52
1974
19933
177
224
1690
19557
135
279
1056
18468
Differential panel, method unspecified - Blood
69738-3 [42870588]
6.8e-01
1.5e+00
2.4e+00
2.1e+00
2.3e+00
1.8e+00
1.7e+00
cases:11.70%
controls:6.27%
cases:24.25%
controls:6.38%
cases:13.90%
controls:1.40%
cases:0.45%
controls:0.06%
cases:10.70%
controls:1.19%
cases:29.94%
controls:6.72%
cases:51.30%
controls:16.53%
234
1254
1766
18746
485
1275
1515
18725
278
279
1722
19721
9
11
1991
19989
214
238
1786
19747
559
1330
1308
18451
611
3098
580
15649
Simple enzyme inhibitor or similar therapy of methastized malignancy
WD505 [2001310690]
—
—
1.0e+50
1.0e+50
1.0e+50
7.0e+00
5.4e+00
—
—
—
—
cases:10.30%
controls:0.00%
cases:2.00%
controls:0.00%
cases:12.10%
controls:0.00%
cases:22.17%
controls:0.03%
cases:22.33%
controls:0.13%
—
—
206
0
1794
20000
40
0
1960
20000
242
0
1758
19985
414
5
1453
19776
266
24
925
18723
Subcutaneous
ZX112 [2001311492]
2.1e+00
1.9e+00
2.3e+00
—
1.9e+00
2.4e+00
1.8e+00
cases:2.45%
controls:0.32%
cases:1.25%
controls:0.20%
cases:0.40%
controls:0.04%
—
—
cases:0.35%
controls:0.05%
cases:1.07%
controls:0.10%
cases:1.34%
controls:0.23%
49
64
1951
19936
25
39
1975
19961
8
8
1992
19992
—
7
10
1993
19975
20
19
1847
19762
16
43
1175
18704
Breast cancer
115 [2001600115]
1.8e+00
2.6e+00
4.8e+00
—
-1.0e+50
1.6e+00
1.5e+00
cases:7.65%
controls:1.31%
cases:4.70%
controls:0.38%
cases:2.95%
controls:0.03%
—
—
cases:0.00%
controls:0.03%
cases:1.02%
controls:0.20%
cases:3.11%
controls:0.68%
153
263
1847
19737
94
76
1906
19924
59
5
1941
19995
—
0
5
2000
19980
19
39
1848
19742
37
128
1154
18619
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
6.3e-01
2.0e+00
3.7e+00
—
2.4e+00
2.3e+00
1.8e+00
cases:0.85%
controls:0.46%
cases:2.50%
controls:0.35%
cases:1.00%
controls:0.03%
—
—
cases:0.40%
controls:0.04%
cases:2.52%
controls:0.26%
cases:6.13%
controls:1.03%
17
91
1983
19909
50
70
1950
19930
20
5
1980
19995
—
8
7
1992
19978
47
51
1820
19730
73
193
1118
18554
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
1.6e+00
2.7e+00
3.3e+00
—
2.1e+00
1.7e+00
8.2e-01
cases:6.00%
controls:1.25%
cases:8.85%
controls:0.68%
cases:2.55%
controls:0.10%
—
—
cases:0.85%
controls:0.10%
cases:2.25%
controls:0.43%
cases:4.28%
controls:1.93%
120
249
1880
19751
177
136
1823
19864
51
20
1949
19980
—
17
20
1983
19965
42
85
1825
19696
51
361
1140
18386
Extensive abdominal CT
JN3BD [2001305556]
6.2e-01
1.8e+00
2.9e+00
—
2.6e+00
2.3e+00
2.0e+00
cases:4.15%
controls:2.27%
cases:4.30%
controls:0.75%
cases:1.20%
controls:0.07%
—
—
cases:0.80%
controls:0.06%
cases:4.12%
controls:0.45%
cases:5.79%
controls:0.81%
83
455
1917
19545
86
150
1914
19850
24
14
1976
19986
—
16
12
1984
19973
77
89
1790
19692
69
152
1122
18595
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
7.2e-01
1.4e+00
3.5e+00
—
3.1e+00
2.0e+00
1.3e+00
cases:7.15%
controls:3.61%
cases:9.30%
controls:2.44%
cases:10.90%
controls:0.38%
—
—
cases:9.15%
controls:0.43%
cases:16.39%
controls:2.59%
cases:27.46%
controls:9.32%
143
722
1857
19278
186
488
1814
19512
218
76
1782
19924
—
183
86
1817
19899
306
513
1561
19268
327
1747
864
17000
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
5.9e-01
1.7e+00
3.4e+00
—
2.8e+00
2.2e+00
1.3e+00
cases:2.10%
controls:1.17%
cases:4.75%
controls:0.92%
cases:4.15%
controls:0.14%
—
—
cases:1.90%
controls:0.12%
cases:8.14%
controls:1.02%
cases:13.10%
controls:3.80%
42
234
1958
19766
95
183
1905
19817
83
29
1917
19971
—
38
24
1962
19961
152
201
1715
19580
156
713
1035
18034
Intravenous
ZX120 [2001311495]
1.7e+00
2.3e+00
2.4e+00
—
1.6e+00
2.2e+00
1.8e+00
cases:9.00%
controls:1.76%
cases:7.50%
controls:0.82%
cases:1.65%
controls:0.15%
—
—
cases:0.75%
controls:0.16%
cases:4.93%
controls:0.59%
cases:6.63%
controls:1.18%
180
352
1820
19648
150
163
1850
19837
33
30
1967
19970
—
15
31
1985
19954
92
117
1775
19664
79
222
1112
18525
Malignant neoplasm: Upper lobe, bronchus or lung
C34.1 [45595646]
2.6e+00
3.5e+00
1.0e+50
—
—
3.3e+00
2.5e+00
cases:0.45%
controls:0.04%
cases:0.80%
controls:0.03%
cases:2.05%
controls:0.00%
—
—
—
—
cases:1.12%
controls:0.04%
cases:1.93%
controls:0.15%
9
7
1991
19993
16
5
1984
19995
41
0
1959
20000
—
—
21
8
1846
19773
23
29
1168
18718
Other technic of radiotherapy
ZX090 [2001311480]
1.9e+00
2.4e+00
2.9e+00
—
—
2.2e+00
2.5e+00
cases:3.70%
controls:0.60%
cases:2.45%
controls:0.23%
cases:0.55%
controls:0.03%
—
—
—
—
cases:1.07%
controls:0.12%
cases:1.51%
controls:0.13%
74
120
1926
19880
49
45
1951
19955
11
6
1989
19994
—
—
20
23
1847
19758
18
24
1173
18723
Mantle cell lymphoma
C83.1 [45542646]
2.9e+00
3.5e+00
—
—
—
2.8e+00
2.7e+00
cases:0.70%
controls:0.04%
cases:0.85%
controls:0.03%
—
—
—
—
—
—
cases:0.59%
controls:0.04%
cases:0.76%
controls:0.05%
14
8
1986
19992
17
5
1983
19995
—
—
—
11
7
1856
19774
9
10
1182
18737
Extensive CT of head and brain
AA1BD [2001300110]
1.7e+00
3.0e+00
—
—
—
3.8e+00
3.4e+00
cases:2.20%
controls:0.43%
cases:2.10%
controls:0.11%
—
—
—
—
—
—
cases:2.73%
controls:0.06%
cases:2.52%
controls:0.09%
44
86
1956
19914
42
22
1958
19978
—
—
—
51
12
1816
19769
30
16
1161
18731
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.4e-01
9.9e-01
2.9e+00
2.6e+00
3.0e+00
1.5e+00
6.4e-01
cases:51.20%
controls:45.13%
cases:62.80%
controls:38.55%
cases:58.25%
controls:7.05%
cases:3.60%
controls:0.28%
cases:58.30%
controls:6.75%
cases:75.63%
controls:41.11%
cases:86.99%
controls:77.98%
1024
9025
976
10975
1256
7711
744
12289
1165
1410
835
18590
72
55
1928
19945
1166
1349
834
18636
1412
8132
455
11649
1036
14618
155
4129
Malignant melanoma of the trunk other or unspecified histology
C43.59 [2000500754]
2.4e+00
3.1e+00
—
—
—
3.4e+00
3.0e+00
cases:1.05%
controls:0.10%
cases:1.05%
controls:0.05%
—
—
—
—
—
—
cases:1.34%
controls:0.05%
cases:1.09%
controls:0.05%
21
20
1979
19980
21
10
1979
19990
—
—
—
25
9
1842
19772
13
10
1178
18737
High resolution CT examination of lungs
GD1DD [2001303632]
1.7e+00
2.7e+00
2.9e+00
—
—
2.3e+00
2.3e+00
cases:3.40%
controls:0.67%
cases:3.30%
controls:0.23%
cases:0.70%
controls:0.04%
—
—
—
—
cases:2.52%
controls:0.26%
cases:8.14%
controls:0.90%
68
134
1932
19866
66
46
1934
19954
14
8
1986
19992
—
—
47
51
1820
19730
97
169
1094
18578
Monocytes/Leukocytes in Blood
26485-3 [3019069]
4.8e-01
1.4e+00
2.2e+00
2.2e+00
2.2e+00
1.7e+00
1.5e+00
cases:17.15%
controls:11.38%
cases:28.95%
controls:8.97%
cases:15.65%
controls:1.94%
cases:0.65%
controls:0.07%
cases:13.25%
controls:1.70%
cases:35.99%
controls:9.27%
cases:59.45%
controls:24.00%
343
2276
1657
17724
579
1795
1421
18205
313
388
1687
19612
13
14
1987
19986
265
340
1735
19645
672
1833
1195
17948
708
4499
483
14248
Basophils/Leukocytes in Blood
30180-4 [3022096]
4.9e-01
1.4e+00
2.3e+00
2.2e+00
2.2e+00
1.7e+00
1.5e+00
cases:17.05%
controls:11.22%
cases:28.95%
controls:8.87%
cases:15.60%
controls:1.91%
cases:0.60%
controls:0.07%
cases:13.00%
controls:1.67%
cases:35.89%
controls:9.16%
cases:59.36%
controls:23.93%
341
2245
1659
17755
579
1773
1421
18227
312
381
1688
19619
12
14
1988
19986
260
334
1740
19651
670
1812
1197
17969
707
4486
484
14261
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
4.6e-01
1.4e+00
2.2e+00
2.3e+00
2.1e+00
1.7e+00
1.5e+00
cases:17.05%
controls:11.52%
cases:28.80%
controls:9.14%
cases:15.75%
controls:1.94%
cases:0.65%
controls:0.07%
cases:13.15%
controls:1.74%
cases:35.89%
controls:9.54%
cases:59.78%
controls:24.64%
341
2303
1659
17697
576
1828
1424
18172
315
388
1685
19612
13
13
1987
19987
263
348
1737
19637
670
1888
1197
17893
712
4619
479
14128
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
4.9e-01
1.4e+00
2.2e+00
2.2e+00
2.2e+00
1.7e+00
1.5e+00
cases:17.25%
controls:11.34%
cases:29.10%
controls:8.91%
cases:15.50%
controls:1.93%
cases:0.60%
controls:0.07%
cases:13.05%
controls:1.68%
cases:35.99%
controls:9.21%
cases:59.19%
controls:23.93%
345
2267
1655
17733
582
1782
1418
18218
310
385
1690
19615
12
14
1988
19986
261
336
1739
19649
672
1821
1195
17960
705
4487
486
14260
Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 [3037551]
1.2e+00
2.0e+00
3.2e+00
—
1.4e+00
2.3e+00
1.7e+00
cases:3.30%
controls:1.01%
cases:5.40%
controls:0.78%
cases:2.75%
controls:0.12%
—
—
cases:0.65%
controls:0.17%
cases:5.09%
controls:0.53%
cases:8.31%
controls:1.66%
66
203
1934
19797
108
155
1892
19845
55
24
1945
19976
—
13
33
1987
19952
95
105
1772
19676
99
312
1092
18435
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
8.5e-01
1.5e+00
2.6e+00
—
2.6e+00
2.4e+00
1.6e+00
cases:1.70%
controls:0.74%
cases:1.05%
controls:0.24%
cases:0.35%
controls:0.03%
—
—
cases:0.35%
controls:0.03%
cases:1.29%
controls:0.12%
cases:2.35%
controls:0.47%
34
147
1966
19853
21
47
1979
19953
7
5
1993
19995
—
7
5
1993
19980
24
23
1843
19758
28
89
1163
18658
Thorax extensive CT-examination
GD1BD [2001303621]
1.5e+00
2.6e+00
3.0e+00
—
1.6e+00
2.4e+00
2.2e+00
cases:4.55%
controls:1.10%
cases:5.10%
controls:0.41%
cases:0.95%
controls:0.05%
—
—
cases:0.25%
controls:0.05%
cases:2.73%
controls:0.24%
cases:3.27%
controls:0.37%
91
221
1909
19779
102
82
1898
19918
19
10
1981
19990
—
5
10
1995
19975
51
48
1816
19733
39
69
1152
18678
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
1.3e+00
2.3e+00
2.7e+00
—
—
2.7e+00
2.6e+00
cases:0.80%
controls:0.21%
cases:2.10%
controls:0.23%
cases:0.45%
controls:0.03%
—
—
—
—
cases:3.05%
controls:0.22%
cases:7.05%
controls:0.54%
16
42
1984
19958
42
45
1958
19955
9
6
1991
19994
—
—
57
43
1810
19738
84
101
1107
18646
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
1.2e+00
1.9e+00
1.9e+00
—
2.9e+00
2.1e+00
1.6e+00
cases:1.00%
controls:0.31%
cases:2.10%
controls:0.31%
cases:0.35%
controls:0.06%
—
—
cases:0.55%
controls:0.03%
cases:2.30%
controls:0.28%
cases:8.98%
controls:1.94%
20
62
1980
19938
42
62
1958
19938
7
11
1993
19989
—
11
6
1989
19979
43
55
1824
19726
107
364
1084
18383
Metastasis to retroperitoneum
OMOP5031838 [35226284]
—
2.8e+00
—
—
3.1e+00
2.6e+00
3.1e+00
—
—
cases:0.60%
controls:0.04%
—
—
—
—
cases:0.75%
controls:0.04%
cases:0.91%
controls:0.07%
cases:1.68%
controls:0.08%
—
12
7
1988
19993
—
—
15
7
1985
19978
17
13
1850
19768
20
15
1171
18732
Metastasis to peritoneum
OMOP5031802 [35226253]
—
2.8e+00
—
—
3.1e+00
2.6e+00
3.1e+00
—
—
cases:0.60%
controls:0.04%
—
—
—
—
cases:0.75%
controls:0.04%
cases:0.91%
controls:0.07%
cases:1.68%
controls:0.08%
—
12
7
1988
19993
—
—
15
7
1985
19978
17
13
1850
19768
20
15
1171
18732
Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.6 [45547522]
—
2.8e+00
—
—
3.1e+00
2.6e+00
3.1e+00
—
—
cases:0.60%
controls:0.04%
—
—
—
—
cases:0.75%
controls:0.04%
cases:0.91%
controls:0.07%
cases:1.68%
controls:0.08%
—
12
7
1988
19993
—
—
15
7
1985
19978
17
13
1850
19768
20
15
1171
18732
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
1.2e-01
1.8e+00
3.3e+00
—
2.5e+00
2.2e+00
1.8e+00
cases:0.60%
controls:0.54%
cases:2.00%
controls:0.35%
cases:0.65%
controls:0.03%
—
—
cases:0.30%
controls:0.03%
cases:2.46%
controls:0.27%
cases:5.46%
controls:0.90%
12
107
1988
19893
40
70
1960
19930
13
5
1987
19995
—
6
5
1994
19980
46
54
1821
19727
65
169
1126
18578
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.6e-01
1.3e+00
2.5e+00
2.2e+00
2.4e+00
1.7e+00
1.1e+00
cases:44.20%
controls:37.86%
cases:60.10%
controls:29.04%
cases:44.90%
controls:6.00%
cases:2.70%
controls:0.30%
cases:40.90%
controls:5.83%
cases:69.36%
controls:29.54%
cases:84.72%
controls:63.98%
884
7572
1116
12428
1202
5808
798
14192
898
1201
1102
18799
54
60
1946
19940
818
1166
1182
18819
1295
5843
572
13938
1009
11995
182
6752
Immunohistochemistry procedure
117617002 [4035726]
1.6e+00
2.8e+00
3.7e+00
—
1.3e+00
1.8e+00
1.6e+00
cases:7.10%
controls:1.46%
cases:15.35%
controls:1.14%
cases:4.05%
controls:0.11%
—
—
cases:0.25%
controls:0.07%
cases:3.75%
controls:0.62%
cases:11.17%
controls:2.43%
142
292
1858
19708
307
228
1693
19772
81
21
1919
19979
—
5
14
1995
19971
70
123
1797
19658
133
456
1058
18291
Malignant tumor of the anterior, bronchial or pulmonary epidermoid carcinoma
C34.11 [2000500600]
2.8e+00
2.7e+00
3.2e+00
—
—
2.7e+00
—
cases:0.60%
controls:0.04%
cases:0.85%
controls:0.06%
cases:0.60%
controls:0.03%
—
—
—
—
cases:0.70%
controls:0.05%
—
—
12
7
1988
19993
17
11
1983
19989
12
5
1988
19995
—
—
13
9
1854
19772
—
Papillary carcinoma of the thyroid gland (thyroid gland)
C73.91 [2000501197]
2.0e+00
2.2e+00
3.3e+00
—
—
2.1e+00
1.9e+00
cases:1.35%
controls:0.19%
cases:1.25%
controls:0.14%
cases:0.95%
controls:0.04%
—
—
—
—
cases:1.29%
controls:0.15%
cases:1.68%
controls:0.26%
27
38
1973
19962
25
29
1975
19971
19
7
1981
19993
—
—
24
30
1843
19751
20
49
1171
18698
Extensive CT of torso and neck
JN6BD [2001310939]
2.1e+00
2.4e+00
—
—
—
3.4e+00
3.6e+00
cases:0.85%
controls:0.11%
cases:1.10%
controls:0.10%
—
—
—
—
—
—
cases:1.29%
controls:0.05%
cases:1.34%
controls:0.04%
17
21
1983
19979
22
20
1978
19980
—
—
—
24
9
1843
19772
16
7
1175
18740
Bacterial infection, unspecified
A49.9 [45590816]
1.1e+00
1.8e+00
1.8e+00
—
2.9e+00
2.3e+00
1.6e+00
cases:4.40%
controls:1.47%
cases:3.55%
controls:0.63%
cases:0.80%
controls:0.13%
—
—
cases:2.15%
controls:0.13%
cases:6.11%
controls:0.67%
cases:11.42%
controls:2.60%
88
293
1912
19707
71
126
1929
19874
16
26
1984
19974
—
43
25
1957
19960
114
132
1753
19649
136
488
1055
18259
Malignant neoplasm: Liver cell carcinoma
C22.0 [45552247]
—
4.2e+00
—
1.0e+50
—
4.4e+00
2.8e+00
—
—
cases:2.55%
controls:0.04%
—
—
cases:0.65%
controls:0.00%
—
—
cases:4.02%
controls:0.05%
cases:2.10%
controls:0.13%
—
51
8
1949
19992
—
13
0
1987
20000
—
75
10
1792
19771
25
25
1166
18722
Clinic/Center
261Q00000X [38004207]
7.5e-01
1.8e+00
2.8e+00
—
2.2e+00
1.9e+00
1.9e+00
cases:3.00%
controls:1.44%
cases:4.10%
controls:0.73%
cases:2.15%
controls:0.14%
—
—
cases:1.20%
controls:0.14%
cases:3.75%
controls:0.59%
cases:4.53%
controls:0.69%
60
287
1940
19713
82
146
1918
19854
43
27
1957
19973
—
24
27
1976
19958
70
116
1797
19665
54
129
1137
18618
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
1.3e+00
2.3e+00
2.9e+00
—
1.7e+00
2.4e+00
2.4e+00
cases:0.85%
controls:0.24%
cases:2.20%
controls:0.24%
cases:0.55%
controls:0.03%
—
—
cases:0.25%
controls:0.05%
cases:3.11%
controls:0.28%
cases:9.07%
controls:0.90%
17
47
1983
19953
44
47
1956
19953
11
6
1989
19994
—
5
9
1995
19976
58
56
1809
19725
108
169
1083
18578
Malignant melanoma of the torso without histology
C43.50 [2000500749]
2.6e+00
2.8e+00
1.0e+50
—
—
3.3e+00
2.6e+00
cases:0.85%
controls:0.07%
cases:0.60%
controls:0.04%
cases:0.40%
controls:0.00%
—
—
—
—
cases:0.80%
controls:0.03%
cases:0.76%
controls:0.06%
17
13
1983
19987
12
7
1988
19993
8
0
1992
20000
—
—
15
6
1852
19775
9
11
1182
18736
Malignant tumor of the lower inner quadrant of the mammary gland, ductal tumor
C50.31 [2000500998]
1.5e+00
1.8e+00
2.1e+00
—
2.1e+00
2.1e+00
1.6e+00
cases:0.70%
controls:0.17%
cases:0.80%
controls:0.13%
cases:0.60%
controls:0.08%
—
—
cases:0.55%
controls:0.07%
cases:0.91%
controls:0.12%
cases:1.01%
controls:0.20%
14
33
1986
19967
16
26
1984
19974
12
15
1988
19985
—
11
13
1989
19972
17
23
1850
19758
12
37
1179
18710
Flexible bronchoscopy
UGC12 [2001303610]
1.6e+00
3.1e+00
3.0e+00
—
—
1.8e+00
1.6e+00
cases:4.55%
controls:0.92%
cases:7.30%
controls:0.37%
cases:0.70%
controls:0.04%
—
—
—
—
cases:1.61%
controls:0.26%
cases:4.62%
controls:0.96%
91
183
1909
19817
146
73
1854
19927
14
7
1986
19993
—
—
30
51
1837
19730
55
180
1136
18567
Abdominal ultrasound examination
JN3AE [2001305555]
1.1e+00
2.2e+00
4.1e+00
—
1.3e+00
2.0e+00
1.8e+00
cases:7.25%
controls:2.49%
cases:5.80%
controls:0.68%
cases:2.40%
controls:0.04%
—
—
cases:0.35%
controls:0.10%
cases:3.75%
controls:0.54%
cases:9.07%
controls:1.69%
145
498
1855
19502
116
136
1884
19864
48
8
1952
19992
—
7
19
1993
19966
70
107
1797
19674
108
316
1083
18431
Malignant neoplasm of bronchus and lung
C34 [45595645]
3.0e+00
4.8e+00
—
—
—
—
3.4e+00
cases:1.00%
controls:0.05%
cases:2.90%
controls:0.03%
—
—
—
—
—
—
—
—
cases:4.03%
controls:0.14%
20
10
1980
19990
58
5
1942
19995
—
—
—
—
48
27
1143
18720
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
7.3e-01
1.6e+00
3.0e+00
—
2.7e+00
1.8e+00
1.3e+00
cases:4.60%
controls:2.27%
cases:7.10%
controls:1.50%
cases:3.75%
controls:0.20%
—
—
cases:2.40%
controls:0.17%
cases:7.87%
controls:1.36%
cases:17.30%
controls:5.41%
92
455
1908
19545
142
300
1858
19700
75
39
1925
19961
—
48
34
1952
19951
147
269
1720
19512
206
1014
985
17733
Malignant tumor in another specified localization in ductal mammary gland
C50.91 [2000501018]
2.3e+00
3.2e+00
—
—
—
3.2e+00
2.3e+00
cases:1.50%
controls:0.15%
cases:1.75%
controls:0.08%
—
—
—
—
—
—
cases:1.87%
controls:0.08%
cases:2.10%
controls:0.21%
30
30
1970
19970
35
15
1965
19985
—
—
—
35
15
1832
19766
25
39
1166
18708
Thorax X-ray examination
GD1AA [2001303617]
7.9e-01
1.8e+00
2.6e+00
2.0e+00
2.3e+00
2.0e+00
1.5e+00
cases:26.35%
controls:13.97%
cases:26.90%
controls:5.53%
cases:7.95%
controls:0.64%
cases:0.25%
controls:0.04%
cases:5.30%
controls:0.58%
cases:24.69%
controls:4.12%
cases:44.42%
controls:15.29%
527
2794
1473
17206
538
1105
1462
18895
159
128
1841
19872
5
7
1995
19993
106
116
1894
19869
461
815
1406
18966
529
2866
662
15881
CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Blood
54218-3 [40757349]
2.6e+00
2.6e+00
—
—
—
3.2e+00
2.7e+00
cases:0.45%
controls:0.04%
cases:0.45%
controls:0.04%
—
—
—
—
—
—
cases:0.59%
controls:0.03%
cases:1.85%
controls:0.12%
9
7
1991
19993
9
7
1991
19993
—
—
—
11
5
1856
19776
22
23
1169
18724
Malignant tumor of the upper outer quadrant of the mammary gland, other or undeterminated histology
C50.49 [2000501004]
1.7e+00
2.1e+00
3.0e+00
—
—
2.3e+00
1.9e+00
cases:1.20%
controls:0.23%
cases:0.90%
controls:0.11%
cases:0.70%
controls:0.04%
—
—
—
—
cases:0.86%
controls:0.09%
cases:0.92%
controls:0.13%
24
46
1976
19954
18
22
1982
19978
14
7
1986
19993
—
—
16
18
1851
19763
11
25
1180
18722
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
1.1e+00
2.1e+00
3.5e+00
—
—
2.3e+00
2.1e+00
cases:0.75%
controls:0.26%
cases:1.85%
controls:0.24%
cases:0.80%
controls:0.03%
—
—
—
—
cases:1.55%
controls:0.16%
cases:3.27%
controls:0.43%
15
51
1985
19949
37
48
1963
19952
16
5
1984
19995
—
—
29
32
1838
19749
39
81
1152
18666
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
6.1e-01
1.5e+00
2.3e+00
—
2.8e+00
2.2e+00
1.5e+00
cases:2.55%
controls:1.40%
cases:2.05%
controls:0.48%
cases:0.70%
controls:0.07%
—
—
cases:0.90%
controls:0.06%
cases:2.46%
controls:0.28%
cases:2.77%
controls:0.60%
51
280
1949
19720
41
96
1959
19904
14
14
1986
19986
—
18
11
1982
19974
46
55
1821
19726
33
113
1158
18634
palonosetron, combinations
A04AA55 [45893275]
1.4e+00
2.2e+00
2.2e+00
—
-1.0e+50
2.5e+00
2.7e+00
cases:0.85%
controls:0.22%
cases:2.25%
controls:0.25%
cases:0.30%
controls:0.04%
—
—
cases:0.00%
controls:0.04%
cases:1.55%
controls:0.13%
cases:6.13%
controls:0.46%
17
44
1983
19956
45
49
1955
19951
6
7
1994
19993
—
0
8
2000
19977
29
26
1838
19755
73
86
1118
18661
darbepoetin alfa; parenteral
B03XA02 [21601134]
1.1e+00
1.8e+00
2.2e+00
—
1.6e+00
1.9e+00
2.3e+00
cases:0.70%
controls:0.23%
cases:1.35%
controls:0.23%
cases:0.60%
controls:0.07%
—
—
cases:0.55%
controls:0.12%
cases:1.45%
controls:0.23%
cases:4.03%
controls:0.41%
14
45
1986
19955
27
45
1973
19955
12
14
1988
19986
—
11
23
1989
19962
27
45
1840
19736
48
76
1143
18671
hydroxycarbamide; oral
L01XX05 [21603787]
2.7e+00
2.3e+00
3.1e+00
—
1.5e+00
1.3e+00
1.4e+00
cases:2.85%
controls:0.20%
cases:2.15%
controls:0.22%
cases:1.60%
controls:0.07%
—
—
cases:0.35%
controls:0.08%
cases:0.91%
controls:0.25%
cases:1.34%
controls:0.35%
57
40
1943
19960
43
43
1957
19957
32
14
1968
19986
—
7
15
1993
19970
17
49
1850
19732
16
65
1175
18682
Ultrasound examination of mammary glands
HA1AE [2001303886]
1.8e+00
2.0e+00
2.1e+00
—
2.1e+00
1.4e+00
1.5e+00
cases:7.55%
controls:1.40%
cases:4.00%
controls:0.54%
cases:0.80%
controls:0.10%
—
—
cases:0.35%
controls:0.05%
cases:1.82%
controls:0.45%
cases:4.45%
controls:1.08%
151
279
1849
19721
80
107
1920
19893
16
20
1984
19980
—
7
9
1993
19976
34
90
1833
19691
53
202
1138
18545
Thoracal epidural anesthesia
WX302 [2001310795]
1.6e+00
2.6e+00
2.6e+00
—
—
2.1e+00
1.9e+00
cases:2.90%
controls:0.62%
cases:4.15%
controls:0.33%
cases:0.35%
controls:0.03%
—
—
—
—
cases:1.34%
controls:0.16%
cases:2.77%
controls:0.44%
58
123
1942
19877
83
65
1917
19935
7
5
1993
19995
—
—
25
32
1842
19749
33
83
1158
18664
Malignant melanoma of skin
C43 [45571501]
2.9e+00
3.4e+00
—
—
—
—
4.5e+00
cases:0.65%
controls:0.04%
cases:0.85%
controls:0.03%
—
—
—
—
—
—
—
—
cases:3.19%
controls:0.04%
13
7
1987
19993
17
6
1983
19994
—
—
—
—
38
7
1153
18740
Eosinophils [#/volume] in Blood
26449-9 [3013115]
4.7e-01
1.4e+00
2.0e+00
2.0e+00
1.9e+00
1.6e+00
1.4e+00
cases:18.50%
controls:12.45%
cases:29.50%
controls:9.71%
cases:13.75%
controls:2.13%
cases:0.55%
controls:0.08%
cases:11.45%
controls:1.87%
cases:35.94%
controls:10.30%
cases:60.62%
controls:26.88%
370
2489
1630
17511
590
1942
1410
18058
275
425
1725
19575
11
15
1989
19985
229
373
1771
19612
671
2037
1196
17744
722
5040
469
13707
Thorax and upper abdomen combined extensive CT examination of
GD5BD [2001303656]
1.6e+00
3.1e+00
1.0e+50
—
—
3.3e+00
2.7e+00
cases:1.50%
controls:0.30%
cases:2.35%
controls:0.11%
cases:0.70%
controls:0.00%
—
—
—
—
cases:1.87%
controls:0.07%
cases:1.76%
controls:0.12%
30
59
1970
19941
47
22
1953
19978
14
0
1986
20000
—
—
35
14
1832
19767
21
22
1170
18725
Metamyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count
71668-8 [43055361]
1.4e+00
2.0e+00
3.3e+00
—
3.3e+00
2.1e+00
1.3e+00
cases:0.35%
controls:0.09%
cases:0.60%
controls:0.08%
cases:0.70%
controls:0.03%
—
—
cases:0.65%
controls:0.03%
cases:0.96%
controls:0.12%
cases:0.84%
controls:0.23%
7
17
1993
19983
12
16
1988
19984
14
5
1986
19995
—
13
5
1987
19980
18
24
1849
19757
10
43
1181
18704
anastrozole; oral
L02BG03 [21603841]
2.0e+00
1.8e+00
2.3e+00
—
—
1.9e+00
2.6e+00
cases:1.60%
controls:0.22%
cases:0.75%
controls:0.13%
cases:0.30%
controls:0.03%
—
—
—
—
cases:1.02%
controls:0.15%
cases:2.18%
controls:0.16%
32
43
1968
19957
15
26
1985
19974
6
6
1994
19994
—
—
19
29
1848
19752
26
30
1165
18717
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
5.1e-01
1.4e+00
2.9e+00
—
2.5e+00
1.8e+00
1.5e+00
cases:15.40%
controls:9.81%
cases:25.35%
controls:7.59%
cases:18.75%
controls:1.25%
—
—
cases:13.20%
controls:1.23%
cases:32.73%
controls:7.63%
cases:56.84%
controls:23.00%
308
1963
1692
18037
507
1518
1493
18482
375
251
1625
19749
—
264
245
1736
19740
611
1509
1256
18272
677
4312
514
14435
Malignant neoplasm: Upper-inner quadrant of breast
C50.2 [45561811]
2.3e+00
2.9e+00
1.0e+50
—
—
2.4e+00
3.1e+00
cases:0.85%
controls:0.09%
cases:0.45%
controls:0.03%
cases:0.55%
controls:0.00%
—
—
—
—
cases:0.37%
controls:0.04%
cases:1.26%
controls:0.06%
17
18
1983
19982
9
5
1991
19995
11
0
1989
20000
—
—
7
7
1860
19774
15
11
1176
18736
Spirometry
127783003 [4133840]
1.2e+00
2.2e+00
2.6e+00
—
—
2.4e+00
2.1e+00
cases:2.10%
controls:0.66%
cases:3.05%
controls:0.35%
cases:0.55%
controls:0.04%
—
—
—
—
cases:3.32%
controls:0.30%
cases:3.95%
controls:0.49%
42
132
1958
19868
61
69
1939
19931
11
8
1989
19992
—
—
62
59
1805
19722
47
91
1144
18656
Total body bone isotope imaging
NK6AN [2001308473]
2.2e+00
3.0e+00
—
—
—
2.9e+00
2.5e+00
cases:3.35%
controls:0.40%
cases:3.35%
controls:0.18%
—
—
—
—
—
—
cases:1.98%
controls:0.11%
cases:2.85%
controls:0.25%
67
79
1933
19921
67
35
1933
19965
—
—
—
37
21
1830
19760
34
47
1157
18700
Supplier / Service Provider
OMOP5117446 [33004]
-4.0e-01
3.8e-01
1.2e+00
—
3.4e+00
3.2e+00
2.7e+00
cases:18.15%
controls:24.89%
cases:18.95%
controls:13.80%
cases:4.50%
controls:1.40%
—
—
cases:3.10%
controls:0.11%
cases:14.57%
controls:0.69%
cases:28.55%
controls:2.59%
363
4979
1637
15021
379
2761
1621
17239
90
279
1910
19721
—
62
21
1938
19964
272
136
1595
19645
340
486
851
18261
Basophils [#/volume] in Blood
26444-0 [3006315]
4.6e-01
1.3e+00
1.9e+00
1.8e+00
1.9e+00
1.6e+00
1.4e+00
cases:16.95%
controls:11.45%
cases:27.80%
controls:9.22%
cases:12.25%
controls:2.00%
cases:0.45%
controls:0.08%
cases:10.55%
controls:1.75%
cases:34.98%
controls:9.91%
cases:59.36%
controls:25.89%
339
2290
1661
17710
556
1844
1444
18156
245
400
1755
19600
9
15
1991
19985
211
349
1789
19636
653
1961
1214
17820
707
4853
484
13894
Monocytes [#/volume] in Blood
26484-6 [3001604]
4.5e-01
1.3e+00
1.9e+00
1.8e+00
1.9e+00
1.6e+00
1.4e+00
cases:16.65%
controls:11.35%
cases:27.75%
controls:9.19%
cases:12.25%
controls:2.00%
cases:0.45%
controls:0.08%
cases:10.55%
controls:1.76%
cases:34.87%
controls:9.86%
cases:59.45%
controls:25.84%
333
2269
1667
17731
555
1838
1445
18162
245
400
1755
19600
9
15
1991
19985
211
351
1789
19634
651
1951
1216
17830
708
4844
483
13903
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
3.7e-01
1.2e+00
1.9e+00
2.0e+00
1.9e+00
1.5e+00
1.4e+00
cases:15.60%
controls:11.28%
cases:24.15%
controls:8.78%
cases:11.30%
controls:1.86%
cases:0.45%
controls:0.06%
cases:10.40%
controls:1.67%
cases:32.14%
controls:9.29%
cases:57.60%
controls:24.28%
312
2255
1688
17745
483
1756
1517
18244
226
372
1774
19628
9
12
1991
19988
208
333
1792
19652
600
1837
1267
17944
686
4551
505
14196
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.5e-01
9.7e-01
2.6e+00
2.2e+00
2.5e+00
1.2e+00
5.5e-01
cases:55.55%
controls:49.23%
cases:68.55%
controls:45.37%
cases:59.60%
controls:9.59%
cases:3.85%
controls:0.46%
cases:56.70%
controls:9.47%
cases:76.06%
controls:48.28%
cases:88.16%
controls:81.08%
1111
9845
889
10155
1371
9073
629
10927
1192
1918
808
18082
77
91
1923
19909
1134
1892
866
18093
1420
9550
447
10231
1050
15200
141
3547
Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
83084-4 [42529201]
1.6e+00
2.5e+00
3.6e+00
—
—
1.5e+00
1.2e+00
cases:0.95%
controls:0.20%
cases:2.60%
controls:0.23%
cases:1.30%
controls:0.04%
—
—
—
—
cases:1.07%
controls:0.25%
cases:2.35%
controls:0.75%
19
39
1981
19961
52
45
1948
19955
26
7
1974
19993
—
—
20
49
1847
19732
28
140
1163
18607
Multiple cystostatic therapy of methastized malignancy
WD115 [2001310679]
2.6e+00
3.0e+00
—
—
—
3.0e+00
1.7e+00
cases:2.45%
controls:0.19%
cases:1.45%
controls:0.07%
—
—
—
—
—
—
cases:0.91%
controls:0.05%
cases:1.18%
controls:0.22%
49
38
1951
19962
29
14
1971
19986
—
—
—
17
9
1850
19772
14
41
1177
18706
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
4.3e-01
1.3e+00
1.9e+00
1.8e+00
1.9e+00
1.6e+00
1.4e+00
cases:17.55%
controls:12.11%
cases:28.25%
controls:9.62%
cases:12.65%
controls:2.04%
cases:0.45%
controls:0.08%
cases:10.75%
controls:1.83%
cases:35.19%
controls:10.31%
cases:59.87%
controls:26.65%
351
2422
1649
17578
565
1924
1435
18076
253
408
1747
19592
9
15
1991
19985
215
366
1785
19619
657
2039
1210
17742
713
4996
478
13751
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
9.7e-01
1.8e+00
3.4e+00
—
—
2.2e+00
1.9e+00
cases:0.85%
controls:0.33%
cases:1.65%
controls:0.28%
cases:0.90%
controls:0.03%
—
—
—
—
cases:1.71%
controls:0.19%
cases:3.61%
controls:0.55%
17
65
1983
19935
33
55
1967
19945
18
6
1982
19994
—
—
32
38
1835
19743
43
104
1148
18643
Malignant neoplasm: Overlapping lesion of breast
C50.8 [45532913]
2.8e+00
3.5e+00
1.0e+50
—
—
—
4.0e+00
cases:1.70%
controls:0.11%
cases:0.95%
controls:0.03%
cases:1.55%
controls:0.00%
—
—
—
—
—
—
cases:3.44%
controls:0.06%
34
22
1966
19978
19
6
1981
19994
31
0
1969
20000
—
—
—
41
12
1150
18735
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
7.1e-01
1.7e+00
2.1e+00
—
2.7e+00
2.0e+00
1.0e+00
cases:6.90%
controls:3.50%
cases:4.55%
controls:0.91%
cases:0.95%
controls:0.12%
—
—
cases:1.15%
controls:0.08%
cases:5.30%
controls:0.76%
cases:7.72%
controls:2.96%
138
701
1862
19299
91
181
1909
19819
19
23
1981
19977
—
23
15
1977
19970
99
151
1768
19630
92
555
1099
18192
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.3e-01
9.8e-01
2.5e+00
2.3e+00
2.4e+00
1.2e+00
6.5e-01
cases:33.55%
controls:26.67%
cases:51.45%
controls:28.42%
cases:42.80%
controls:6.00%
cases:2.55%
controls:0.28%
cases:39.75%
controls:5.86%
cases:60.58%
controls:32.00%
cases:78.67%
controls:65.89%
671
5334
1329
14666
1029
5684
971
14316
856
1201
1144
18799
51
55
1949
19945
795
1172
1205
18813
1131
6329
736
13452
937
12352
254
6395
Normoblasts [#/volume] in Blood
715-3 [3021589]
5.8e-01
1.1e+00
2.0e+00
2.2e+00
2.0e+00
1.3e+00
1.0e+00
cases:10.35%
controls:6.08%
cases:17.75%
controls:6.88%
cases:11.40%
controls:1.66%
cases:0.70%
controls:0.08%
cases:10.85%
controls:1.57%
cases:26.30%
controls:8.78%
cases:48.70%
controls:25.85%
207
1215
1793
18785
355
1376
1645
18624
228
332
1772
19668
14
16
1986
19984
217
313
1783
19672
491
1737
1376
18044
580
4847
611
13900
Malignant tumor of the lower outer quadrant of the mammary gland, lobular tumor
C50.52 [2000501007]
2.3e+00
2.4e+00
—
—
—
2.9e+00
2.6e+00
cases:0.55%
controls:0.06%
cases:0.45%
controls:0.04%
—
—
—
—
—
—
cases:0.70%
controls:0.04%
cases:1.01%
controls:0.07%
11
11
1989
19989
9
8
1991
19992
—
—
—
13
8
1854
19773
12
14
1179
18733
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
9.5e-01
2.6e+00
2.8e+00
—
—
2.2e+00
1.7e+00
cases:1.30%
controls:0.51%
cases:5.25%
controls:0.41%
cases:0.70%
controls:0.05%
—
—
—
—
cases:2.46%
controls:0.29%
cases:7.64%
controls:1.47%
26
101
1974
19899
105
82
1895
19918
14
9
1986
19991
—
—
46
57
1821
19724
91
275
1100
18472
Parainfluenza virus 4 RNA [Presence] in Specimen by NAA with probe detection
41010-0 [3038297]
1.9e+00
2.2e+00
—
—
—
3.1e+00
3.0e+00
cases:0.40%
controls:0.06%
cases:0.95%
controls:0.11%
—
—
—
—
—
—
cases:1.45%
controls:0.07%
cases:3.36%
controls:0.18%
8
12
1992
19988
19
21
1981
19979
—
—
—
27
13
1840
19768
40
34
1151
18713
Oral Surgery
19 [38004464]
7.1e-01
1.1e+00
2.1e+00
—
2.4e+00
2.2e+00
1.6e+00
cases:1.95%
controls:0.97%
cases:1.20%
controls:0.40%
cases:0.45%
controls:0.06%
—
—
cases:0.60%
controls:0.06%
cases:3.37%
controls:0.38%
cases:4.79%
controls:0.97%
39
194
1961
19806
24
80
1976
19920
9
11
1991
19989
—
12
11
1988
19974
63
76
1804
19705
57
181
1134
18566
Parainfluenza virus 1 RNA [Presence] in Specimen by NAA with probe detection
29908-1 [3025634]
1.9e+00
2.2e+00
—
—
—
3.1e+00
3.0e+00
cases:0.40%
controls:0.06%
cases:0.95%
controls:0.11%
—
—
—
—
—
—
cases:1.39%
controls:0.07%
cases:3.36%
controls:0.18%
8
12
1992
19988
19
21
1981
19979
—
—
—
26
13
1841
19768
40
34
1151
18713
Parainfluenza virus 3 RNA [Presence] in Specimen by NAA with probe detection
29910-7 [3006262]
1.9e+00
2.2e+00
—
—
—
3.1e+00
3.0e+00
cases:0.40%
controls:0.06%
cases:0.95%
controls:0.11%
—
—
—
—
—
—
cases:1.39%
controls:0.07%
cases:3.36%
controls:0.18%
8
12
1992
19988
19
21
1981
19979
—
—
—
26
13
1841
19768
40
34
1151
18713
Parainfluenza virus 2 RNA [Presence] in Specimen by NAA with probe detection
29909-9 [3012158]
1.9e+00
2.2e+00
—
—
—
3.1e+00
3.0e+00
cases:0.40%
controls:0.06%
cases:0.95%
controls:0.11%
—
—
—
—
—
—
cases:1.39%
controls:0.07%
cases:3.36%
controls:0.18%
8
12
1992
19988
19
21
1981
19979
—
—
—
26
13
1841
19768
40
34
1151
18713
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
6.8e-01
1.8e+00
2.0e+00
—
2.3e+00
1.9e+00
1.4e+00
cases:2.65%
controls:1.36%
cases:6.80%
controls:1.25%
cases:1.20%
controls:0.16%
—
—
cases:1.50%
controls:0.16%
cases:7.28%
controls:1.21%
cases:28.21%
controls:8.59%
53
271
1947
19729
136
250
1864
19750
24
32
1976
19968
—
30
32
1970
19953
136
239
1731
19542
336
1611
855
17136
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
3.7e-01
8.3e-01
2.3e+00
2.3e+00
2.3e+00
1.1e+00
7.8e-01
cases:9.55%
controls:6.81%
cases:8.85%
controls:4.07%
cases:5.25%
controls:0.56%
cases:0.30%
controls:0.03%
cases:5.15%
controls:0.53%
cases:10.87%
controls:4.02%
cases:23.68%
controls:12.46%
191
1362
1809
18638
177
813
1823
19187
105
111
1895
19889
6
6
1994
19994
103
106
1897
19879
203
795
1664
18986
282
2335
909
16412
Malignant neoplasm: Stomach, unspecified
C16.9 [45571490]
—
3.1e+00
—
—
—
3.8e+00
3.1e+00
—
—
cases:0.55%
controls:0.03%
—
—
—
—
—
—
cases:1.12%
controls:0.03%
cases:1.68%
controls:0.08%
—
11
5
1989
19995
—
—
—
21
5
1846
19776
20
15
1171
18732
Thrombin time
3243-3 [3036489]
-1.7e-01
1.6e+00
2.5e+00
—
2.3e+00
1.9e+00
1.6e+00
cases:0.60%
controls:0.71%
cases:2.20%
controls:0.44%
cases:0.60%
controls:0.05%
—
—
cases:0.30%
controls:0.03%
cases:2.41%
controls:0.36%
cases:5.71%
controls:1.20%
12
142
1988
19858
44
88
1956
19912
12
10
1988
19990
—
6
6
1994
19979
45
71
1822
19710
68
225
1123
18522
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
4.2e-01
1.3e+00
3.4e+00
—
1.9e+00
2.0e+00
1.2e+00
cases:1.50%
controls:0.99%
cases:2.85%
controls:0.76%
cases:1.70%
controls:0.06%
—
—
cases:0.45%
controls:0.07%
cases:3.32%
controls:0.47%
cases:6.55%
controls:1.99%
30
198
1970
19802
57
152
1943
19848
34
11
1966
19989
—
9
14
1991
19971
62
92
1805
19689
78
373
1113
18374
Platelets [#/volume] in Blood
26515-7 [3007461]
1.9e-01
8.9e-01
2.5e+00
2.2e+00
2.5e+00
1.1e+00
4.1e-01
cases:57.20%
controls:52.44%
cases:69.65%
controls:48.49%
cases:60.55%
controls:10.82%
cases:4.50%
controls:0.51%
cases:59.10%
controls:10.70%
cases:76.33%
controls:51.19%
cases:88.25%
controls:83.35%
1144
10488
856
9512
1393
9699
607
10301
1211
2165
789
17835
90
102
1910
19898
1182
2138
818
17847
1425
10125
442
9656
1051
15625
140
3122
temozolomide
L01AX03 [21601419]
2.4e+00
2.7e+00
—
—
—
2.4e+00
2.4e+00
cases:0.40%
controls:0.04%
cases:0.50%
controls:0.04%
—
—
—
—
—
—
cases:0.43%
controls:0.04%
cases:0.92%
controls:0.09%
8
7
1992
19993
10
7
1990
19993
—
—
—
8
8
1859
19773
11
16
1180
18731
calcium (different salts in combination); oral
A12AA20 [21600872]
6.3e-01
8.3e-01
1.2e+00
3.7e+00
8.5e-01
1.3e+00
1.3e+00
cases:22.00%
controls:13.07%
cases:21.15%
controls:10.47%
cases:8.55%
controls:2.62%
cases:2.10%
controls:0.06%
cases:6.10%
controls:2.71%
cases:31.49%
controls:11.06%
cases:41.98%
controls:16.14%
440
2614
1560
17386
423
2095
1577
17905
171
524
1829
19476
42
11
1958
19989
122
541
1878
19444
588
2187
1279
17594
500
3026
691
15721
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.9e-01
8.9e-01
2.5e+00
2.2e+00
2.5e+00
1.1e+00
4.1e-01
cases:57.30%
controls:52.61%
cases:69.75%
controls:48.62%
cases:60.60%
controls:10.88%
cases:4.55%
controls:0.52%
cases:59.20%
controls:10.71%
cases:76.27%
controls:51.37%
cases:88.33%
controls:83.46%
1146
10522
854
9478
1395
9723
605
10277
1212
2175
788
17825
91
103
1909
19897
1184
2141
816
17844
1424
10161
443
9620
1052
15647
139
3100
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.9e-01
8.9e-01
2.5e+00
2.2e+00
2.5e+00
1.1e+00
4.1e-01
cases:57.30%
controls:52.61%
cases:69.70%
controls:48.60%
cases:60.55%
controls:10.88%
cases:4.50%
controls:0.51%
cases:59.10%
controls:10.73%
cases:76.33%
controls:51.33%
cases:88.33%
controls:83.39%
1146
10522
854
9478
1394
9720
606
10280
1211
2176
789
17824
90
102
1910
19898
1182
2144
818
17841
1425
10153
442
9628
1052
15634
139
3113
MCH [Entitic mass]
28539-5 [3035941]
1.9e-01
8.9e-01
2.5e+00
2.2e+00
2.5e+00
1.1e+00
4.0e-01
cases:57.25%
controls:52.47%
cases:69.60%
controls:48.48%
cases:60.55%
controls:10.84%
cases:4.50%
controls:0.52%
cases:59.10%
controls:10.69%
cases:76.33%
controls:51.25%
cases:88.25%
controls:83.39%
1145
10493
855
9507
1392
9697
608
10303
1211
2168
789
17832
90
103
1910
19897
1182
2137
818
17848
1425
10137
442
9644
1051
15634
140
3113
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.9e-01
8.9e-01
2.5e+00
2.2e+00
2.5e+00
1.1e+00
4.1e-01
cases:57.30%
controls:52.60%
cases:69.65%
controls:48.60%
cases:60.55%
controls:10.86%
cases:4.50%
controls:0.52%
cases:59.15%
controls:10.70%
cases:76.33%
controls:51.34%
cases:88.33%
controls:83.43%
1146
10520
854
9480
1393
9721
607
10279
1211
2171
789
17829
90
103
1910
19897
1183
2139
817
17846
1425
10155
442
9626
1052
15640
139
3107
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.9e-01
8.9e-01
2.5e+00
2.2e+00
2.5e+00
1.1e+00
4.0e-01
cases:57.30%
controls:52.72%
cases:69.75%
controls:48.68%
cases:60.60%
controls:10.89%
cases:4.55%
controls:0.52%
cases:59.15%
controls:10.72%
cases:76.33%
controls:51.37%
cases:88.33%
controls:83.52%
1146
10543
854
9457
1395
9736
605
10264
1212
2179
788
17821
91
103
1909
19897
1183
2143
817
17842
1425
10162
442
9619
1052
15657
139
3090
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.9e-01
8.9e-01
2.5e+00
2.2e+00
2.5e+00
1.1e+00
4.0e-01
cases:57.30%
controls:52.59%
cases:69.70%
controls:48.60%
cases:60.55%
controls:10.86%
cases:4.50%
controls:0.52%
cases:59.10%
controls:10.70%
cases:76.33%
controls:51.33%
cases:88.25%
controls:83.39%
1146
10518
854
9482
1394
9720
606
10280
1211
2171
789
17829
90
103
1910
19897
1182
2138
818
17847
1425
10153
442
9628
1051
15633
140
3114
Bacteria identified in Blood by Culture
600-7 [3023368]
6.4e-01
1.6e+00
2.1e+00
—
2.3e+00
1.9e+00
1.4e+00
cases:8.10%
controls:4.42%
cases:15.15%
controls:3.63%
cases:3.35%
controls:0.43%
—
—
cases:4.70%
controls:0.51%
cases:19.34%
controls:3.57%
cases:37.95%
controls:13.07%
162
885
1838
19115
303
726
1697
19274
67
85
1933
19915
—
94
102
1906
19883
361
706
1506
19075
452
2451
739
16296
Pneumocystis jirovecii DNA [Presence] in Specimen by NAA with probe detection
6521-9 [3009595]
1.6e+00
2.7e+00
—
—
—
2.7e+00
2.8e+00
cases:0.40%
controls:0.08%
cases:1.30%
controls:0.09%
—
—
—
—
—
—
cases:1.23%
controls:0.09%
cases:4.79%
controls:0.31%
8
16
1992
19984
26
18
1974
19982
—
—
—
23
17
1844
19764
57
59
1134
18688
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
9.7e-01
2.0e+00
3.6e+00
—
—
2.2e+00
1.9e+00
cases:0.75%
controls:0.28%
cases:1.80%
controls:0.26%
cases:0.90%
controls:0.03%
—
—
—
—
cases:1.66%
controls:0.18%
cases:3.69%
controls:0.55%
15
57
1985
19943
36
52
1964
19948
18
5
1982
19995
—
—
31
36
1836
19745
44
103
1147
18644
Malignant neoplasm: Malignant melanoma of trunk
C43.5 [45537804]
3.0e+00
3.4e+00
—
—
—
—
3.2e+00
cases:0.80%
controls:0.04%
cases:0.75%
controls:0.03%
—
—
—
—
—
—
—
—
cases:1.34%
controls:0.05%
16
8
1984
19992
15
5
1985
19995
—
—
—
—
16
10
1175
18737
CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood
14135-8 [3001405]
1.9e+00
2.7e+00
—
—
—
2.6e+00
2.5e+00
cases:0.55%
controls:0.09%
cases:0.90%
controls:0.06%
—
—
—
—
—
—
cases:0.86%
controls:0.07%
cases:2.60%
controls:0.22%
11
17
1989
19983
18
12
1982
19988
—
—
—
16
13
1851
19768
31
42
1160
18705
Rhinovirus RNA [Presence] in Specimen by NAA with probe detection
7993-9 [3025023]
1.2e+00
2.3e+00
2.2e+00
—
—
2.5e+00
2.7e+00
cases:0.40%
controls:0.12%
cases:1.15%
controls:0.12%
cases:0.30%
controls:0.04%
—
—
—
—
cases:1.55%
controls:0.13%
cases:4.62%
controls:0.34%
8
24
1992
19976
23
23
1977
19977
6
7
1994
19993
—
—
29
26
1838
19755
55
63
1136
18684
Extensive MRI examination of upper part of abdomen with high intensity magnet
JN1CG [2001305527]
1.6e+00
3.0e+00
—
—
—
2.7e+00
2.2e+00
cases:1.70%
controls:0.34%
cases:1.55%
controls:0.08%
—
—
—
—
—
—
cases:1.45%
controls:0.10%
cases:2.35%
controls:0.26%
34
68
1966
19932
31
15
1969
19985
—
—
—
27
19
1840
19762
28
49
1163
18698
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
3.4e-01
1.3e+00
2.6e+00
—
2.7e+00
1.6e+00
1.0e+00
cases:11.30%
controls:8.30%
cases:16.65%
controls:5.05%
cases:9.05%
controls:0.71%
—
—
cases:9.05%
controls:0.69%
cases:20.41%
controls:4.88%
cases:33.84%
controls:15.57%
226
1660
1774
18340
333
1011
1667
18989
181
141
1819
19859
—
181
137
1819
19848
381
965
1486
18816
403
2919
788
15828
Malignant neoplasm: Pancreas, unspecified
C25.9 [45537797]
2.0e+00
2.8e+00
—
—
—
2.4e+00
2.4e+00
cases:0.30%
controls:0.04%
cases:0.60%
controls:0.04%
—
—
—
—
—
—
cases:0.54%
controls:0.05%
cases:0.84%
controls:0.08%
6
8
1994
19992
12
7
1988
19993
—
—
—
10
10
1857
19771
10
15
1181
18732
allopurinol; oral, parenteral
M04AA01 [21604131]
8.2e-01
7.0e-01
1.8e+00
3.7e+00
1.0e+00
8.2e-01
6.5e-01
cases:8.30%
controls:3.85%
cases:5.85%
controls:3.00%
cases:4.55%
controls:0.75%
cases:1.25%
controls:0.03%
cases:2.15%
controls:0.79%
cases:6.75%
controls:3.10%
cases:8.56%
controls:4.68%
166
769
1834
19231
117
601
1883
19399
91
150
1909
19850
25
6
1975
19994
43
157
1957
19828
126
614
1741
19167
102
877
1089
17870
Complement+Immunoglobulin [Units/volume] in Red Blood Cells
4533-6 [3024403]
1.5e+00
2.3e+00
3.0e+00
—
—
1.4e+00
1.4e+00
cases:1.35%
controls:0.31%
cases:2.55%
controls:0.26%
cases:0.70%
controls:0.04%
—
—
—
—
cases:1.23%
controls:0.31%
cases:4.03%
controls:1.03%
27
62
1973
19938
51
52
1949
19948
14
7
1986
19993
—
—
23
62
1844
19719
48
193
1143
18554
Very extensive MRI examination of brain with high intensity magnet
AA1DG [2001300120]
9.4e-01
2.3e+00
2.5e+00
—
—
1.9e+00
1.9e+00
cases:0.90%
controls:0.36%
cases:0.80%
controls:0.08%
cases:0.30%
controls:0.03%
—
—
—
—
cases:0.64%
controls:0.10%
cases:1.93%
controls:0.29%
18
71
1982
19929
16
16
1984
19984
6
5
1994
19995
—
—
12
19
1855
19762
23
54
1168
18693
Karyotype in Bone marrow
81861-7 [21494434]
1.7e+00
3.0e+00
—
—
—
3.5e+00
1.4e+00
cases:0.65%
controls:0.13%
cases:1.80%
controls:0.10%
—
—
—
—
—
—
cases:1.77%
controls:0.06%
cases:1.60%
controls:0.39%
13
25
1987
19975
36
19
1964
19981
—
—
—
33
11
1834
19770
19
73
1172
18674
Enterovirus RNA [Presence] in Specimen by NAA with probe detection
29591-5 [3016881]
9.2e-01
2.3e+00
2.3e+00
—
—
2.3e+00
2.6e+00
cases:0.40%
controls:0.16%
cases:1.15%
controls:0.12%
cases:0.35%
controls:0.04%
—
—
—
—
cases:1.55%
controls:0.15%
cases:4.62%
controls:0.36%
8
32
1992
19968
23
24
1977
19976
7
7
1993
19993
—
—
29
30
1838
19751
55
68
1136
18679
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
1.1e+00
2.1e+00
—
—
2.6e+00
2.0e+00
1.6e+00
cases:0.70%
controls:0.23%
cases:1.70%
controls:0.21%
—
—
—
—
cases:0.35%
controls:0.03%
cases:1.55%
controls:0.21%
cases:8.31%
controls:1.78%
14
45
1986
19955
34
42
1966
19958
—
—
7
5
1993
19980
29
42
1838
19739
99
333
1092
18414
CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood
9728-7 [3025271]
1.9e+00
2.7e+00
—
—
—
2.6e+00
2.3e+00
cases:0.55%
controls:0.08%
cases:0.85%
controls:0.06%
—
—
—
—
—
—
cases:0.86%
controls:0.07%
cases:2.27%
controls:0.23%
11
16
1989
19984
17
12
1983
19988
—
—
—
16
13
1851
19768
27
43
1164
18704
Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
46083-2 [3043362]
4.9e-01
1.3e+00
2.2e+00
—
2.7e+00
1.8e+00
1.5e+00
cases:1.20%
controls:0.74%
cases:1.70%
controls:0.47%
cases:0.30%
controls:0.04%
—
—
cases:0.50%
controls:0.04%
cases:1.82%
controls:0.29%
cases:1.68%
controls:0.38%
24
147
1976
19853
34
93
1966
19907
6
7
1994
19993
—
10
7
1990
19978
34
58
1833
19723
20
71
1171
18676
Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
46082-4 [3046524]
4.9e-01
1.3e+00
2.2e+00
—
2.7e+00
1.8e+00
1.5e+00
cases:1.20%
controls:0.74%
cases:1.70%
controls:0.47%
cases:0.30%
controls:0.04%
—
—
cases:0.50%
controls:0.04%
cases:1.82%
controls:0.29%
cases:1.68%
controls:0.38%
24
147
1976
19853
34
93
1966
19907
6
7
1994
19993
—
10
7
1990
19978
34
58
1833
19723
20
71
1171
18676
Ascites
R18 [45548949]
1.1e+00
2.2e+00
2.9e+00
—
—
2.4e+00
2.0e+00
cases:0.25%
controls:0.09%
cases:0.60%
controls:0.07%
cases:0.45%
controls:0.03%
—
—
—
—
cases:0.64%
controls:0.06%
cases:1.51%
controls:0.20%
5
17
1995
19983
12
14
1988
19986
9
5
1991
19995
—
—
12
12
1855
19769
18
38
1173
18709
Social worker
Z2446 [2001311559]
1.2e+00
2.1e+00
2.0e+00
—
2.5e+00
2.4e+00
1.3e+00
cases:3.05%
controls:0.97%
cases:1.40%
controls:0.18%
cases:0.25%
controls:0.04%
—
—
cases:0.30%
controls:0.03%
cases:0.91%
controls:0.09%
cases:1.09%
controls:0.29%
61
193
1939
19807
28
36
1972
19964
5
7
1995
19993
—
6
5
1994
19980
17
17
1850
19764
13
55
1178
18692
Herpes simplex virus Ag [Presence] in Specimen
16945-8 [3001964]
1.5e+00
2.3e+00
—
—
—
2.5e+00
3.1e+00
cases:0.45%
controls:0.10%
cases:0.45%
controls:0.05%
—
—
—
—
—
—
cases:0.54%
controls:0.05%
cases:0.84%
controls:0.04%
9
20
1991
19980
9
9
1991
19991
—
—
—
10
9
1857
19772
10
7
1181
18740
Protein [Mass/volume] in Urine
2888-6 [3037121]
4.8e-01
1.6e+00
2.8e+00
—
2.1e+00
1.7e+00
1.3e+00
cases:1.40%
controls:0.87%
cases:2.85%
controls:0.59%
cases:1.15%
controls:0.07%
—
—
cases:0.75%
controls:0.10%
cases:2.73%
controls:0.53%
cases:4.87%
controls:1.44%
28
174
1972
19826
57
117
1943
19883
23
14
1977
19986
—
15
19
1985
19966
51
105
1816
19676
58
270
1133
18477
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
5.4e-01
1.5e+00
2.5e+00
—
2.1e+00
1.7e+00
1.1e+00
cases:3.75%
controls:2.23%
cases:5.85%
controls:1.36%
cases:2.05%
controls:0.18%
—
—
cases:1.60%
controls:0.21%
cases:6.53%
controls:1.23%
cases:12.85%
controls:4.70%
75
445
1925
19555
117
272
1883
19728
41
36
1959
19964
—
32
41
1968
19944
122
243
1745
19538
153
882
1038
17865
pH of Specimen
17433-4 [3019225]
4.9e-01
1.3e+00
2.8e+00
—
2.1e+00
1.5e+00
1.1e+00
cases:4.25%
controls:2.63%
cases:6.60%
controls:1.89%
cases:5.25%
controls:0.33%
—
—
cases:2.65%
controls:0.33%
cases:8.46%
controls:1.97%
cases:13.94%
controls:5.08%
85
527
1915
19473
132
377
1868
19623
105
65
1895
19935
—
53
65
1947
19920
158
390
1709
19391
166
953
1025
17794
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
7.7e-01
1.6e+00
2.6e+00
-1.0e+50
1.5e+00
1.5e+00
1.4e+00
cases:2.85%
controls:1.35%
cases:5.10%
controls:1.05%
cases:1.65%
controls:0.13%
cases:0.00%
controls:0.03%
cases:0.60%
controls:0.14%
cases:4.87%
controls:1.08%
cases:10.92%
controls:2.93%
57
269
1943
19731
102
211
1898
19789
33
26
1967
19974
0
6
2000
19994
12
28
1988
19957
91
213
1776
19568
130
550
1061
18197
Malignant neoplasm: Lower lobe, bronchus or lung
C34.3 [45605263]
—
3.1e+00
1.0e+50
—
—
2.6e+00
3.6e+00
—
—
cases:0.55%
controls:0.03%
cases:1.45%
controls:0.00%
—
—
—
—
cases:0.48%
controls:0.04%
cases:2.10%
controls:0.06%
—
11
5
1989
19995
29
0
1971
20000
—
—
9
7
1858
19774
25
11
1166
18736
Bone marrow Pathology biopsy report
33721-2 [3045142]
2.1e+00
3.1e+00
—
—
—
2.3e+00
1.7e+00
cases:1.35%
controls:0.17%
cases:2.60%
controls:0.12%
—
—
—
—
—
—
cases:0.80%
controls:0.08%
cases:2.60%
controls:0.48%
27
34
1973
19966
52
23
1948
19977
—
—
—
15
16
1852
19765
31
90
1160
18657
Malignant melanoma on the torso: 'superficial spreading' type
C43.52 [2000500751]
1.9e+00
2.7e+00
—
—
—
2.7e+00
1.9e+00
cases:0.75%
controls:0.11%
cases:1.00%
controls:0.07%
—
—
—
—
—
—
cases:0.96%
controls:0.07%
cases:1.34%
controls:0.20%
15
22
1985
19978
20
14
1980
19986
—
—
—
18
13
1849
19768
16
37
1175
18710
Ultrasound examination of lower leg veins
PH2AE [2001309451]
5.4e-01
9.2e-01
2.3e+00
—
2.7e+00
1.6e+00
1.1e+00
cases:3.35%
controls:1.98%
cases:1.45%
controls:0.59%
cases:0.40%
controls:0.04%
—
—
cases:0.45%
controls:0.03%
cases:2.46%
controls:0.49%
cases:6.63%
controls:2.31%
67
395
1933
19605
29
117
1971
19883
8
8
1992
19992
—
9
6
1991
19979
46
97
1821
19684
79
433
1112
18314
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
1.3e+00
1.7e+00
2.5e+00
—
—
2.3e+00
1.4e+00
cases:2.30%
controls:0.63%
cases:1.25%
controls:0.23%
cases:0.30%
controls:0.03%
—
—
—
—
cases:1.18%
controls:0.12%
cases:2.60%
controls:0.68%
46
125
1954
19875
25
46
1975
19954
6
5
1994
19995
—
—
22
24
1845
19757
31
128
1160
18619
Multidisciplinary treatment meeting
WZC20 [2001310890]
7.7e-01
2.4e+00
3.6e+00
—
-1.0e+50
1.6e+00
1.5e+00
cases:0.60%
controls:0.28%
cases:3.35%
controls:0.31%
cases:1.70%
controls:0.05%
—
—
cases:0.00%
controls:0.04%
cases:1.02%
controls:0.21%
cases:4.11%
controls:0.98%
12
56
1988
19944
67
61
1933
19939
34
9
1966
19991
—
0
8
2000
19977
19
41
1848
19740
49
184
1142
18563
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
5.9e-01
1.7e+00
2.5e+00
—
1.7e+00
1.4e+00
1.1e+00
cases:2.60%
controls:1.46%
cases:5.55%
controls:1.03%
cases:2.10%
controls:0.18%
—
—
cases:1.20%
controls:0.22%
cases:4.23%
controls:1.03%
cases:11.00%
controls:3.86%
52
292
1948
19708
111
206
1889
19794
42
35
1958
19965
—
24
43
1976
19942
79
204
1788
19577
131
723
1060
18024
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
6.1e-01
1.5e+00
2.4e+00
—
1.7e+00
1.6e+00
1.2e+00
cases:9.80%
controls:5.57%
cases:17.15%
controls:4.23%
cases:6.25%
controls:0.57%
—
—
cases:2.80%
controls:0.53%
cases:15.69%
controls:3.56%
cases:30.06%
controls:11.62%
196
1114
1804
18886
343
846
1657
19154
125
115
1875
19885
—
56
105
1944
19880
293
705
1574
19076
358
2179
833
16568
Extensive CT examination of thorax for dose design of radiotherapy
YG1BD [2001303664]
1.6e+00
2.2e+00
—
—
—
2.9e+00
2.4e+00
cases:2.70%
controls:0.57%
cases:1.70%
controls:0.20%
—
—
—
—
—
—
cases:1.55%
controls:0.09%
cases:2.18%
controls:0.20%
54
114
1946
19886
34
39
1966
19961
—
—
—
29
17
1838
19764
26
38
1165
18709
Internal Medicine
11 [38004456]
4.0e-01
1.1e+00
1.5e+00
2.1e+00
1.6e+00
1.2e+00
1.1e+00
cases:33.15%
controls:24.95%
cases:26.90%
controls:10.60%
cases:7.70%
controls:1.76%
cases:0.55%
controls:0.07%
cases:7.40%
controls:1.58%
cases:27.32%
controls:9.72%
cases:43.58%
controls:21.10%
663
4991
1337
15009
538
2119
1462
17881
154
352
1846
19648
11
14
1989
19986
148
315
1852
19670
510
1923
1357
17858
519
3956
672
14791
aprepitant; oral, parenteral
A04AD12 [21600505]
2.1e+00
2.5e+00
—
—
—
1.9e+00
2.5e+00
cases:3.20%
controls:0.39%
cases:1.95%
controls:0.17%
—
—
—
—
—
—
cases:0.59%
controls:0.09%
cases:1.01%
controls:0.09%
64
77
1936
19923
39
33
1961
19967
—
—
—
11
17
1856
19764
12
16
1179
18731
Drug-induced neutropenia
D70.82 [2000501376]
2.2e+00
2.4e+00
—
—
—
3.0e+00
1.5e+00
cases:1.50%
controls:0.17%
cases:0.70%
controls:0.07%
—
—
—
—
—
—
cases:0.48%
controls:0.03%
cases:0.84%
controls:0.19%
30
34
1970
19966
14
13
1986
19987
—
—
—
9
5
1858
19776
10
35
1181
18712
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.0e-01
7.1e-01
2.2e+00
2.4e+00
2.2e+00
9.1e-01
3.6e-01
cases:31.70%
controls:27.57%
cases:43.80%
controls:27.78%
cases:38.30%
controls:6.47%
cases:2.95%
controls:0.27%
cases:38.10%
controls:6.38%
cases:53.03%
controls:31.31%
cases:66.25%
controls:57.84%
634
5513
1366
14487
876
5556
1124
14444
766
1294
1234
18706
59
53
1941
19947
762
1276
1238
18709
990
6194
877
13587
789
10844
402
7903
Palbociclib
1501 [2001600136]
—
—
1.0e+50
1.0e+50
—
4.4e+00
4.7e+00
—
—
—
—
cases:11.90%
controls:0.00%
cases:0.25%
controls:0.00%
—
—
cases:2.30%
controls:0.03%
cases:4.79%
controls:0.05%
—
—
238
0
1762
20000
5
0
1995
20000
—
43
6
1824
19775
57
9
1134
18738
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
4.6e-01
1.7e+00
2.2e+00
—
2.1e+00
1.8e+00
1.2e+00
cases:1.45%
controls:0.92%
cases:4.55%
controls:0.87%
cases:0.80%
controls:0.09%
—
—
cases:0.95%
controls:0.12%
cases:4.77%
controls:0.84%
cases:18.81%
controls:6.29%
29
184
1971
19816
91
174
1909
19826
16
18
1984
19982
—
19
24
1981
19961
89
166
1778
19615
224
1179
967
17568
Total nephrectomy with capsule
KAC10 [2001305668]
3.8e+00
5.2e+00
—
—
—
—
—
cases:2.15%
controls:0.05%
cases:4.30%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
43
10
1957
19990
86
5
1914
19995
—
—
—
—
—
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
0.0e+00
1.7e+00
3.2e+00
—
—
2.2e+00
1.9e+00
cases:0.50%
controls:0.50%
cases:1.80%
controls:0.35%
cases:0.60%
controls:0.03%
—
—
—
—
cases:2.20%
controls:0.24%
cases:5.37%
controls:0.84%
10
100
1990
19900
36
70
1964
19930
12
5
1988
19995
—
—
41
48
1826
19733
64
158
1127
18589
Excision of other lesion extending through all layers of skin of trunk
QBE10 [2001309853]
1.1e+00
2.2e+00
2.6e+00
—
—
1.8e+00
1.2e+00
cases:2.60%
controls:0.86%
cases:2.10%
controls:0.24%
cases:0.35%
controls:0.03%
—
—
—
—
cases:1.12%
controls:0.19%
cases:2.60%
controls:0.84%
52
172
1948
19828
42
47
1958
19953
7
5
1993
19995
—
—
21
37
1846
19744
31
157
1160
18590
Implantation of vascular injection port
TPX10 [2001309608]
2.0e+00
2.1e+00
—
—
—
2.8e+00
2.0e+00
cases:1.60%
controls:0.21%
cases:1.05%
controls:0.14%
—
—
—
—
—
—
cases:1.18%
controls:0.08%
cases:2.94%
controls:0.39%
32
42
1968
19958
21
27
1979
19973
—
—
—
22
15
1845
19766
35
73
1156
18674
Bronchial lavation
TGC00 [2001303585]
1.7e+00
2.7e+00
—
—
—
2.0e+00
2.4e+00
cases:1.60%
controls:0.29%
cases:2.15%
controls:0.14%
—
—
—
—
—
—
cases:0.80%
controls:0.11%
cases:2.77%
controls:0.26%
32
58
1968
19942
43
29
1957
19971
—
—
—
15
21
1852
19760
33
49
1158
18698
Extensive CT examination of pelvis for dose design of radiotherapy
YL1BD [2001305594]
1.7e+00
2.3e+00
1.0e+50
—
—
2.9e+00
2.0e+00
cases:1.45%
controls:0.28%
cases:0.90%
controls:0.10%
cases:0.30%
controls:0.00%
—
—
—
—
cases:0.91%
controls:0.05%
cases:1.34%
controls:0.18%
29
56
1971
19944
18
19
1982
19981
6
0
1994
20000
—
—
17
10
1850
19771
16
34
1175
18713
Morphology [Interpretation] in Bone marrow Narrative
51628-6 [3042111]
1.8e+00
2.7e+00
—
—
—
2.9e+00
1.5e+00
cases:1.60%
controls:0.28%
cases:3.10%
controls:0.23%
—
—
—
—
—
—
cases:2.30%
controls:0.13%
cases:3.02%
controls:0.68%
32
56
1968
19944
62
45
1938
19955
—
—
—
43
26
1824
19755
36
127
1155
18620
Paranasal sinuses X-ray examination without contrast
DM1AA [2001301740]
1.3e+00
2.3e+00
—
—
—
2.7e+00
2.5e+00
cases:1.60%
controls:0.44%
cases:1.00%
controls:0.10%
—
—
—
—
—
—
cases:1.23%
controls:0.08%
cases:2.85%
controls:0.25%
32
88
1968
19912
20
20
1980
19980
—
—
—
23
16
1844
19765
34
47
1157
18700
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
5.0e-01
1.7e+00
2.5e+00
—
1.6e+00
1.8e+00
1.3e+00
cases:2.55%
controls:1.56%
cases:6.10%
controls:1.22%
cases:1.85%
controls:0.16%
—
—
cases:0.70%
controls:0.14%
cases:5.78%
controls:1.04%
cases:11.75%
controls:3.61%
51
313
1949
19687
122
243
1878
19757
37
32
1963
19968
—
14
28
1986
19957
108
205
1759
19576
140
677
1051
18070
Cancer Ag 19-9 [Units/volume] in Serum or Plasma
24108-3 [3022914]
1.4e+00
2.3e+00
2.8e+00
—
1.1e+00
1.5e+00
7.7e-01
cases:2.30%
controls:0.60%
cases:5.25%
controls:0.54%
cases:2.45%
controls:0.15%
—
—
cases:0.30%
controls:0.11%
cases:2.46%
controls:0.56%
cases:3.11%
controls:1.46%
46
120
1954
19880
105
108
1895
19892
49
30
1951
19970
—
6
21
1994
19964
46
111
1821
19670
37
274
1154
18473
Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma
19176-7 [3015916]
1.6e+00
2.9e+00
—
—
—
2.5e+00
1.7e+00
cases:1.00%
controls:0.20%
cases:3.10%
controls:0.18%
—
—
—
—
—
—
cases:2.46%
controls:0.20%
cases:2.60%
controls:0.48%
20
39
1980
19961
62
36
1938
19964
—
—
—
46
40
1821
19741
31
90
1160
18657
Oncology Clinic/Center
261QX0200X [38004268]
1.5e+00
3.0e+00
3.6e+00
—
6.7e-01
6.1e-01
3.2e-01
cases:27.35%
controls:7.46%
cases:33.75%
controls:2.54%
cases:6.50%
controls:0.19%
—
—
cases:0.35%
controls:0.18%
cases:3.27%
controls:1.81%
cases:10.33%
controls:7.69%
547
1492
1453
18508
675
509
1325
19491
130
37
1870
19963
—
7
36
1993
19949
61
358
1806
19423
123
1442
1068
17305
Diffusion capacity of lung
54715006 [4182985]
1.4e+00
2.9e+00
—
—
—
2.6e+00
1.9e+00
cases:1.30%
controls:0.34%
cases:2.55%
controls:0.14%
—
—
—
—
—
—
cases:1.93%
controls:0.15%
cases:2.85%
controls:0.44%
26
68
1974
19932
51
28
1949
19972
—
—
—
36
30
1831
19751
34
83
1157
18664
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
5.2e-01
1.7e+00
2.1e+00
—
2.0e+00
1.8e+00
1.2e+00
cases:1.65%
controls:0.99%
cases:4.60%
controls:0.91%
cases:0.85%
controls:0.11%
—
—
cases:0.95%
controls:0.13%
cases:4.87%
controls:0.87%
cases:17.80%
controls:6.13%
33
198
1967
19802
92
182
1908
19818
17
21
1983
19979
—
19
26
1981
19959
91
172
1776
19609
212
1150
979
17597
CD19 cells [#/volume] in Blood
8116-6 [3010503]
2.0e+00
2.1e+00
—
—
—
2.1e+00
2.4e+00
cases:0.50%
controls:0.07%
cases:0.70%
controls:0.09%
—
—
—
—
—
—
cases:0.75%
controls:0.10%
cases:2.94%
controls:0.26%
10
13
1990
19987
14
17
1986
19983
—
—
—
14
19
1853
19762
35
49
1156
18698
Metastasis to cerebrum
OMOP5031569 [35226101]
—
—
—
—
—
4.5e+00
4.2e+00
—
—
—
—
—
—
—
—
—
—
cases:3.00%
controls:0.04%
cases:4.70%
controls:0.07%
—
—
—
—
—
56
7
1811
19774
56
14
1135
18733
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.9e-01
8.7e-01
2.2e+00
1.6e+00
2.0e+00
1.1e+00
6.7e-01
cases:51.00%
controls:46.18%
cases:62.20%
controls:40.78%
cases:42.90%
controls:7.74%
cases:1.95%
controls:0.39%
cases:38.85%
controls:7.83%
cases:69.47%
controls:43.39%
cases:86.73%
controls:77.00%
1020
9236
980
10764
1244
8156
756
11844
858
1547
1142
18453
39
78
1961
19922
777
1564
1223
18421
1297
8582
570
11199
1033
14435
158
4312
Malignant tumor of the rectum invasive carcinoma
C20.91 [2000500574]
1.3e+00
1.6e+00
2.3e+00
1.0e+50
2.0e+00
1.4e+00
-1.3e-01
cases:1.35%
controls:0.38%
cases:1.55%
controls:0.33%
cases:1.20%
controls:0.12%
cases:0.25%
controls:0.00%
cases:1.10%
controls:0.15%
cases:1.29%
controls:0.31%
cases:0.42%
controls:0.48%
27
75
1973
19925
31
65
1969
19935
24
24
1976
19976
5
0
1995
20000
22
29
1978
19956
24
61
1843
19720
5
90
1186
18657
Other extensive CT eamination for dose design of radiotherapy
YX9BD [2001311066]
1.5e+00
2.8e+00
—
—
—
2.6e+00
3.3e+00
cases:0.35%
controls:0.08%
cases:0.40%
controls:0.03%
—
—
—
—
—
—
cases:0.48%
controls:0.04%
cases:1.09%
controls:0.04%
7
15
1993
19985
8
5
1992
19995
—
—
—
9
7
1858
19774
13
8
1178
18739
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.0e-01
8.9e-01
2.2e+00
1.6e+00
2.0e+00
1.1e+00
6.7e-01
cases:50.80%
controls:45.74%
cases:62.10%
controls:40.28%
cases:42.40%
controls:7.62%
cases:1.80%
controls:0.38%
cases:38.15%
controls:7.65%
cases:69.15%
controls:42.78%
cases:86.48%
controls:76.61%
1016
9149
984
10851
1242
8056
758
11944
848
1523
1152
18477
36
75
1964
19925
763
1528
1237
18457
1291
8462
576
11319
1030
14363
161
4384
Therapeutic Radiology Physician
2085R0203X [38004006]
1.6e+00
2.2e+00
1.7e+00
—
1.0e+00
1.6e+00
1.6e+00
cases:2.10%
controls:0.43%
cases:2.50%
controls:0.30%
cases:0.60%
controls:0.12%
—
—
cases:0.25%
controls:0.09%
cases:1.02%
controls:0.21%
cases:1.85%
controls:0.36%
42
86
1958
19914
50
59
1950
19941
12
23
1988
19977
—
5
18
1995
19967
19
42
1848
19739
22
68
1169
18679
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
2.5e-01
1.7e+00
2.7e+00
—
1.6e+00
1.5e+00
1.2e+00
cases:3.60%
controls:2.82%
cases:9.10%
controls:1.85%
cases:3.05%
controls:0.22%
—
—
cases:1.10%
controls:0.23%
cases:6.64%
controls:1.53%
cases:17.55%
controls:6.30%
72
564
1928
19436
182
370
1818
19630
61
43
1939
19957
—
22
45
1978
19940
124
302
1743
19479
209
1181
982
17566
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
4.6e-01
1.3e+00
2.8e+00
—
1.9e+00
1.6e+00
1.1e+00
cases:2.70%
controls:1.72%
cases:4.35%
controls:1.25%
cases:2.00%
controls:0.13%
—
—
cases:0.55%
controls:0.09%
cases:3.86%
controls:0.82%
cases:9.74%
controls:3.52%
54
344
1946
19656
87
249
1913
19751
40
25
1960
19975
—
11
17
1989
19968
72
162
1795
19619
116
659
1075
18088
moxifloxacin; oral, parenteral
J01MA14 [21603021]
9.4e-01
1.8e+00
2.3e+00
—
—
1.8e+00
1.7e+00
cases:3.45%
controls:1.38%
cases:2.05%
controls:0.34%
cases:0.45%
controls:0.05%
—
—
—
—
cases:2.20%
controls:0.36%
cases:4.70%
controls:0.89%
69
275
1931
19725
41
67
1959
19933
9
9
1991
19991
—
—
41
72
1826
19709
56
166
1135
18581
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.6e-01
1.0e+00
1.1e+00
2.9e+00
1.0e+00
1.2e+00
9.3e-01
cases:31.90%
controls:22.80%
cases:30.65%
controls:13.63%
cases:8.25%
controls:3.02%
cases:1.85%
controls:0.11%
cases:7.45%
controls:2.85%
cases:36.10%
controls:14.33%
cases:51.81%
controls:29.69%
638
4561
1362
15439
613
2726
1387
17274
165
604
1835
19396
37
21
1963
19979
149
569
1851
19416
674
2835
1193
16946
617
5566
574
13181
Corticotropin [Mass/volume] in Plasma
2141-0 [3035637]
1.4e+00
1.9e+00
—
—
—
3.1e+00
2.2e+00
cases:0.50%
controls:0.12%
cases:0.80%
controls:0.13%
—
—
—
—
—
—
cases:2.41%
controls:0.12%
cases:4.03%
controls:0.44%
10
24
1990
19976
16
25
1984
19975
—
—
—
45
23
1822
19758
48
83
1143
18664
Image guided radiotherapy
ZX080 [2001311479]
1.4e+00
2.2e+00
—
—
—
2.8e+00
2.2e+00
cases:0.75%
controls:0.19%
cases:0.80%
controls:0.09%
—
—
—
—
—
—
cases:1.18%
controls:0.07%
cases:1.85%
controls:0.21%
15
38
1985
19962
16
18
1984
19982
—
—
—
22
14
1845
19767
22
39
1169
18708
Intercostal insertion of pleural drainage tube
GAA10 [2001303430]
4.8e-01
3.1e+00
—
—
—
3.0e+00
2.5e+00
cases:0.25%
controls:0.16%
cases:1.05%
controls:0.05%
—
—
—
—
—
—
cases:0.91%
controls:0.05%
cases:2.10%
controls:0.17%
5
31
1995
19969
21
10
1979
19990
—
—
—
17
9
1850
19772
25
32
1166
18715
Human coronavirus RNA [Presence] in Specimen by NAA with probe detection
41001-9 [3042596]
1.4e+00
2.2e+00
—
—
—
2.5e+00
2.4e+00
cases:0.50%
controls:0.13%
cases:1.10%
controls:0.12%
—
—
—
—
—
—
cases:1.55%
controls:0.13%
cases:4.11%
controls:0.38%
10
25
1990
19975
22
24
1978
19976
—
—
—
29
25
1838
19756
49
71
1142
18676
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
3.6e-01
1.3e+00
2.4e+00
—
2.1e+00
1.5e+00
9.1e-01
cases:5.40%
controls:3.82%
cases:10.50%
controls:3.10%
cases:6.30%
controls:0.60%
—
—
cases:4.90%
controls:0.62%
cases:13.55%
controls:3.53%
cases:22.33%
controls:10.34%
108
763
1892
19237
210
619
1790
19381
126
120
1874
19880
—
98
124
1902
19861
253
698
1614
19083
266
1939
925
16808
Extensive high resolution CT examination of lungs
GD1ED [2001303637]
1.6e+00
2.1e+00
—
—
—
2.4e+00
2.4e+00
cases:2.35%
controls:0.49%
cases:2.05%
controls:0.26%
—
—
—
—
—
—
cases:1.61%
controls:0.14%
cases:1.68%
controls:0.15%
47
97
1953
19903
41
52
1959
19948
—
—
—
30
28
1837
19753
20
29
1171
18718
PET-CT of upper body metabolism
JN5DR [2001310926]
1.5e+00
2.4e+00
—
—
—
2.7e+00
1.9e+00
cases:0.85%
controls:0.20%
cases:1.10%
controls:0.10%
—
—
—
—
—
—
cases:0.75%
controls:0.05%
cases:1.43%
controls:0.21%
17
40
1983
19960
22
20
1978
19980
—
—
—
14
10
1853
19771
17
39
1174
18708
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
8.1e-01
1.4e+00
2.7e+00
—
—
1.9e+00
1.6e+00
cases:2.70%
controls:1.22%
cases:2.10%
controls:0.52%
cases:0.45%
controls:0.03%
—
—
—
—
cases:2.57%
controls:0.38%
cases:5.71%
controls:1.22%
54
243
1946
19757
42
104
1958
19896
9
6
1991
19994
—
—
48
75
1819
19706
68
228
1123
18519
Respiratory syncytial virus A RNA [Presence] in Specimen by NAA with probe detection
30075-6 [3005156]
1.7e+00
2.4e+00
—
—
—
3.0e+00
3.1e+00
cases:0.30%
controls:0.06%
cases:0.90%
controls:0.09%
—
—
—
—
—
—
cases:1.23%
controls:0.06%
cases:3.02%
controls:0.14%
6
11
1994
19989
18
17
1982
19983
—
—
—
23
12
1844
19769
36
27
1155
18720
Respiratory syncytial virus B RNA [Presence] in Specimen by NAA with probe detection
30076-4 [3000108]
1.7e+00
2.4e+00
—
—
—
3.0e+00
3.1e+00
cases:0.30%
controls:0.06%
cases:0.90%
controls:0.09%
—
—
—
—
—
—
cases:1.23%
controls:0.06%
cases:3.02%
controls:0.14%
6
11
1994
19989
18
17
1982
19983
—
—
—
23
12
1844
19769
36
27
1155
18720
Respiratory pathogens DNA and RNA tested for in Respiratory system specimen by NAA with probe detection
82134-8 [21493195]
1.7e+00
2.3e+00
—
—
—
3.1e+00
3.0e+00
cases:0.30%
controls:0.06%
cases:0.90%
controls:0.09%
—
—
—
—
—
—
cases:1.29%
controls:0.06%
cases:2.94%
controls:0.14%
6
11
1994
19989
18
18
1982
19982
—
—
—
24
12
1843
19769
35
27
1156
18720
Malignant neoplasm: Upper-outer quadrant of breast
C50.4 [45561816]
1.3e+00
2.3e+00
1.0e+50
—
—
2.2e+00
2.6e+00
cases:1.80%
controls:0.52%
cases:1.30%
controls:0.13%
cases:1.25%
controls:0.00%
—
—
—
—
cases:0.75%
controls:0.08%
cases:3.36%
controls:0.26%
36
103
1964
19897
26
26
1974
19974
25
0
1975
20000
—
—
14
16
1853
19765
40
48
1151
18699
CT examination of head and neck for dose design of radiotherapy
YA1AD [2001300718]
—
2.8e+00
—
—
—
3.0e+00
2.7e+00
—
—
cases:0.80%
controls:0.05%
—
—
—
—
—
—
cases:0.59%
controls:0.03%
cases:1.51%
controls:0.11%
—
16
10
1984
19990
—
—
—
11
6
1856
19775
18
20
1173
18727
Pulmonary embolism without mention of acute cor pulmonale
I26.9 [45552785]
9.3e-01
1.6e+00
2.2e+00
—
1.6e+00
1.8e+00
1.9e+00
cases:1.60%
controls:0.64%
cases:1.60%
controls:0.32%
cases:0.50%
controls:0.06%
—
—
cases:0.35%
controls:0.07%
cases:2.14%
controls:0.37%
cases:6.05%
controls:0.99%
32
127
1968
19873
32
64
1968
19936
10
11
1990
19989
—
7
14
1993
19971
40
73
1827
19708
72
186
1119
18561
Very extensive MRI examination of upper part of abdomen with high intensity magnet
JN1DG [2001305530]
1.6e+00
2.6e+00
—
—
—
2.0e+00
2.2e+00
cases:0.85%
controls:0.17%
cases:1.05%
controls:0.08%
—
—
—
—
—
—
cases:0.48%
controls:0.07%
cases:2.18%
controls:0.25%
17
34
1983
19966
21
16
1979
19984
—
—
—
9
13
1858
19768
26
46
1165
18701
Malignant tumor of the central part of the mammary gland,lobular tumor
C50.12 [2000500991]
2.7e+00
3.0e+00
—
—
—
2.7e+00
2.1e+00
cases:0.45%
controls:0.03%
cases:0.50%
controls:0.03%
—
—
—
—
—
—
cases:0.43%
controls:0.03%
cases:0.42%
controls:0.05%
9
6
1991
19994
10
5
1990
19995
—
—
—
8
6
1859
19775
5
10
1186
18737
naloxegol; oral
A06AH03 [43534741]
—
2.3e+00
—
—
—
3.0e+00
3.0e+00
—
—
cases:0.40%
controls:0.04%
—
—
—
—
—
—
cases:2.20%
controls:0.11%
cases:2.94%
controls:0.14%
—
8
8
1992
19992
—
—
—
41
22
1826
19759
35
27
1156
18720
Clear cell adenocarcinoma, NOS, of kidney, NOS
8310/3-C64.9 [44499553]
3.4e+00
5.0e+00
—
—
—
—
—
cases:2.70%
controls:0.10%
cases:5.40%
controls:0.04%
—
—
—
—
—
—
—
—
—
—
54
19
1946
19981
108
8
1892
19992
—
—
—
—
—
Case Management Agency
251B00000X [38004193]
3.6e-01
9.2e-01
2.6e+00
1.8e+00
9.3e-01
7.6e-01
9.7e-01
cases:87.60%
controls:83.11%
cases:87.45%
controls:73.53%
cases:84.50%
controls:28.00%
cases:8.80%
controls:1.65%
cases:48.70%
controls:27.25%
cases:88.22%
controls:77.85%
cases:98.99%
controls:97.39%
1752
16622
248
3378
1749
14705
251
5295
1690
5599
310
14401
176
329
1824
19671
974
5445
1026
14540
1647
15400
220
4381
1179
18257
12
490
CD3 cells [#/volume] in Blood
8122-4 [3011412]
1.7e+00
2.3e+00
—
—
—
2.0e+00
2.3e+00
cases:0.60%
controls:0.11%
cases:1.10%
controls:0.11%
—
—
—
—
—
—
cases:1.02%
controls:0.14%
cases:3.44%
controls:0.36%
12
22
1988
19978
22
22
1978
19978
—
—
—
19
27
1848
19754
41
67
1150
18680
Cytology of lymphnode with ultrasound guidance
PJ3AT [2001309683]
2.6e+00
3.2e+00
—
—
—
—
2.5e+00
cases:1.30%
controls:0.10%
cases:0.85%
controls:0.04%
—
—
—
—
—
—
—
—
cases:0.67%
controls:0.05%
26
20
1974
19980
17
7
1983
19993
—
—
—
—
8
10
1183
18737
Reticulocyte production index
31111-8 [3000012]
1.6e+00
2.6e+00
—
—
—
2.6e+00
1.6e+00
cases:0.65%
controls:0.14%
cases:1.10%
controls:0.09%
—
—
—
—
—
—
cases:1.02%
controls:0.08%
cases:3.27%
controls:0.71%
13
27
1987
19973
22
17
1978
19983
—
—
—
19
15
1848
19766
39
133
1152
18614
Bone marrow aspiration report
48807-2 [3048879]
2.1e+00
2.9e+00
—
—
—
3.2e+00
2.2e+00
cases:0.25%
controls:0.03%
cases:0.55%
controls:0.03%
—
—
—
—
—
—
cases:0.59%
controls:0.03%
cases:0.84%
controls:0.09%
5
6
1995
19994
11
6
1989
19994
—
—
—
11
5
1856
19776
10
17
1181
18730
Ultrasound examination of thorax
GA1AE [2001303415]
1.8e+00
2.5e+00
—
—
—
2.2e+00
1.9e+00
cases:1.35%
controls:0.24%
cases:1.10%
controls:0.10%
—
—
—
—
—
—
cases:0.70%
controls:0.08%
cases:1.68%
controls:0.25%
27
47
1973
19953
22
19
1978
19981
—
—
—
13
16
1854
19765
20
47
1171
18700
Office Visit
OMOP4822458 [581477]
5.3e-01
1.4e+00
2.1e+00
—
1.5e+00
1.4e+00
1.3e+00
cases:18.65%
controls:11.91%
cases:13.90%
controls:3.90%
cases:3.75%
controls:0.50%
—
—
cases:2.25%
controls:0.49%
cases:10.71%
controls:2.77%
cases:14.19%
controls:4.14%
373
2382
1627
17618
278
779
1722
19221
75
99
1925
19901
—
45
98
1955
19887
200
548
1667
19233
169
776
1022
17971
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
8.9e-01
1.6e+00
2.9e+00
—
1.7e+00
1.7e+00
1.2e+00
cases:2.50%
controls:1.04%
cases:3.65%
controls:0.76%
cases:1.30%
controls:0.07%
—
—
cases:0.35%
controls:0.07%
cases:3.05%
controls:0.59%
cases:6.80%
controls:2.18%
50
209
1950
19791
73
151
1927
19849
26
14
1974
19986
—
7
13
1993
19972
57
117
1810
19664
81
408
1110
18339

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
1035
3531
5.00
280.18
8.2
3.3
0.81
0.82
mmol/l
1.60
1017
3337
1813
10407
8.86
239.40
35.1
6.8
10.15
11.87
umol/l
14.78
1799
9965
674
1833
5.04
236.44
1.6
1.4
—
—
—
0
0
1270
5848
4.20
212.89
6.5
4.6
—
—
—
0
0
1785
10896
6.89
196.49
41.6
9.8
3.62
4.16
e9/l
15.77
1762
9431
694
2336
4.02
177.28
9.2
4.2
27.25
20.33
ug/l
0.35
622
1919
1274
6680
3.49
158.18
14.8
6.3
—
—
—
0
0
1644
10244
4.38
153.64
17.7
7.6
1.21
1.21
mmol/l
0.23
1435
8876
1524
9244
3.72
143.12
14.1
6.8
1.21
1.21
mmol/l
1.60
1499
8557
1484
8949
3.54
138.50
15.2
6.7
9.07
9.02
%
0.20
1462
8372
1477
8938
3.49
135.79
15.1
6.6
2.68
2.82
%
1.46
1456
8360
1491
9096
3.50
134.76
15.1
6.6
26.21
27.01
%
1.54
1475
8609
1474
8937
3.46
134.46
15.2
6.7
0.74
0.67
%
2.68
1454
8357
1482
9072
3.44
131.78
12.2
5.3
33.07
35.26
g/l
37.36
1447
8528
1143
6212
2.96
121.91
11.2
4.3
7.40
7.40
ph
0.39
1005
4504
1426
8930
3.07
113.67
13.8
6.5
57.65
57.75
%
0.10
1407
8526
200
349
6.26
111.29
8.3
3.9
1.93
1.40
%
1.20
191
317
1499
9726
3.15
110.55
13.4
6.4
0.04
0.04
e9/l
1.42
1392
8252
1496
9699
3.15
110.42
13.5
6.4
0.61
0.60
e9/l
0.30
1394
8228
1470
9473
3.08
108.99
11.0
16.8
1.15
1.28
inr
30.63
1337
7918
1210
7055
2.81
108.26
20.6
3.6
2.35
2.36
mmol/l
1.48
1179
6393
1521
10012
3.16
108.03
14.7
6.6
0.19
0.19
e9/l
0.13
1419
8645
1504
9875
3.10
106.55
13.7
6.5
1.93
1.92
e9/l
0.05
1417
8601
652
2903
2.85
96.43
9.1
6.0
1.03
1.04
mmol/l
0.34
626
2702
194
400
5.26
89.87
5.8
3.3
55.22
58.72
%
2.17
194
400
1453
17694
0.35
88.06
4.8
6.4
2.62
2.62
mmol/l
0.03
1277
16337
145
239
6.46
85.03
1.7
1.5
37.29
30.40
ng/l
0.46
145
239
1401
17283
0.37
83.25
4.5
5.4
1.37
1.46
mmol/l
10.92
1242
15910
164
311
5.65
83.23
1.4
1.5
36.11
32.24
g/l
3.47
157
281
1425
17396
0.37
79.66
4.5
5.5
4.50
4.55
mmol/l
0.95
1262
16135
1844
14556
4.38
79.40
40.9
8.7
90.65
80.68
u/l
10.46
1827
13833
1359
16920
0.39
78.62
6.0
7.1
39.73
39.92
mmol/mol
0.35
1234
15734
150
278
5.75
77.94
1.5
1.5
1659.72
4930.99
e6/l
0.51
118
189
653
3199
2.55
76.93
3.2
2.1
29.64
29.77
s
0.19
640
3108
138
241
6.08
76.27
1.4
1.5
125142.78
112329.85
e6/l
0.07
93
130
454
1870
2.85
75.53
9.5
4.4
1.42
0.85
%
3.91
323
593
133
231
6.10
73.89
1.5
1.7
—
—
—
0
0
1043
6395
2.32
72.94
4.4
2.6
—
—
—
0
0
878
5060
2.31
70.43
7.8
4.3
90.72
87.56
%
3.74
860
4961
1561
11493
2.63
70.40
9.0
5.4
6.72
6.78
mmol/l
0.59
1537
11010
1017
6238
2.28
70.17
9.3
3.2
42.15
33.42
u/l
2.57
983
5879
460
2023
2.65
66.52
10.0
7.6
9.25
10.30
mmol/l
2.61
448
1946
588
2914
2.44
65.96
2.3
2.1
—
—
—
0
0
277
932
3.29
65.15
2.2
1.9
6.71
2.16
ug/l
0.46
263
837
759
4221
2.29
65.08
10.4
3.1
2.48
2.46
mmol/l
5.69
730
3817
422
1826
2.66
62.70
5.7
2.3
402.14
379.16
nmol/l
1.51
414
1690
137
287
5.05
61.95
2.3
2.6
—
—
—
0
0
124
238
5.49
61.88
1.4
1.5
—
—
—
0
0
596
3059
2.35
61.04
2.7
2.8
20.84
22.58
%
2.41
583
2858
987
6220
2.16
60.81
5.1
2.7
62.52
73.98
u/l
0.41
962
5772
410
1782
2.64
60.15
10.1
4.2
1.06
0.63
%
3.70
286
563
623
3286
2.30
59.63
2.8
2.7
2.21
2.29
g/l
2.42
601
3049
128
262
5.15
59.42
1.7
1.3
—
—
—
0
0
1359
16575
0.44
59.22
4.1
4.6
1.45
1.29
mmol/l
4.88
1190
15098
528
2601
2.40
59.13
5.4
2.7
1.94
1.83
%
1.68
493
2318
934
5849
2.12
57.51
31.3
6.5
—
—
—
0
0
405
1787
2.59
57.37
9.9
4.5
0.18
0.10
%
1.93
275
512
644
3499
2.24
56.94
2.9
2.8
11.58
12.73
umol/l
3.94
626
3272
158
399
4.21
56.57
2.3
1.6
—
—
—
0
0
426
7879
0.42
56.11
2.0
2.0
1.63
1.33
mmol/l
3.61
349
6535
470
2254
2.42
55.48
5.5
2.8
11.50
8.61
umol/l
1.34
446
2027
113
226
5.24
53.81
1.5
1.2
—
—
—
0
0
438
2080
2.42
52.55
2.7
2.2
0.20
0.21
g/l
1.65
410
1951
136
324
4.43
52.48
1.3
1.4
150.89
162.56
au/ml
0.42
39
106
141
346
4.31
52.37
1.6
1.3
14.80
10.18
u/l
2.16
119
274
145
365
4.20
52.08
1.3
1.3
—
—
—
0
0
120
268
4.70
50.18
2.6
1.4
—
—
—
0
0
120
268
4.70
50.18
2.6
1.4
—
—
—
0
0
120
268
4.70
50.18
2.6
1.4
—
—
—
0
0
120
268
4.70
50.18
2.6
1.4
—
—
—
0
0
144
372
4.09
49.92
1.3
1.3
—
18.97
—
0
10
426
2057
2.36
48.87
5.9
2.7
72.44
69.68
e9/l
0.79
319
1513
401
1918
2.36
46.82
3.8
3.0
64.06
66.44
g/l
7.01
385
1778
660
3883
2.04
45.53
3.6
3.1
523.60
529.99
mosm/kgh2o
0.34
617
3409
106
233
4.75
45.16
1.5
1.5
—
—
—
0
0
873
5690
1.95
44.65
4.1
3.4
0.57
0.45
e6/l
0.50
736
4219
49
48
10.44
44.09
1.0
1.0
—
—
—
0
0
203
715
3.05
43.57
4.3
3.3
306.88
381.12
mg/l
0.37
164
311
970
6586
1.92
43.52
4.2
3.6
55.37
82.97
e6/l
0.89
823
5080
103
231
4.65
42.81
10.7
3.7
55.15
57.49
%
0.41
93
203
100
220
4.73
42.55
13.7
4.1
—
—
—
0
0
1537
12250
2.10
42.09
5.5
5.0
902.67
1644.46
e6/l
0.45
24
180
1216
8994
1.90
40.84
4.9
2.9
—
—
estimate
—
0
0
46
47
9.99
40.16
1.2
1.1
—
—
—
0
0
214
825
2.78
38.83
3.4
3.6
71.13
1968.61
u/ml
0.95
185
718
366
1817
2.24
38.50
10.2
4.6
0.60
0.11
%
1.04
236
490
69
122
5.82
37.50
1.3
1.4
7.42
7.40
ph
0.29
55
82
1131
8335
1.82
36.69
28.1
12.3
0.04
0.00
e9/l
3.02
1007
6789
108
288
3.91
35.74
6.2
2.3
298.66
60.24
u/ml
1.12
108
281
1051
7641
1.79
35.04
2.7
2.2
—
—
—
0
0
259
1159
2.42
34.45
1.4
1.4
—
—
—
0
0
314
1532
2.24
34.16
4.3
2.9
9.14
10.78
g/l
7.93
296
1411
41
45
9.28
33.95
3.3
1.5
—
—
—
0
0
293
1395
2.29
33.78
4.4
3.9
7.42
7.42
ph
0.18
252
1173
79
174
4.69
33.55
4.5
1.9
2244.43
1135.88
e6/l
0.45
72
154
1519
17224
0.51
33.20
5.3
5.7
6.10
6.03
mmol/l
1.03
1344
15719
327
1644
2.18
32.96
9.3
3.9
1.22
1.23
mmol/l
0.36
316
1429
295
1429
2.25
32.57
4.4
3.9
5.09
5.16
kpa
0.77
278
1377
185
726
2.71
32.29
3.6
2.0
21.62
21.21
s
0.50
178
659
70
146
4.93
31.72
1.3
1.4
—
—
—
0
0
445
2541
1.97
31.66
7.3
7.7
1.16
0.92
mmol/l
0.61
352
2100
73
160
4.70
31.19
1.4
1.4
11.55
13.41
u/l
1.53
73
152
628
4026
1.82
31.08
11.0
4.9
—
—
—
0
0
76
173
4.53
31.00
2.4
2.4
15.14
37.32
iu/ml
1.21
11
30
540
3314
1.86
30.73
3.7
3.2
2.37
2.20
e6/l
0.17
336
1655
443
2553
1.94
30.55
7.4
7.8
7.43
7.41
ph
2.79
277
1396
371
2013
2.03
30.39
1.5
1.5
—
—
—
0
0
443
2558
1.94
30.35
7.4
7.8
4.95
5.10
kpa
2.93
424
2466
336
1759
2.09
30.32
1.5
1.6
—
—
—
0
0
233
1053
2.37
30.16
2.0
1.8
1.59
1.53
g/l
0.28
206
916
442
2559
1.93
30.01
7.4
7.8
12.13
12.23
kpa
0.13
421
2466
994
7348
1.70
29.19
4.9
4.2
75.94
111.60
e6/l
0.93
829
5284
122
402
3.17
29.18
6.5
4.9
2.83
2.53
mmol/l
0.55
96
278
57
112
5.21
27.66
5.5
2.0
1224.27
536.13
e6/l
0.55
49
91
43
64
6.84
27.65
1.6
1.1
—
—
—
0
0
382
6177
0.53
27.21
2.9
3.5
—
—
—
0
0
70
166
4.33
27.12
1.6
1.3
35.50
33.29
u/l
0.19
64
133
679
4603
1.72
26.88
3.2
2.8
5.51
5.40
e6/l
0.05
640
4213
39
55
7.21
26.32
2.2
1.4
—
—
—
0
0
47
81
5.92
26.23
1.3
1.6
71.53
59.58
%
1.24
34
66
126
451
2.91
26.08
4.9
4.1
—
—
—
0
0
99
308
3.33
26.01
2.6
2.4
—
—
—
0
0
341
1914
1.94
24.96
3.0
2.5
71.35
40.23
u/l
0.39
310
1613
55
117
4.81
24.37
2.4
2.7
36.43
40.05
%
0.59
20
65
348
1987
1.91
24.13
8.0
7.7
1.47
1.34
mmol/l
1.38
342
1953
101
335
3.12
23.89
1.2
1.2
308.51
260.76
u/ml
0.79
67
189
124
472
2.73
22.88
2.2
2.8
40.63
33.12
umol/l
2.47
117
424
170
755
2.37
22.73
4.7
4.0
24.72
24.91
mmol/l
0.38
157
705
40
70
5.81
21.99
1.2
1.6
2.87
2.99
%
0.02
29
60
237
1221
2.07
21.95
3.5
1.9
1.82
1.45
g/l
0.70
211
1126
121
468
2.69
21.64
1.2
1.2
—
—
—
0
0
42
79
5.41
21.40
1.2
1.1
—
—
—
0
0
252
1346
2.00
21.09
9.0
9.7
24.38
24.27
mmol/l
0.20
245
1326
132
542
2.54
20.92
3.8
3.6
4.10
2.03
index
1.62
77
283
338
1999
1.83
20.75
11.1
4.5
7.38
7.35
ph
2.61
317
1431
198
991
2.11
19.74
4.7
3.9
—
—
—
0
0
55
139
4.04
19.64
3.2
1.8
65.15
73.23
%
1.63
48
127
531
3613
1.64
19.54
3.6
3.1
1.16
1.11
e6/l
0.10
331
1965
371
2294
1.76
19.51
8.1
8.0
94.98
95.60
%
0.96
353
2219
351
2138
1.78
19.43
5.5
3.7
1.82
1.87
mmol/l
0.08
286
1864
122
500
2.53
19.41
3.3
3.3
596.21
851.06
u/ml
0.17
110
465
498
7025
0.61
19.30
3.5
3.6
113.76
46.11
mg/l
4.20
354
4523
361
2221
1.76
19.30
5.4
3.8
7.38
7.38
ph
0.13
238
1272
31
49
6.41
18.84
1.0
1.4
28.74
28.69
s
0.01
31
49
806
6123
1.53
18.11
3.3
3.4
—
—
—
0
0
713
5283
1.54
17.92
2.3
2.4
3.50
2.85
mg/l
5.03
647
4552
351
2196
1.73
17.55
5.5
3.7
5.72
5.83
kpa
1.00
344
2141
204
1084
1.98
17.22
4.1
3.5
4.25
4.42
pmol/l
1.47
187
960
44
104
4.30
17.17
8.1
6.7
458.37
205.40
ug/l
0.26
36
62
528
7186
0.64
16.68
3.4
3.5
6.98
7.34
mmol/l
1.28
429
6045
694
5180
1.52
16.55
7.4
3.0
356.38
348.64
umol/l
1.01
630
4532
559
3983
1.56
16.48
4.8
4.1
487.98
402.50
ng/l
0.26
468
3300
527
7148
0.64
16.25
4.1
4.3
19.26
8.26
mg/mmol
3.63
353
4479
846
6600
1.49
16.18
3.3
3.3
1560.79
1310.14
ng/l
0.92
778
5750
28
48
5.90
15.73
3.5
4.8
—
—
—
0
0
119
532
2.32
15.65
1.6
1.4
27.04
32.23
iu/l
0.87
97
457
43
1371
0.30
15.38
1.4
2.1
3.28
3.47
ratio
0.61
37
1106
108
471
2.37
15.04
1.3
1.3
—
—
—
0
0
33
69
4.85
14.97
1.3
1.5
8.89
28.58
%
4.50
25
63
96
400
2.47
14.78
1.4
1.3
89.33
40.64
u/l
1.09
83
350
349
2281
1.64
14.58
1.8
1.8
—
—
—
0
0
945
7635
1.45
14.58
4.5
4.1
30.30
75.44
ng/l
2.46
829
5770
252
3987
0.58
14.55
1.2
1.3
0.98
1.46
u/ml
1.37
58
1047
31
63
4.98
14.53
1.2
1.3
715.05
61.82
ug/l
1.34
23
25
304
1922
1.69
14.43
10.7
8.9
—
—
—
0
0
83
329
2.59
14.18
5.4
2.2
0.97
0.89
%
0.56
69
232
810
6386
1.45
14.08
3.6
2.2
167.80
217.72
u/l
1.33
776
6052
276
1715
1.71
13.95
3.1
3.1
168.47
199.18
ng/l
0.95
253
1581
148
756
2.03
13.92
1.1
1.2
—
—
—
0
0
168
898
1.95
13.90
1.3
1.3
—
—
—
0
0
79
312
2.59
13.61
1.2
1.0
—
—
—
0
0
23
982
0.23
13.60
1.2
1.9
3.42
3.48
mmol/l
0.10
17
719
51
159
3.27
13.45
7.9
5.2
213.49
38.77
u/ml
0.86
23
49
123
599
2.12
13.15
7.5
3.2
1.52
1.66
mg/l
1.33
117
538
558
4136
1.48
13.15
2.3
1.8
2.27
1.37
mg/l
3.01
486
3241
1854
17371
1.91
13.02
51.4
18.1
27.93
25.81
mg/l
2.08
1813
14523
323
2147
1.60
12.46
9.1
8.5
118.46
120.84
g/l
1.12
314
2097
350
2373
1.58
12.41
2.3
1.4
—
—
—
0
0
401
5502
0.66
12.07
3.4
4.9
21.00
21.48
%
0.25
194
2898
32
83
3.90
11.11
2.1
2.1
1156.32
812.43
e6/l
0.33
22
67
104
508
2.10
11.06
1.5
2.1
11.05
12.19
mg/l
0.56
94
473
104
508
2.10
11.06
2.5
2.3
123.26
129.09
g/l
1.22
66
411
59
224
2.68
11.04
1.2
1.2
—
—
—
0
0
20
18
11.21
11.04
1.2
1.6
22.20
16.73
%
0.20
15
11
27
62
4.40
10.99
2.2
1.8
—
—
—
0
0
280
4066
0.64
10.83
2.7
3.5
0.89
0.77
ug/l
0.94
203
2835
29
72
4.07
10.69
2.0
1.9
11248.86
25423.52
e6/l
0.26
14
46
34
1013
0.32
10.63
1.0
1.4
—
—
—
0
0
231
1472
1.64
10.51
4.6
4.2
—
—
—
0
0
72
310
2.37
10.39
8.1
6.5
11.15
12.24
mg/l
1.46
67
294
49
177
2.81
10.10
2.2
2.4
—
—
—
0
0
36
109
3.34
10.00
1.1
1.1
—
—
—
0
0
60
242
2.53
9.98
5.5
3.5
14.23
27.29
nmol/l
0.24
60
237
60
246
2.48
9.65
1.1
1.2
2.69
5.65
u/ml
1.42
35
111
211
1343
1.64
9.63
5.5
6.6
24.67
24.47
mmol/l
0.34
199
1283
89
434
2.10
9.54
1.4
1.4
58.20
59.35
mmol/l
0.10
71
346
44
156
2.86
9.40
1.2
1.2
—
—
—
0
0
201
1272
1.64
9.38
11.4
10.2
15.57
15.94
%
0.98
192
1227
19
38
5.04
9.09
1.4
1.4
—
—
—
0
0
20
43
4.69
8.82
1.9
1.6
—
—
—
0
0
112
611
1.88
8.76
5.3
5.9
1.31
1.32
mmol/l
0.04
96
540
266
1827
1.53
8.74
5.2
3.1
4.55
4.53
kpa
0.07
259
1779
75
355
2.16
8.70
1.1
1.2
220.11
224.31
miu/ml
0.02
18
139
21
32
6.62
8.65
1.2
1.9
2.64
8.47
%
1.34
11
17
13
8
16.35
8.55
1.0
1.0
—
—
—
0
0
13
8
16.35
8.55
1.0
1.0
—
—
—
0
0
13
8
16.35
8.55
1.0
1.0
—
—
—
0
0
317
2284
1.46
8.21
1.5
1.6
—
—
—
0
0
37
130
2.88
8.08
1.1
1.1
—
—
—
0
0
43
164
2.66
8.06
1.5
1.4
0.20
0.29
nmol/l
0.87
30
120
49
200
2.49
8.01
1.2
1.2
—
—
—
0
0
362
2686
1.42
8.00
1.5
1.3
—
—
—
0
0
12
8
15.08
7.71
1.0
1.0
—
—
—
0
0
12
8
15.08
7.71
1.0
1.0
—
—
—
0
0
89
477
1.91
7.39
1.5
2.0
2.84
15.66
iu/l
0.55
25
196
44
178
2.50
7.35
1.2
1.2
—
—
—
0
0
16
22
7.32
7.18
7.7
2.2
—
—
—
0
0
21
56
3.78
7.08
2.2
2.4
—
—
—
0
0
62
297
2.12
7.04
1.2
1.1
—
—
—
0
0
330
2469
1.40
6.89
5.3
3.3
6.55
4.56
e9/l
0.69
301
2113
24
72
3.36
6.83
45.6
36.4
8.46
7.01
ug/l
2.52
18
64
447
3524
1.35
6.73
1.8
1.8
1175.11
1178.53
nmol/l
0.02
361
2667
95
537
1.81
6.70
1.1
1.2
148.57
96.82
titre
—
7
44
12
12
10.05
6.53
2.0
1.1
—
—
—
0
0
48
214
2.27
6.51
1.1
1.2
—
—
—
0
0
338
2565
1.38
6.47
1.3
1.3
476.46
505.61
titre
0.10
79
595
17
30
5.71
6.45
1.9
1.6
—
—
—
0
0
77
413
1.90
6.42
1.4
1.2
—
—
—
0
0
15
23
6.56
6.33
1.7
1.1
—
—
—
0
0
15
23
6.56
6.33
1.7
1.1
—
—
—
0
0
15
23
6.56
6.33
1.7
1.1
—
—
—
0
0
573
6847
0.77
6.27
4.1
6.0
2.48
2.95
ug/l
0.99
502
6166
24
643
0.37
6.11
2.1
1.8
—
—
—
0
0
14
21
6.70
6.03
1.9
2.2
0.99
1.23
mg/l
—
8
16
29
709
0.40
6.01
1.1
1.1
—
—
—
0
0
57
285
2.03
5.84
1.1
1.1
1.60
1.53
g/l
0.78
52
262
74
1275
0.56
5.60
1.2
1.3
—
—
—
0
0
762
8706
0.80
5.48
2.7
2.5
75.53
78.79
nmol/l
2.50
702
7795
18
514
0.34
5.29
1.0
1.1
—
—
—
0
0
590
5003
1.25
4.89
1.5
1.3
—
—
—
0
0
16
38
4.24
4.82
1.3
1.1
—
—
—
0
0
36
164
2.22
4.73
1.3
1.2
117.97
103.39
pmol/l
0.69
36
164
91
1414
0.63
4.59
1.1
1.2
—
—
—
0
0
13
403
0.32
4.55
1.2
1.2
1.62
1.55
g/l
0.29
13
403
200
1483
1.39
4.39
11.5
9.7
92.85
94.03
%
1.16
200
1476
251
3215
0.75
4.37
1.2
1.3
10.25
12.95
u/ml
0.24
76
1183
98
634
1.57
4.29
1.4
1.5
234.92
275.73
ug/g
1.13
63
390
42
780
0.53
4.17
1.1
1.1
—
129.50
titre
—
0
18
36
691
0.51
3.98
1.1
1.6
0.10
0.33
mg/l
—
10
315
32
150
2.15
3.97
1.3
1.1
36.11
34.88
mmol/l
0.10
32
134
69
424
1.65
3.76
6.3
6.8
104.44
105.20
mmol/l
0.87
62
378
69
424
1.65
3.76
6.3
6.8
11.00
11.26
mmol/l
0.30
62
378
13
34
3.84
3.69
3.2
2.0
2.04
2.46
%
0.23
13
34
1570
16378
0.81
3.65
8.9
5.6
2.32
1.98
mu/l
5.45
1477
15021
14
40
3.52
3.60
7.1
2.0
0.12
0.22
e9/l
—
6
15
195
1492
1.34
3.54
11.4
9.5
1.22
1.25
%
0.19
195
1481
158
1171
1.38
3.52
4.1
2.8
1.18
1.16
%
0.14
158
1163
23
99
2.34
3.50
1.7
2.7
1510.87
1348.46
u/ml
0.14
23
99
18
69
2.62
3.47
1.1
1.6
—
—
—
0
0
135
977
1.41
3.46
5.0
4.9
1.60
1.56
%
0.28
128
921
18
70
2.59
3.38
3.4
2.5
0.59
0.61
mmol/l
0.56
18
70
9
18
5.02
3.37
1.0
1.0
—
—
—
0
0
1321
13975
0.84
3.35
65.0
23.9
328.95
331.74
g/l
19.04
1311
13910
139
1017
1.39
3.35
4.7
4.3
36.95
36.91
°c
0.69
139
1008
29
559
0.51
3.30
1.4
1.6
11039.74
14767.34
e6/l
0.50
23
388
27
128
2.12
3.30
3.0
2.5
17.54
16.04
%
1.14
27
128
14
48
2.93
3.30
6.2
2.5
6.00
4.60
ug/l
0.35
14
48
1858
18102
1.37
3.26
49.5
21.9
138.80
139.69
mmol/l
39.47
1839
17778
13
43
3.04
3.25
2.5
1.8
—
—
—
0
0
10
291
0.34
3.18
1.8
1.7
—
—
—
0
0
40
222
1.82
3.16
1.3
1.2
—
—
—
0
0
213
1683
1.30
3.10
3.6
3.9
106.86
91.68
ng/l
1.21
189
1460
6
8
7.52
3.05
1.3
1.4
0.22
0.15
umol/l
—
6
8
8
16
5.02
3.05
1.0
1.3
—
—
—
0
0
1858
18130
1.35
2.97
50.6
22.1
4.02
3.99
mmol/l
4.61
1837
17783
37
205
1.82
2.95
1.2
1.2
—
—
—
0
0
169
2161
0.76
2.90
2.3
2.4
249.85
144.50
ug/g
1.42
141
1728
75
505
1.50
2.84
1.1
1.2
—
—
—
0
0
223
1795
1.27
2.82
2.2
2.5
9.00
7.48
ug/l
0.40
197
1612
11
33
3.35
2.81
1.5
1.3
2661.00
1121.50
u/l
0.26
11
22
151
1159
1.33
2.73
4.2
2.8
0.62
0.61
%
0.34
151
1153
120
892
1.37
2.68
5.3
5.2
0.86
0.86
%
0.00
112
840
106
773
1.39
2.66
1.3
1.6
—
—
—
0
0
24
119
2.03
2.66
1.7
2.2
475.71
488.64
min
0.26
17
86
30
164
1.84
2.53
1.2
1.1
—
51.98
—
0
9
903
8354
1.15
2.42
3.5
3.1
313.71
140.11
ug/l
12.89
853
7745
5
8
6.26
2.37
1.0
1.0
—
—
—
0
0
39
237
1.66
2.33
5.0
6.1
6.95
7.37
mmol/l
0.50
33
201
68
964
0.70
2.30
2.4
2.0
—
—
—
0
0
19
92
2.08
2.27
2.0
2.8
1803.16
1871.44
ml
0.10
19
80
156
1949
0.78
2.26
2.4
2.2
0.00
0.01
estimate
0.78
25
386
54
358
1.52
2.26
1.4
1.5
116.61
255.59
pmol/l
1.87
54
352
839
9042
0.88
2.25
2.1
2.2
88.57
95.13
pmol/l
3.73
528
4775
28
160
1.76
2.10
1.9
2.3
637.56
623.79
ml
0.07
18
103
30
175
1.73
2.10
1.3
1.3
—
—
—
0
0
42
269
1.57
2.07
2.2
2.3
1.36
1.24
g/24h
0.11
30
155
53
359
1.49
2.03
1.1
1.4
—
9.63
—
0
8
11
44
2.51
2.01
1.2
1.1
—
—
—
0
0
7
21
3.34
1.96
1.1
1.0
—
—
—
0
0
7
21
3.34
1.96
1.1
1.1
—
—
—
0
0
81
598
1.37
1.96
3.3
3.9
3.99
3.90
mmol/l
0.89
81
591
30
485
0.61
1.94
1.1
1.2
—
—
—
0
0
5
11
4.55
1.94
1.0
1.0
—
—
—
0
0
39
250
1.57
1.93
1.4
1.2
—
—
—
0
0
11
45
2.45
1.93
1.1
1.1
—
—
—
0
0
19
99
1.93
1.90
3.4
2.8
—
—
—
0
0
0
52
0.00
1.88
0.0
1.1
—
0.41
—
0
12
66
477
1.40
1.83
5.0
4.6
—
—
—
0
0
32
199
1.62
1.80
2.2
1.8
67.23
2835.06
u/l
—
9
71
95
734
1.31
1.73
1.9
3.7
6.51
3.37
ratio
0.46
65
431
60
432
1.40
1.72
3.9
3.5
7.48
7.52
mmol/l
0.04
60
418
1472
14226
1.13
1.67
63.4
22.5
15.14
13.75
%
130.54
1463
14042
8
31
2.59
1.66
2.0
1.5
—
—
—
0
0
103
816
1.28
1.58
2.0
3.9
68.17
56.41
mg/l
0.28
84
704
28
176
1.60
1.55
1.4
1.3
0.43
0.39
g/l
0.19
20
128
28
176
1.60
1.55
1.4
1.3
7.87
6.81
g/l
0.50
20
129
28
176
1.60
1.55
1.4
1.3
2.57
2.90
g/l
0.46
19
130
0
42
0.00
1.52
0.0
2.4
—
3.24
—
0
18
302
3406
0.87
1.52
1.3
1.3
38.85
35.23
iu/ml
0.19
89
1088
30
453
0.66
1.50
2.2
1.8
42.70
42.21
nmol/l
0.04
30
431
135
1113
1.23
1.48
1.2
1.2
153.25
130.89
u/ml
0.18
32
407
72
550
1.32
1.46
1.2
1.3
4.49
8.08
u/ml
0.57
12
84
56
412
1.37
1.45
3.4
1.4
—
—
—
0
0
68
517
1.33
1.43
1.5
1.7
—
—
—
0
0
22
133
1.66
1.42
1.7
1.8
—
—
—
0
0
101
814
1.25
1.38
2.0
3.9
33.98
80.02
mg/l
1.59
82
703
550
5080
1.11
1.37
4.4
3.6
0.22
0.19
estimate
0.04
231
1638
604
5609
1.11
1.36
4.6
4.3
0.00
0.00
estimate
0.01
236
1938
71
549
1.30
1.35
1.3
1.2
2.10
3.50
u/ml
—
8
50
9
42
2.15
1.33
1.0
1.1
—
—
—
0
0
98
791
1.25
1.33
1.4
1.8
5.87
7.98
iu/ml
0.58
14
186
47
635
0.73
1.30
1.7
1.6
42.03
18.82
u/ml
—
9
113
9
172
0.52
1.29
1.7
1.9
—
—
—
0
0
1341
13806
0.91
1.14
5.8
4.6
21.79
13.13
mm/h
30.84
1244
12873
218
2458
0.87
1.12
3.7
5.3
29.66
32.92
%
4.75
157
1580
400
4341
0.90
1.09
4.9
4.3
1.02
1.36
kg/l
0.50
301
2916
198
1750
1.15
1.04
3.0
2.5
0.40
0.49
e6/l
0.27
192
1681
9
50
1.80
0.96
1.1
1.4
—
127.33
titre
—
0
9
0
32
0.00
0.95
0.0
1.3
—
65.47
—
0
32
21
141
1.49
0.95
1.3
1.3
—
—
—
0
0
82
984
0.83
0.94
2.6
2.3
0.00
0.89
estimate
0.50
12
281
93
1101
0.84
0.92
1.2
1.4
—
—
—
0
0
98
828
1.19
0.92
3.1
2.7
9.80
10.52
g/l
0.67
91
750
40
305
1.32
0.90
1.4
1.7
0.94
0.87
g/l
0.10
28
242
203
2258
0.89
0.88
1.3
1.4
—
—
—
0
0
23
161
1.43
0.86
1.7
2.0
1.55
1.67
u/field
0.04
11
87
46
581
0.79
0.86
14.0
11.3
—
—
—
0
0
29
213
1.37
0.84
1.1
1.1
—
—
—
0
0
101
869
1.17
0.80
2.4
2.6
—
—
—
0
0
331
3567
0.91
0.80
1.7
1.5
2.33
2.59
g/l
1.84
241
2143
35
268
1.31
0.79
1.8
1.4
29.57
78.66
mu/l
1.45
30
240
0
25
0.00
0.79
0.0
1.2
—
1.85
—
0
25
5
97
0.51
0.78
3.2
1.7
41.18
39.66
g/l
—
5
97
55
449
1.23
0.76
3.1
1.3
3.64
3.78
mmol/l
0.57
50
422
20
277
0.72
0.73
1.3
1.3
0.66
7.16
nmol/l
0.50
20
262
6
106
0.56
0.72
1.8
1.6
—
—
—
0
0
20
142
1.41
0.72
1.4
1.8
—
—
—
0
0
5
26
1.93
0.70
1.0
2.6
41.00
44.61
umol/l
—
5
19
1181
11508
1.06
0.70
5.5
3.4
96.47
53.27
u/l
10.48
1125
10721
488
5142
0.93
0.68
3.5
3.1
0.00
0.02
0.50
13
130
21
284
0.74
0.67
1.3
1.3
0.20
0.43
nmol/l
—
5
16
30
232
1.30
0.66
3.1
1.4
—
—
—
0
0
115
1296
0.88
0.65
2.7
2.5
21.52
21.42
au/ml
—
10
106
109
962
1.14
0.65
3.0
2.6
4.03
4.20
g/l
1.83
103
889
109
962
1.14
0.65
3.0
2.6
3.52
3.75
g/l
0.75
103
888
102
898
1.14
0.63
1.3
1.2
—
—
—
0
0
1849
18336
1.11
0.60
45.5
13.3
26.55
25.54
u/l
2.11
1833
17799
0
21
0.00
0.60
0.0
1.0
—
89.90
—
0
21
23
174
1.33
0.60
2.4
3.3
26.91
30.49
mg/l
0.10
18
134
10
64
1.57
0.58
1.0
1.0
—
—
—
0
0
10
64
1.57
0.58
1.0
1.0
—
—
—
0
0
10
64
1.57
0.58
1.0
1.0
—
—
—
0
0
28
219
1.28
0.58
5.4
1.6
—
—
—
0
0
19
140
1.36
0.58
1.5
1.3
0.26
0.99
u/ml
0.86
12
73
113
1009
1.13
0.58
4.0
3.6
1.02
1.02
ratio
0.59
107
929
10
147
0.68
0.53
2.4
2.3
4.38
3.06
ug/l
—
10
139
12
169
0.71
0.52
1.0
1.1
—
—
—
0
0
116
1048
1.11
0.51
2.5
2.4
—
—
—
0
0
9
65
1.39
0.50
1.0
2.4
15.62
142.65
ug/l
—
9
56
19
246
0.77
0.49
2.5
2.6
—
—
—
0
0
10
144
0.69
0.49
2.4
2.2
2.03
1.88
ug/l
—
10
123
51
437
1.17
0.48
3.4
1.4
24.16
49.36
e6/l
0.46
37
318
28
226
1.24
0.48
1.3
1.3
—
—
—
0
0
16
120
1.34
0.46
1.1
1.3
1.47
1.15
nmol/l
0.33
11
83
51
440
1.16
0.45
3.5
1.5
151.75
740.31
e6/l
1.15
40
337
11
77
1.43
0.45
1.5
1.5
100.00
82.56
umol/l
—
6
48
39
459
0.85
0.44
3.1
3.5
0.85
0.81
nmol/l
0.30
32
377
5
33
1.52
0.41
1.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
17.15
—
0
11
11
79
1.39
0.40
1.6
1.2
—
77.45
%
—
0
11
7
103
0.68
0.39
1.1
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
56
495
1.14
0.38
2.2
2.3
94.44
102.33
ug/min
0.10
34
293
8
114
0.70
0.37
1.4
1.6
—
—
—
0
0
11
81
1.36
0.36
1.2
1.2
275.89
212.37
iu/ml
0.25
11
81
6
42
1.43
0.35
1.2
1.2
—
—
—
0
0
6
44
1.36
0.34
1.5
1.1
18.95
16.72
umol/l
—
6
35
17
136
1.25
0.33
2.8
2.3
7.34
8.28
mmol/l
0.98
17
136
46
407
1.13
0.32
1.3
1.6
0.91
0.83
nmol/l
0.36
41
333
620
6049
1.04
0.30
1.9
1.7
17.43
20.32
nmol/l
6.37
569
5049
11
84
1.31
0.30
1.2
1.1
—
—
—
0
0
25
292
0.85
0.29
1.3
1.5
—
—
—
0
0
8
107
0.75
0.29
1.0
1.0
—
—
—
0
0
1394
13796
1.03
0.28
8.1
4.5
15.24
14.94
pmol/l
4.02
1326
12570
9
116
0.77
0.27
1.2
1.6
84.44
90.93
umol/l
—
9
116
434
4217
1.04
0.27
1.7
1.8
29050766.63
24389978.19
pmol/l
0.06
358
3481
25
289
0.86
0.26
1.3
1.5
—
—
—
0
0
12
95
1.26
0.26
2.2
1.3
—
—
—
0
0
120
1134
1.06
0.24
1.3
1.3
154.82
226.42
u/ml
0.95
98
1052
7
91
0.77
0.22
1.4
2.0
15.36
5.80
nmol/l
—
7
77
1858
18510
1.05
0.22
66.4
24.2
87.42
80.10
umol/l
8.33
1841
18316
155
1481
1.05
0.22
2.3
2.3
11.07
13.14
nmol/l
2.75
145
1318
18
210
0.86
0.22
1.4
1.3
1.06
1.48
nmol/l
1.08
18
186
1012
9994
1.03
0.22
4.6
4.2
0.00
0.16
estimate
0.56
269
1997
0
11
0.00
0.21
0.0
1.1
—
0.02
—
0
5
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
0.03
—
0
10
0
12
0.00
0.21
0.0
1.3
—
364.92
—
0
12
8
103
0.78
0.21
2.8
1.3
205.25
135.19
nmol/l
—
8
103
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
0.43
—
0
9
25
221
1.13
0.20
1.4
1.1
—
—
—
0
0
26
292
0.89
0.20
1.3
1.5
—
—
—
0
0
20
228
0.88
0.19
1.3
1.2
—
—
nmol/l
—
0
0
24
269
0.89
0.18
1.3
1.5
—
—
—
0
0
25
223
1.12
0.18
1.4
1.1
—
—
—
0
0
7
59
1.19
0.18
1.4
1.7
1596.57
546.10
nmol/24h
—
7
59
15
173
0.87
0.16
1.7
2.7
—
—
—
0
0
26
288
0.90
0.16
1.3
1.4
—
—
—
0
0
990
9801
1.02
0.16
4.6
4.1
0.00
0.00
estimate
0.50
273
2104
22
246
0.89
0.16
1.1
1.2
—
—
—
0
0
27
244
1.11
0.16
1.1
2.2
—
—
—
0
0
7
90
0.78
0.14
1.9
1.3
134.76
162.36
pmol/l
—
7
90
1866
18697
0.97
0.10
74.0
27.9
123.85
134.09
g/l
136.61
1848
18493
998
9917
1.01
0.09
4.6
4.1
0.02
3.73
estimate
1.57
280
2158
1866
18694
0.97
0.09
73.7
27.7
7.33
6.76
e9/l
2.81
1845
18243
145
1485
0.97
0.09
3.1
2.8
6.05
6.03
ph
0.11
122
1035
5
48
1.04
0.09
4.2
7.6
7.42
5.24
kpa
—
5
48
1866
18693
0.97
0.09
74.6
28.3
37.71
40.06
%
87.55
1846
18476
1866
18693
0.97
0.09
73.6
27.7
4.08
4.44
e12/l
127.62
1846
18238
1866
18692
0.97
0.09
73.3
27.6
30.71
30.44
pg
5.51
1847
18484
42
400
1.05
0.08
2.4
3.8
26.77
27.61
mg/l
0.05
31
270
1866
18691
0.98
0.08
73.4
27.6
93.32
91.62
fl
29.39
1848
18484
1866
18690
0.98
0.08
73.8
27.7
239.04
246.41
e9/l
3.77
1849
18305
7
80
0.87
0.07
1.1
1.3
152.43
173.57
mmol/24h
—
7
80
37
354
1.05
0.06
1.2
1.2
—
—
—
0
0
17
183
0.93
0.06
2.6
2.2
—
—
—
0
0
25
237
1.06
0.05
1.6
1.6
58.73
60.60
%
0.09
15
147
728
7314
0.99
0.05
4.9
4.1
0.11
0.11
estimate
0.02
236
1728
26
248
1.05
0.05
1.3
1.3
289.05
305.07
pmol/l
0.09
21
214
783
7858
0.99
0.04
4.0
3.6
6.30
6.25
ph
0.60
448
4328
283
2811
1.01
0.03
1.3
1.3
—
—
—
0
0
11
118
0.93
0.02
1.3
1.3
10.82
9.82
mmol/l
0.21
11
110
15
145
1.03
0.00
1.1
1.1
—
—
—
0
0
17
175
0.97
0.00
1.5
1.5
21.57
31.23
%
—
7
106
13
128
1.02
0.00
1.5
1.9
83.62
110.29
ng/l
0.66
13
128
10
102
0.98
0.00
2.2
2.1
—
39.30
—
0
6
13
133
0.98
0.00
1.0
1.8
—
—
—
0
0
16
157
1.02
0.00
1.1
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
87.33
—
0
9
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
5
58
0.86
-0.00
1.2
1.5
6.80
7.10
mmol/l
—
5
58
9
98
0.92
-0.00
1.6
1.2
959.22
403.79
u/l
—
9
92
7
76
0.92
-0.00
3.6
3.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
293.46
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
85
0.94
-0.00
3.3
3.5
—
—
—
0
0
7
79
0.89
-0.00
3.7
3.0
14.11
22.09
mu/l
—
7
74
7
79
0.89
-0.00
1.0
1.1
1128.86
1573.22
miu/ml
—
7
79
0
8
0.00
-0.00
0.0
1.8
—
281.63
—
0
8
6
59
1.02
-0.00
1.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
61.21
—
0
8
0
6
0.00
-0.00
0.0
1.5
—
2.43
—
0
6
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: RX_L01XE – L01XE Protein kinase inhibitors

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).